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ABSTRACT 
Technetium-99m (99mTc) is the most useful radioisotope in medical imaging 
due to its favourable nuclear characteristics, wide availability and low cost. Since 
99mTc is a metal, it must be chelated using appropriate ligands to impart affinity for 
target tissues. 
A series of new 2-pyrrolylthiones were synthesised as potential ligands for 
transition metals, particularly 99mTc, and were fully characterised. Both lipophilic and 
water-soluble compounds were obtained. Chemical reactions of the 2-pyrrolylthiones 
were studied. It was found that physical and chemical properties of these ligands are 
highly dependent on the substituents in the outer periphery of the molecule. 
Transition metals such as Ni, Cu, Co, Cd, and Zn react smoothly with 
synthesised 2-pyrrolylthiones. A general complexation procedure was developed for 
technetium and rhenium. 99Tc and non-radioactive Re complexes were used to 
establish the chemical structure of the new 99mTc compounds and to study their 
properties. 
Labelling of the 2-pyrrolylthiones with 99mrc was perfonned. The 
biodistribution and pharmacokinetics of the selected complexes were studied. The 
biodistribution pattern of the new 99mTc-complexes greatly depends on their 
lipophilicity. Chemical changes in the ligand periphery, from highly lipophilic 
through amphiphilic to water-soluble, allow for fine tuming of the biological 
properties of the corresponding technetium complexes. 
Novel 2-pyrrolylthiones would provide a new class of radiopharmaceuticals 
for medical imaging, where the periphery of the radiopharmaceutical can be modified 
according to desirable properties, while the central technetium core remains the same. 
RESUME 
Technetium-99m (99mTc) est le radio-isotope le plus utile dans l'imagerie 
médicale en raison de ses caractéristiques nucléaires favorables, disponibilité et coût. 
Posséder les propriétés métalliques, 99mTc doit être chélatée en utilisant les ligands 
appropriés pour donner l'affinité pour des tissus de cible. 
Une série de nouveau 2-pyrrolylthiones a été synthétisée en tant que ligands 
potentiels pour les métaux de transition, en particulier 99mTc, et a été entièrement 
caractérisée. Des composés liphophiles et hydrophiles ont été obtenus. Des réactions 
chimiques du 2-pyrrolylthiones ont été étudiées. On l'a constaté que les propriétés 
physiques et chimiques de ces ligands dépendent fortement des substituants dans la 
périphérie externe de la molécule. 
Les métaux de transition tels que les Ni, Cu, Co, Cd, et Zn réagissent sans à-
coup avec 2-pyrrolylthiones synthétisé. Un procédé général de complexation a été 
développé pour le technetium et le rhénium. Complexes de 99 Tc et de rhénium non 
radioactifs ont été employés pour établir la structure chimique des nouveaux 
composés de 99mTc et pour étudier leurs propriétés. 
Marquage du 2-pyrrolylthiones avec 99mTc a été exécuté. Le biodistribution et 
la pharmacocinétique des complexes choisis sont ont été étudiés. La configuration de 
biodistribution du nouveau 99mTc-complexes dépend considérablement de leur 
lipophilicity. Les changements chimiques dans la périphérie de ligand tiennent 
compte de la rotation fine des propriétés biologiques des complexes correspondants 
de technetium. 
La serie de 2-pyrrolylthiones fournirait une nouvelle classe des produits 
radiopharmaceutiques pour l'imagerie médicale, où la périphérie du produit 
radiopharmaceutique peut être modifiée selon les propriétés souhaitables, alors que le 
noyau central de technetium demeure le même. 
INTRODUCTION 
The role of nuclear medicine in health care has expanded rapidly over the past 
few decades. The design and development of new radiopharmaceuticals plays here a 
great role. The search for moœ specific, more stable, more convenient 
radiopharmaceuticals continues and attracts the attention of a wide range of scientists 
and medical specialists. 
99mTc-radiopharmaceuticals are the most useful imaging agents in clinic. This 
is due to extremely favourable nuclear characteristics of 99mTc-radioisotope, its wide 
availability and low cost. 
The element technetium is not found in nature. Thus, it is absent in molecules 
of a living organism. There is a basic difference between the chemistry of 99mTc-
compounds and other radionuclides 1 used in medical imaging, such as 11 C, 13N, and 
150 that are radioactive analogues of naturally occurring atoms, or radiohalogens, 
which can covalently bind to organic molecules. Due to its metallic properties, 99mTc 
must be chelated using appropriate ligands - chelating agents - to impart affinity for 
target tissues. A chelating agent is an organic molecule, which binds strongly to 
metal ions using one or more covalent, or coordination links. The resulting complex 
can be designed as "metal essential" or "metal tagged". 
"Technetium essential", or the first generation agents are small molecules 
where Tc is an essential part of the structure. The biodistribution and targeting ability 
1 A radionuclide is a nucleus with a set of cbaracteristic properties, such as the specific nucleon 
composition, the mode of radioactive decay and type of emissions, the transition energy, and the 
average lifetime ofa nucleus of the radionuclide before it undergoes radioactive decay. 
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of these radiophannaceuticals depend on their size, charge, and lipophilicity and are 
determined by blood flow or perfusion. Most 99mTc-based imaging agents that are 
approved for clinicat use are considered first generation radiopharmaceuticals. 
"Technetium tagged" - second generation agents - have a more sophisticated 
structure and chemistry. These are biologically active molecules, typically a small 
peptide, which act as an agonist or antagonist for a specific receptor site, or a 
monoclonal antibody, which are labelled with 99mTc directly or through a chelating 
group. The targeting ability of such radiophannaceuticals depends on the biologically 
active moiety of the complex, which carries 99mTc to the target organ. Tissue uptake 
and retention depend on a specific biochemical process or binding to a specific 
receptor. 
99mTc can be attached to a carrier molecule using a bifunctional chelating 
agent (the conjugale or bifunctional chelate approach). Sometimes the mass of the 
tagged chelating system comprising Tc is large enough to double the size and mass of 
the original bioactive molecule. These changes can have serious consequences for 
the properties of resulting complexes in terms of biodistribution and targeting ability 
of the radiophannaceutical. The site of attachment to the small bioactive molecule, 
the size, charge and lipophilicity of the conjugate and the length of the covalent linker 
ail need to be optimised for maximum receptor binding. lt is a challenge to attach a 
technetium moiety to a bioactive molecule and preserve the biochemical properties of 
the original small molecule. The bifunctional chelate approach bas found wide 
application in labelling of antibodies and their fragments (Arano, 1999; Dilworth and 
Parrott, 1998). 
2 
Another route in the design of Tc-radiophannaceuticals is the integrated 
approach, where the metal ion is incorporated in the structure of the carrier molecule. 
This involves the design of a biologically active molecule, where 99mTc is an essential 
part of the molecular structure, such that the Tc-complex mimics the parent molecule. 
To date none of such synthesised mimics display satisfactory biological properties 
and lack stability under in vitro binding condition. The conjugate and integrated 
synthetic approaches are both currently at their early stages of development. 
The aim of this work was to find an improved 99mTc radiophannaceutical, 
through the synthesis and evaluation a series of new chelating agents. In particular 
we sought to find a chelator, which would allow for easy substitution around its core 
to give exceptional dynamics and versatility to the resulting complex. 2-
Pyrrolylthiones were selected to study their potential as chelating agents for 
technetium and rhenium. Ali synthesised 2-pyrrolylthiones were able to react with a 
range ofmetal ions forming stable complexes. 
We found that two of the newly synthesised water-soluble 
radiopharmaceuticals were taken up by the kidneys. The pharmacokinetics of these 
compounds is comparable and, in certain aspects, superior to that of the existing 
kidney imaging agent 99mTc-DMSA. Biodistribution studies in the rat suggest that 
these navel complexes may be a useful alternative to 99mTc-DMSA as a kidney 
scanning agent. 
This work is an invention of a new technetium core with an easily varied 
periphery, which allows for the synthesis of navel derivatives with potential 
properties for medical imaging (Kudrevich et al.). 
3 
Since the new 2-pyrrolylthiones were found to be good chelating agents, they 
might well find applications in different biological, medical, and other fields where 
chelators play an important role. 
4 
CHAPTER 1: Biomedical chemistry of technetium-99m 
1.1. Chemical element technetium 
1.1.1. Brief history of the discovery 
The element technetium (Tc) bas the atomic number 43, an atomic weight of 
98, and the electron configuration [Kr]5s24d5• Mendelejeff predicted it on the basis 
of the periodic table as eka-manganese (Mendelejeff, 1872). Perrier and Segré 
discovered the element 43 in 193 7 (Perrier and Segré, 193 7). It was obtained by 
irradiating molybdenum with deuterons in the Berkeley cyclotron. The element 43 
was the first element to be produced artificially from where cornes its name -
technetos, which means "artificial" in Greek. Perrier and Segré discovered 
technetium-95 and technetium-97m with half-lives of 60 and 90 days respectively. 
The long-lived isotope technetium-99 (99 Tc), on which most of the chemistry of the 
element is based, was studied at trace level in 1939 (Seaborg and Segré, 1939) and 
was synthesised in weighable quantities in 1946 (Motta et al., 1947). 
Since the discovery of technetium, searches for the element in terrestrial 
material have been made. Finally in 1962, 99Tc was isolated and identified in African 
pitchblende (a uranium rich ore) in extremely minute quantities as a spontaneous 
fission product of uranium-238 (Kenna and Kuroda, 1962). lt is currently believed 
that the existence of stable technetium isotopes seems very unlikely. 
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1.1.2. Tc-Isotopes 
Currently, more than thirty isotopes of technetium have been reported (85 Tc-
115 Tc). Ali Tc isotopes are radioactive. Three of them are long-lived isotopes: 91Tc 
(t112 = 2.6 x 106 years), 98 Tc (t112 = 4.2 x 106 years), and 99Tc (t112 = 2.1 x 105 years). 
The most useful isotope of technetium is technetium-99m (99mTc, "m" stands for 
metastab/e2 state, the prefix "meta" derives from the Greek word "almost") (Saha, 
1998). It is used mainly in nuclear medicine because of its short half-life of 6.01 
hours and the convenient energyofthe gamma ray emission of 141 keV. 
1. 1 .3. Physical, chemical and nuc/ear characteristics 
Metal technetium is a bright, silvery grey metal. It crystallises in hexagonal 
close-packed arrangement with metallic radii of l .358Â for a twelve coordination 
tMooney, 194 7) and is weakly paramagnetic (XA = 270x l 0-6 c.g.s. units at 298°K) 
(Nelson et al., 1954). 
Technetium exhibits valencies from seven to zero. The common oxidation 
States of technetium are +7, +5, and +4. Under oxidising conditions technetium cvm 
is stable as the pertechnetate ion, Tc04 -. Chemically, technetium powder is readily 
oxidised, which is not the case for massive metal. Technetium does not dissolve in 
hydrochloric acid of any concentration, but will dissolve in dilute or concentrated 
2 Metastable (or isomeric) state is an arrangment of nucleons within a nucleus, which is unstable but 
has relatively long lifetime before transforming to another state. 
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nitric and concentrated sulphuric acids. It easily reacts with fluorine, less with 
chlorine and combines with sulphur at elevated temperatures (Peacock, 1966). The 
chemistry of technetium is believed to be similar to that of rhenium. This point of 
view is very controversial however, because technetium and rhenium compounds 
often behave substantially differently, exhibiting different lipophilicities, redox-
potentials and stability. 
Almost all of the chemistry of technetium is based on the 99 Tc isotope, which 
is a weak P-emitter CPmax = 0.3 MeV). The handling of 99 Tc on a small scale (< 0.05 g) 
does not present a serious health hazard, provided elementary precautions are taken. 
The radiation is effectively stopped by ordinary laboratory glassware, and there is no 
associated y-radiation. Even for larger quantities ( < 0.25 g) the health hazard is small, 
provided the operator maintains a distance of at least 30 cm from the working area to 
avoid the small amount of soft X-rays produced by the action of the P-emission on 
glass. Therefore, the essential requirements for safe handling of 99 Tc are a well-
ventilated box, monitoring of working area and avoidance of manipulations, where 
compound could escape to atmosphere (Peacock, 1966). Nevertheless, the handling 
of technetium must be performed in a special laboratory approved for the radioisotope 
use. 
As was noticed previously, the most useful radioisotope of technetium is 
99mTc. The methods of synthesis, separation and analysis are different for 99mTc, 
compare to 99Tc because of the trace amounts of 99mTc used. The quantity of a ligand 
taken for complexation is usually exceeds the quantity needed to chelate ail 99mTc 
ions available for reaction. An excess of the ligand should be separated at time of 
7 
purification. Separation and purification is often done using HPLC with UV and 
radioactivity detectors. Different spectroscopie and chromatographie methods and 
electrophoresis are used to identify and analyse 99mTc compounds. 99mTc emits y-rays 
of 140 keV with 89% abundance, which can be detected using scintillation cameras 
also know as gamma cameras. Images of its distribution pattern can be obtained by 
recording the emitting radiation. The energy of 99mTc is close to optimum for medical 
imaging with gamma cameras (contemporary detectors can absorb y-rays of 30-300 
keV, and 140 keVof 99mTc isjust in the middle of the range). The radioisotope's half-
life of 6 hours is long enough to complete synthesis and purification, inject 
radiopharmaceutical into a patient and perform imaging. On the other hand, it is short 
enough to minimise the radiation dose to the patient. Work with 99mTc must be done 
in an approved laboratory, in a well-ventilated hood behind a lead barrier shield, and 
gloves should be wom for handling radioactivity. 
1.1.4. 99Mo/ 99"'Tc generator 
Until 1960, 99mTc was available only in small amounts and its price was quite 
high. After the discovery of the 99 Mof99mTc generator it became routinely available 
and economical. The possibility to have a 99 Mo/99mTc generator at virtually any 
hospital makes 99mTc the most popular isotope in diagnostic nuclear medicine. The 
generator is based on transient equilibrium between parent and daughter 
radionuclides, 99 Mo and 99mTc respectively. 99 Mool- is absorbed on an alumina 
column inside a lead shield. There is a vial, which provides a saline solution to elute 
8 
pertechnetate 99mTc04 -, and another 
one to collect the eluted solution. The 
column is connected to the vials with 
stainless steal tubing, shielded by lead. 
This construction is then shielded by 




Figure J. Decay scheme for molybdenum-99. 
of radiation. The generator can be eluted daily and is replaced once a week. 
1.2. Technetium based radiopliarmaceuticals ofthefirst generation 
1.2.1. First 99"'Tc radiopharmaceutical 
Accumulation of pertechnetate in the thyroid of animais was demonstrated in 
1953 (Baumann et al., 1953). The first report on the use of technetium for medical 
imaging appeared in 1963 and involved the use of 99mTc04- for the visualisation of 
the liver by scintillation scanning, following administration and hepatic localisation 
of the parent molybdenum-99 radionuclide (Sorensen and Archambault, 1963; 
Sorensen and Archambault, 1964). Later 99mTc pertechnetate was evaluated for brain 
scanning (McAfee et al., 1964). In 1964 99mTc pertechnetate was used for the 
diagnosis of thyroid disease {Harper, 1964; Andros et al., 1965), based on the 
principle that the pertechnetate anion behaves similarly to iodide, which is known to 
be taken up by the thyroid. The biodistribution and targeting ability of this 
9 
radiophannaceutical depends solely on the size and charge of the complex. This was 
the first of a series of so-called "technetium essential", or the first generation agents. 
1.2.2. Brain imaging radiopharmaceutica/s 
The ideal radiopharmaceutical for brain imaging should be capable of 
traversing an intact blood-brain barrier3 (BBB), accumulate in the brain and stay there 
long enough to perform the imaging. Therefore, useful complexes must be 
moderately lipophilic and have an overall neutral 
charge. 
Research at the University of Missouri in 
the 1980s and further development at Amersham 
International led to the commercially successful 
agent Ceretec™ based on the 
hexamethylpropyleneamineoxime pro ligand 
(HMP AO hexametazime; 3,6,6,9-tetramethyl-
4,8-diazaundecane-2, 10-dione dioxime) (Holmes 
et al., 1985; Leonard et al., 1986; Neirinckx et 
al., 1987). The proligand loses three protons to 
form a neutral, square pyramidal technetium(V) 
mono-oxo complex. (Figure 2) (Jurisson et al., 
99mTc-PnAO 
Figure 2. Schematic structures of 
the technetium complexes with 
propyleneamineoxime derivatives. 
3 The blood-brain barrier (BBB) is a functional mixture of anatomie, physiologie, and metabolic 
phenomena, which excludes alien substances from entering the brain from the blood, while vitally 
important substances are easily cross it. 
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1986; Nikitin and Kulakov, 1997) This complex is approved as a cerebral perfusion 
imaging agent for evaluation of stroke damage. A previously synthesised (Troutner 
et al., 1984) technetium complex with propyleneamineoxime (3,3,9,9-tetramethyl-
4,8-diazaundecane-2,10-dione dioxime) - 99mTc-PnAO - was shown to be taken up 
by the rat brain (Volkert et al. 1984) but unfortunately it also diffuses rapidly back 
out of the brain with a half-life too short to allow for imaging (Holm et al., 1985). 
The final HMP AO derivative was selected from more than one hundred structural 
variants for its optimal biodistribution characteristics. 
The technetium complexes of a wide range of bisamidedithiol (DADS) 
proligands have been investigated as potential agents for brain imaging. The 
technetium ethyl cysteinate dimer (99mTc-ECD) complex is commercially available 
from Dupont as Neurolitern. This compound is one of the recent additions to 
available radiopharmaceuticals for measuring cerebral blood flow. 99mTc-L,L-ECD is 
a neutral, lipophilic Tc(V) complex with mono-oxo core and L,L-ethylcysteine dimer 
bound to the metal via two amine nitrogen and two thiolate sulphur atoms. (Figure J) 
The complex has two isomers. One of them, L,L-enantiomer of ECO, is trapped once 
across the BBB due to the enzymatic hydrolysis of one ester group by an esterase 
enzyme to give the free acid group, generating a more hydrophilic charged complex. 
In contrast, the D,D-enantiomer is inert to the enzymatic hydrolysis and diffuses back 
across the BBB. Such an 
enzymatic conversion reaction 
also occurs in the blood during 
biodistribution, and although is Figure 3. 99mTc-L,L-ECD 
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impairs brain uptake, it facilitates clearance from the blood and non-target tissue via 
the kidneys. 
These agents actually provide images of regional cerebral blood flow (rCBF). 
The regional distribution of the two tracers differs. 99mTc-HMP AO accumulates more 
in the thalamus, frontal lobe, temporal lobe and cerebellum than 99mTc-ECD, which 
accumulates primarily in the occipital and parietal lobes. There is a considerable 
difference in the accumulations of the two tracers in the medial temporal lobe (93.9% 
and 83. l % respectively compared with the mean global cerebral cortical 
accumulation). The results suggest that 99mTc-HMP AO and 99mTc-ECD require 
specific and separate criteria for diagnosing temporal lobe pathologies. 
Interestingly, it was found that brain uptake in rats is not determined by 
lipophilicity only. Uptake is strongly influenced by substituents on the ligand 
periphery (Oya et al., 1998). This fact should be taken in consideration when 
designing novel labelled agents. 
1.2.3. Heart imaging radiopharmaceutica/s 
The design of heart imaging radiopharmaceuticals initially was based on the 
idea that lipophilic complexes with a mono-positive charge should accumulate in 
heart tissue via the Na +/lè ATPase mechanism as /(' ion mimics. This concept 
prompted the synthesis of the cationic 99mTc complex, [99mTc(dmpe)2Ciit, where 
dmpe is 1,2-bis(dimethylphosphino)ethane as a potential myocardial perfusion agent. 
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Figure 4. Technetium complex with 
1,2-bis( dimethylpbosphino )etbane 
Figure 5. 
99mTc[ (2-metboxy-2-methylpropyl)isonitrile )6 • 
Figure 6. Mixed Tc complex with 
cyclobexane-1,2-dione dioxime and 
methyl boronic acid 
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(Figure 4) lt was later found that 
this complex undergoes in vivo 
reduction to the neutral Tc(II) 
complex [99mTc(dmpe)2Cl2]. Loss 
of the positive charge results in 
fast washout from the heart and 
accumulation in the liver. 
Further development of 
cationic complexes as myocardial 
perfusion agents led to the 
approved agent [99mTc(MIBl)6t 
(known also as 99mTc-sestamibi) 
(Cardiolite™, Dupont), where 
MIBI lS (2-methoxy-2-
methylpropyl)isonitrile (Figure 5) 
(Piwnica-Worms et al., 1988). 
The uptake in the humari heart 
reaches about 1.5% of the injected 
dose, slowly decreasing to 1 % 
after 4 h. A good organ to 
background ratio is achieved due 
to low uptake in the blood, lungs, liver, spleen. Animal studies suggest that the 
methoxy-group of 99"'Tc-sestamibi is metabolised in the liver leading to more rapid 
clearance (Kronauge et al., 1990). 
The first approved neutral myocardial perfusion agent is 99mTc-teboroxime 
(Cardiotec™, Bristol-Myers Squibb). The complex is prepared by template synthesis 
where 99mrc04- reacts with a mixture of cyclohexane-1,2-dione dioxime and methyl 
boronic acid with SnCli as a reducing agent. Five minutes after injection 2.2% of the 
administered dose of the Tc(lli) complex is found in the heart. The mechanism of 
accumulation is still unknown at this time. The complex exhibits rapid myocardial 
clearance in normal myocardium. 
One of the recent cationic imaging agents is 99mTc-P53 (where P53 is 
ethylene-bis-[bis-(2-ethoxyethyl)-phosphine), also known as Tetrofosmine™ or 
Myoview™ (Figure 7). In contrast to [99mTc(dmpe)zC[z]+, Myoview™ contains the 
dioxo Tc(V) core, which does not undergo in vivo reduction. The complex contains 
eight alkoxy groups on the bidentate phosphine ligands that help to reduce the 
background activity in the blood and liver. Heart uptake of the complex is 1.2% of 
the injected dose, with slow clearance to 1 % at 2 hours post-injection. 
A report on the comparison of kit 
performances of Cardiolite™, Tetrofosmine™, 
and Technescan ™ Ql2 has been published 
(Cagnolini et al., 1998). 
The uptake and retention mechanism of the 
mono-cationic 99mTc complexes in the Figure 7. Tetrofosmine 
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myocardium remains unknown. However, it bas been shown that accumulation does 
not involve the Na+/K+-ATPase pump. A more likely mechanism of uptake suggests 
that cations such as [99mTc(MIBl)6t and 99mTc-diphosphine complexes accumulate 
via a diffusion mechanism and electrostatic binding due to a high mitochondrial 
membrane potential (Sands et al., 1985; Piwnica-Worms et al., 1988). 
I.2.4. lmaging agents for the hepatobiliary system 
The first iminodiacetic acid derivative employed in nuclear medicine was 2,6-
dimethylphenylcarbamoylmethyl iminodiacetic acid (lidofenin) (Loberg et al., 1976). 
Currently, a few analogues oftechnetium complexes with hepatobiliary iminodiacetic 
acid (HIDA) are used for imaging of hepatobiliary system (liver, bladder, and 
intestines). They include 99mTc-lidofenin (TechneScan TM HIDA, Mallinckrodt), 
99mTc-disofenin (Hepatolite™, Dupont), and 99mTc-mebrofenin (Choletec™, Bristol-
Myers Squibb) (Figure 8). Ali three 
agents show quite similar behaviour. lt 
was found that the metal to ligand ratio 
in Tc-HIDA is 1:2, that the complex 
does not contain tin, and that the 
overall complex charge is -1 (Loberg 
and Fields, 1978). 
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Figure 8. HIDA ligands 
Lidofenin: R1=CH3, Ri=R3=H 
Disofenin: R1=isopropyl, R2=R3=H 
Mebrofenin: R1=R3=CH3, R2=H and Br 
J .2.5. Bone imaging radiopharmaceuticals 
99mTc complexes containing a wide range of diphosphonates, analogues of 
pyrophosphates, present technetium radiophannaceuticals for bone imaging. 
Methylene diphosphonate (MDP), hydroxymethylene diphosphonate (HMDP), 
hydroxyethylidene diphosphonate (HEDP), and ethylenediaminetetramethylene 
phosphonic acid (EDTMP) are only a few examples of this class of compounds 
(Figure 9). 
Technetium methylene diphosphonate (99mTc-MDP) is most frequently used in 
clinic. It is an organic analogue of pyrophosphate and contains an organic P-C-P 
bond. The agent affixes to the bone surface as a result of a chemisorption process. It 
was found that after administration 99mTc-MDP dissociates into its technetium and 
methylene diphosphonate moieties, which are then adsorbed onto the organic (newly-
formed osteoid) and inorganic (forming minerai) 
phases, respectively (Schwartz et al., 1993). 
About 40-50% of the compound will be affixed 
to bone within 3 to 4 hours after injection. 
Excretion is primarily renal and 70% of the 
administered dose is eliminated within 6 hours 
after injection. 
A 99mTc- complex with a new ligand from 
the phosphonate family was reported recently 








1 1 1 
O=P-C-P=-0 
1 1 1 
OHR2 OH 
Dipbospbonate 
Figure 9. Dipbospbonates family 
MDP: R 1=H, R2=H 
HEDP: Ri=OH, R2=CH3 
HMDP: R1=H, R2=0H 
stable and strong complex with 4-amino-1-hydroxybutylidene- l, 1-diphosphonate, 
probably due to the amino group present in the ligand structure. Biological data have 
not yet been published on this compound. 
1.2.6. Radioactive drugsfor kidney imaging 
Renography using radiotracers allows for the determination of both total and 
differential renal function and the detection of obstructions in urine flow. Kidney 
imaging agents can be divided in two groups: radiopharmaceuticals for functional 
imaging or tubular imaging agents, and radiopharmaceuticals for morphological 
imaging or glomerular (cortical) imaging agents. 
Among the oldest and most widely employed techniques for renal function 
evaluation are the renal clearance methods directed toward determination of 
glomerular filtration rate (GFR). The clearance of compounds that undergo extensive 
tubular excretion in addition to filtration allow the evaluation of functional tubular 
mass and the estimation of effective renal plasma flow (ERPF). 
The standard for ERPF determination is p-aminohippurate (PAH): 
approximately 90% of this compound are extracted from the renal arterial plasma in a 
single pass through the renal parenchyma. An 
131 I labelled structural analogue, ortho-
iodohippurate ([131/]0lll; Hippuran) (Figure 
10), has been the clinical standard for the past 
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Figure 10. 131/-iodohippurate 
40 yt:ars (Tubis et al., 1960). Although Olli yields a good approximation of renal 
plasma flow, the 364 keV photon energy of 131/ results in poor spatial resolution and 
the beta emission increases the radiation dose to the patient. Labelling Olli with 123 I 
results in a better imaging agent, but the unavailability and high cost of 123 / limits the 
use ofthis compound (Thakur et al., 1975). 
[
99mTc]-DTPA (where DTPA is diethylenetriaminepentaacetic acid (Figure 
11)) (Eckelman and Richards, 1970) has received regulatory approval for use as a 
kidney imaging agent. The structure of this complex has not yet been determined 
unequivocally, and it is unclear as to whether the complex contains technetium in the 
IV or V oxidation state. This radiopharmaceutical bas very limited clinical 
applications. 
Early attempts to create a 99mrc-based renal imaging agent focused on the 
diamine dithiolate (DADT) ligands. 99mrc-N,N' -bis(mercaptoacetyl)-2,3-
diaminopropanoate has a favourable renal clearance profile, but this compound 
consists of stereoisomers with different rates and specificity for renal clearance 
(Fritzberg et al., 1982). Therefore, HPLC separation of the desired stereoisomer is 
required, which makes routine preparation less convenient. 
The para-aminohippuric acid (P AH) was found almost completely extracted 
"OOC-CHz-..... _....CHrCOff 
- N-CH,-CH,-N-cH,-CHrN -
"OOC-Cfü.....- - - 1 - - 'CH -COO-
- CH, 2 
1 -
COOH 
Fig11re 11. Diethylenetriaminepentaacetic acid 
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from blood flow by the kidneys. Incorporation of an iminodiacetic acid (IDA) moiety 
into P AH yielded p-[(biscarboxymethylaminomethyl)carbamino ]-hippuric acid 
(PAHIDA) with a clearance ofless than 50% ofOIB (Chervu et al., 1984). 
Later, the triamide mercaptide (N3S) class of 99mTc chelating agents was 
developed (Fritzberg et al., 1986). To date, the 
mercaptoacetylglycylglycylglycine (99mTc-MAG3) is considered to be one of the most 
successful agents for functional renal imaging. The structure of 99mTc-MAG3 is 
shown in Figure 12. lt has acore of Tc=ON3S with a carboxylic group on the third 
nitrogen. 99mTc has a coordination number of 5 and the complex has an overall 
negative charge of -1. The structure of this radiopharmaceutical was established 
through direct synthesis and characterisation of the analogous 99 Tc complex 
(Grummon et al., 1995; Nikitin and Kulakov, 1997). 
A few minutes post injection, approximately 1-2% of the injected dose of 
99mTc-MAG3 is found in the kidneys. At the same time, this drug is cleared from the 
kidney tissue very rapidly. lt is the passage into and through the kidneys that 
provides a measure of renal function (ERPF). Although considered to be the renal 
imaging agent of choice, 99mTc-MAG3 is not 
free of certain problems associated with its 
use. For instance, the plasma-protein binding 
of 99mTc-MAG3 is very high (Taylor et al., 
1987; Bubeck et al., 1990); the clearance of 
99mTc-MAG3 is only 50-60% of that of Olli 
and therefore is not suitable for direct 
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Figure 12. Structure of the 99mTc-
MAG3 complex 
measurement of ERPF. In addition, the preparation of 99mTc-MAG3 requires the kit to 
be heated at 100°C for 10 min, thus adding an inconvenient step in the preparation. 
lt was found that the polar metabolite of the brain radiopharmaceutical, 
diethyl Tc-99m-ethylenedicysteine (99mTc-L,L-EC), was rapidly and efficiently 
excreted by the kidneys in mice (Verbruggen et al., 1990). This observation 
prompted the evaluation of 99mTc-L,L-EC as a potential renal imaging agent. Studies 
in mice and baboons showed that the pharmacokinetic properties of 99mTc-L,L-EC are 
superior to those of 99mTc-MAG3. 99mTc-l,L-EC yields a better approximation of 
ERPF. A number of clinicat studies have been conducted to date on patients with a 
variety of renal disorders comparing 99mTc-l,L-EC and 99mTc-MAG3 (Kabasakal et al., 
1995; Gupta et al. 1995; Kibar et al., 1997). There was no significant difference in 
the image quality or in the parameters derived from the renogram between the two 
tracers. The structure of 99mTc-L,L-EC was established through direct synthesis and 
crystallographic studies (Pirmettis et al., 1994). 
MAG3 is synthesised and supplied in commercial kits as an S-benzyl protected 
derivative. This is necessary due to the low chemical stability of the thiol group 
toward oxidation. The kit must be kept in the dark after reconstitution to prevent 
oxidation of the thiol ~lallinckrodt Medical Inc., 1992). To circumvent this problem, 
an attempt was made to substitute an hydroxyl group in MAG3 for the thiol 
(Vanbilloen et al., 1997). The resulting 99mTc-labeled hydroxyacetyltriglycine 
(HAG3) had a slightly higher urinary excretion and faster renal transit than 99mTc-
MAG3. The faster renal clearance of 99mTc-HAG3 can be attributed to its lower 
plasma protein binding. Although the renal excretion characteristics of 99mTc-HAG3 
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are slightly better than those of 99mTc-MAG3 and the labelling is done at room 
temperature, the chemical stability of 99mTc-HAG3 to transchelation is less than that 
of 99mTc-MAG3. 
Certain 99mTc labelled molecules have a high extraction rate from the blood 
stream by the kidneys combined with a high retention rate in the kidneys. Usually 
they have a high affinity to the cortex area. These radiopharmaceuticals can be used 
for morphological imaging. 
99mTcO(glucoheptonate)i (Glucoscan™, Dupont; TechneScan Gluceptaten.1, 
Mallinckrodt) is one of the radiopharmaceuticals of this kind. This is an early kidney 
imaging agent, the precise structure of which has never been detennined. 
Nevertheless, the chemical structure shown on Figure 13 was proposed based on 
different analytical methods (de Kieviet, 
1981). Up to 15 % of injected dose is 
retained in kidneys, with greater retention in 
the cortex than in the medulla, giving 
information on kidney morphology. This 
complex is no longer widely used as an 
imaging agent since ultrasound and magnetic 
resonance imaging have proven more useful 
for morphologie studies and do not require 
the use of radiopharmaceuticals. 
Nevertheless, it is regularly used as a 
precursor for the synthesis of other Tc(V) 
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Glucoheptonate 







Figure 14. DMSA structure 
compounds via ligand exchange. 
Technetium-99m-dimercaptosuccinic acid 
( 99mTc-DMSA; Technetium-99m Succimer 
Injection™) is marketed for morphological studies 
of the kidneys. However, it is possible also to 
assess an individual kidney function. Such examinations constitute a useful approach 
in the diagnosis, location and evaluation of various renal pathologies: inflammation, 
infection, lithiases, traumatisms, tumours, etc. The Tc(III) or Tc(V) complex (of 
unknown structure) is prepared from the reaction of 99mrco4- with DMSA in the 
presence of the reducing agent SnC/2• 99mTc-DMSA has a specific affinity for the 
renal cortex. The renal activity increases until 6 to 8 hours after injection in healthy 
subjects, at which point a steady level of uptake is reached representing some 30% of 
the activity administered. 99mTc-DMSA is almost completely bound to proteins at the 
plasma level. The commercially available kit should be stored in the dark due to its 
sensitivity to light (MDS Nordion S.A., 1998). 
A bidentate chelator N-mercaptoacetylglycine (GAM) was suggested as a 
99mrc-ligand (Gianolli et al., 1996). GAM contains both thiolato sulphur and amido 
nitrogen sirnilar to MAG3 and DADS, but it is a bidentate ligand similar to DMSA. 
The resulting 2: 1 complex (99mTc-2GAM) can adopt either a cis- or trans-
configuration relative to the oxo-technetium core. Biodistribution studies in animais 
and normal volunteers indicate that 99mTc-2GAM has biological properties, which are 
more similar to 99mTc-DMSA, rather than t~ 99mrc-MAG3 or 99mTc-DADS. 99mTc-
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2GAM activity in the kidney reaches a plateau more rapidly than 99mTc-DMSA and 
thus may be a possible replacement for 99mrc-DMSA. 
A series of biguanide ligands were stadied recently as potential chelators for 
99mTc (Neves et al., 1999). The authors suggest that 99mTc-complex with 
unsubstituted biguanide might be a favourable alternative to 99mTc-DMSA, because of 
its better clearance and lower absorbed radiation dose. 
Ail the mentioned above imaging agents are organometallic anions. They are 
transported by organic anion receptors in the renal tubular system. A build-up of 
organic anions in plasma, which happens in patients suffering from uraemia, can 
competitively inhibit renal tubular transport of anionic tracers, thereby leading to 
artificially low estimates of renographic parameters in such patients. 
Another tubular transport mechanism, the cationic transporter system, cannot 
be disrupted by anion accumulation. Tetraazapolyamine chelators, such as cyclam 
and tetramethylcyclam, were evaluated for their ability to fonn stable complexes with 
dioxotechnetium (Herzog et al., 1992). The overall charge of each 99mTc complex 
was +l. The magnitude of the plasma protein binding for these organic cations was 
comparable to that for 99mTc-EC and significantly less than that for OIH and 99mrc-
MAG3. The renal clearance of tetraazapolyamines was similar to that of 99mTc-L,L-
EC. The mode of excretion of these tracers by the tubule cationic transporter system 
was clearly identified. 
A series of cationic 99mTc complexes with N-substituted pyridoxal derivatives 
were synthesised and evaluated as renal function agents (Karube et al., 1994). The 
pyridoxal-derived 99mTc complexes are rapidly excreted in urine and provide clear 
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renal scintigrams in a rat model. However, total clearances are lower than that of 131/-
0IH or 99mTc-MAG3. 
1.3. Design of the technetium tagged radiopharmaceuticals 
Many researchers are currently devoting their efforts to the synthesis of 
conjugate complexes where small bioactive molecules are labelled with 99mTc using 
bifunctional chelating agent. Receptors, monoclonal antibodies, small peptides are 
under close attention in these studies (Jurisson and Lydon, 1999; Liu and Edwards, 
1999). 
J.3.1. Monoclonal antibodies or their fragments 
Monoclonal antibodies or their fragments are potentially ideal vehicles to 
target radioisotopes to specific sites, providing the radiolabel can be introduced 
without interfering with binding to the receptor site. The relatively large size of 
whole antibodies generally confers undesirably slow biodistribution kinetics for 
imaging purposes, and attention is now directed to antibody fragments, which retain 
the specific binding characteristics (Eckelman, 1995; Arano, 1999). The use of 
fragments also reduces the possibility of immunogenecity and adverse allergie 
reactions. 
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1.3.2. Central nervous system receptors 
There are a number of important diseases and psychiatrie conditions that are 
associated with changes in the densities of neurotransmitter receptor sites in the brain. 
Specially designed radiopharmaceuticals can deliver radioisotopes to the receptor 
sites to perform the imaging. Cocaïne and analogues are the most promising 
candidates as carrier molecules for 99mTc as they are antagonists to dopamine 
transporter receptor. 
Recently a tetradentate CHJt:·tD analogue of tropane, TechnepineTM, 
was developed (Figure 15) (Madras et Cocaïne 
al., 1996). Technepine™ 
demonstrates high affinity in vitro 
binding to the dopamine receptor, and 
was the first technetium-based agent F 
to be used to image selectively the Technepïne 
striatum of non-human primates 
(Meltzer et al, 1997). 
Linking of the cocaïne 
derivative via the seven-membered 
ring to a Tc(V) oxo-core involving an 
99mTc-TRODAT 
NiS2 ligand forms a conjugate 99mTc-
TRODAT (Figure 15). 99mTc- Figure 15. Cocaïne and its 99mTc conjugates 
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TRODAT exhibits selective uptake in rat striatum (Kung et al., 1997) and provides 
good contrast for basal ganglia in single photon emission computed tomography 
(SPECT) images taken of human (Kung et al., 1996). The 99mTc-TRODAT presents 
the first human-tested technetium-based SPECT agent that could be used clinically to 
image the dopamine transporter. Recently, there bas been a report on a kit 
formulation for the synthesis of 99mTc-TRODA T (Choi et al., 1999). This 
radiopharmaceutical is the first of second generation agents that can be synthesised 
using a kit. 
This exciting advance confirms the viability of the conjugate approach to 
99mrc imaging of central nervous system receptors. 
Several other neuro-receptor selective molecules (primarily for dopamine 
transporter and seratonin SHTi) have been studied in the last few years (Jurisson and 
Lydon, 1999). 
1.3.3. Steroid receptors 
Imaging of prostate and breast cancers can be done with appropriately labelled 
hormones: most prostate cancers are androgen and progesterone receptor positive, 
whereas breast cancers are estrogen and progesterone receptor positive. The 
structures of three relevant hormones are shown in Figure 16. 
99mTc labelling of progesterone bas been studied utilising conjugation to N2S2 
ligands via a phenyl spacer (Katzenellenbogen, 1995). A few complexes, where 
progesterone bas been substituted at the 21-, 17a-, 16a,17a-, and llp - positions 
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(Figure l '1), have been reported 
(DiZio et al., 1991). Only llP -
analogues display remarkably high 
binding affinity to progesterone 
receptor: the syn pair bas an affinity 
of 161 % relative to progesterone. 
Although the conjugates showed high 
binding, in vivo studies also revealed 
high level of non-specific binding. 
Nevertheless, the approach is 
promising although further fine-
tuning of biodistribution 
characteristics is required. 
The major problem of steroid-
based technetium chelates is their 
strong non-specific binding 
properties under in vivo conditions, 
while in vitro cell binding studies 







Figure 16. Hormones that bind to androgen 
and progesterone receptors. 
Figure 17. Substituted progesterone 
1.4. The integrated approach to mimic bioactive molecules 
The ideal Tc-radiopharmaceutical would be such that the outer surface of the 
complex itself contains the groups necessary to deliver the radioisotope to the target 
organ. This could be achieved by replacing a part of the ligand with a metal chelate 
system. In this way, there is a minimal change in ligand size, shape and structure, and 
biological properties of the original molecule can be preserved as well. The steric 
bulle and the resulting mass of technetium-based complexes are much lower when the 
technetium unit is incorporated into the bioactive molecule than when the conjugate is 
attached to the compound. This approach is far more challenging in terms of the 
chemistry involved, and developments are currently in the early stages. 
The integrated approach strategy was primarily used to synthesise hormone 
mimics for receptor binding (Hom and Katzenellenbogen, 1997, review). A model 
structure for such a complex is shown in Figure 18, where the overall similarity to 
progesterone is apparent. 
The synthesis of bis-bidentate oxorhenium (V) complex has also been 
achieved (Figure 19). lt was designed from the 5a-dihydrotestosterone (DHT) 
frarnework as a potential ligand for the androgen receptor (Hom et al., 1996). While 
modelling suggested that this complex was a good steric mimic ofDHT, it exhibited a 
markedly lower lipophilicity than DHT itself, and showed very low binding for the 
androgen receptor. The oxo-technetium (V) complex was also fonned, but was not 
characterised owing toits low stability. 
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Figure 18. Progesterone bis-
bidentate mimic model 
Figure 19. Organometallic mimic of the 
dihydrotestosterone. M =Tc, Re. 
Figure 20. Estradiot technetium mirnics 
Sorne initial steps toward 
producing an analogue of estradiol have 
been made through the synthesis of bis-
bidentate complexes (Figure 20). 
Synthesised compounds have a phenol 
group, which is essential for estrogen 
receptor binding, even though their 
structures are quite different from 
estradiol. The receptor-binding affinity of 
such complexes was found to be low (Chi 
et al., 1994). 
There have also been attempts to 
synthesise rhenium complexes that mimic 
estradiot structure. The B and C rings of 
estradiol were replaced with a tetradentate 
oxo-rhenium(V)-heteroatom core. 
Although this complex appeared to be a 
good structural mimic of the hormone, it 
was surprisingly unstable in aqueous 
solution, and decomposed to form a 
tridentate (3+ 1) complex (Figure 21). 
This was explained by a poor donor 
ability of the aromatic thioether linkage 
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Estradiot lntegrated oxorbenium comptex from estradiot temptate 
Figure 21. Estradiot and its integrated oxorhenium comptex. 
Figure 22. lntegrated tetradentate 
oxometat comptex from estradiot 
template 
HO 
Figure 23. Hexestrol and 
integrated (3+ l) tridentate 
oxorhenium comptex 
OH 
(Sugano and Katzenellenbogen, 1996). 
An alternate design strategy suggested 
replacing the C and D rings of the steroid 
(Figure 22). This complex was more stable than 
the bis-bidentate rhenium (V) mimic of DHT. 
But the complex exhibited low lipophilicity, and 
relative binding affinity of the complex toward 
the estrogen receptor was found to be low. The 
affinity of such compounds may be attributed to 
the presence of phenolic functions. However, 
the replacement of the C and D rings with the 
rhenium chelate reduces binding affinity (Hom 
and Katzenellenbogen, 1997). 
The preparation of a 3+ 1 system that 
mimics the structure of non-steroidal estrogen 
hexestrol (Figure 23) bas recently been reported 
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(Hom et al., 1997). In vivo biological data on this compound have not been published 
yet. 
As one can note N,S-chelating agents are of great importance in 99mrc-
radiopharmaceuticals synthesis. More sophisticated second generation agents or 
simple small molecules of the first generation agents both use the ability of N,S-
ligands to participate in bonding to technetium. 
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AIM 
Available 99mTc-radiophannaceuticals are presently limited to single small 
molecules with fixed structure. There are not many possibilities for modifying the 
periphery of such ligand molecules in order to fine-tune the solubility of the 
compound and its phannacokinetics. Therefore, there is an interest to develop new 
technetium ligands, which vary the size and lipophilicity of stable 99mTc-complexes 
containing the same type of technetium core. 
The aim of the present work is to obtain various substituted 2-pyrrolylthiones 
in order to examine their potential to form complexes with transition metals and to 
study the properties of such complexes. Furthennore, the suitability of these novel 
ligands as chelators for radiometals, such as for isotopes of technetium and rhenium, 
was explored with the goal of creating a new class of radiopharmaceutical compounds 
for medical imaging. 
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CHAPTER 2: Results and Discussions 
The primary aim of this project was to synthesise porphyrin mimics with an 
integrated technetium core of potential interest for medical imaging. The outer part 
of the porphyrin molecule (Figure 24) is chemically accessible allowing for the 
attachment of different substituents to vary the biological biodistribution pattern. 
It is well known that metal derivatives of phthalocyanines 
(tetrabenzotetraazaporphines) (Figure 25) can be prepared either by condensation, the 
so called template synthesis, from a monomer, such as phthalic acid, phthalic 
anhydride, diiminoisoindoline, or phthalonitrile in the presence of metal ion, or by 
exchange of the central hydrogen or metal ion from pre-formed phthalocyanine. The 
last route encounters two major problems. First of all, the initial reactants should be 
soluble in the same solvent. The second problem is that the selected metal ion should 
have the proper dimension to allow for insertion into the phthalocyanine core. 
Unfortunately, technetium ions such as pertechnetate or reduced compounds (i.e. 
technetium dioxide) do not fit into the porphyrin or phthalocyanine core. Therefore, 
Figure 25. Porphyrin Figure 24. Phthalocyanine 
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direct insertion of the technetium moieties into the cavity of the phthalocyanine 
macrocycle failed. (Rousseau, 1985) Accordingly, the template synthesis should be 
more convenient and promising. The same authors reported such synthesis with a 
final complex where the technetium core was found in an out-of-plane position. This 
fact makes it doubtful that the obtained complex is stable enough for biological 
applications. Nevertheless, preliminary biological tests were conducted showing in 
vivo stability but there were no further results published on the properties of this 
compound. 
It might be possible to imitate the structure of a molecule using smaller sub-
units as building blocks. A few classes of molecules would be suitable to build a 
porphyrin mimic. 
Pyrroles and their derivatives have been used for the synthesis of porphyrins. 
Early work showed different methods to construct porphyrin molecules from 
dipyrromethanes, dipyrromethenes, or pyrrole itself (Paine, 1978). The methods and 
routes of these reactions are conventionally determined by the structure of desired 
final products. Dipyrromethanes and dipyrromethenes are used mostly for the 
synthesis of symmetric compounds, whereas several pyrrole molecules with different 
substituents give unsymmetrical porphyrins. The synthetic strategies for such 
reactions are well established and are still being improved (Gilchrist, 1999; 
Mamardashvili and Golubchikov, 2000). 
To introduce a large metal ion inside the porphyrin mitnic, one needs to use 
building blocks other than dipyrromethanes, such as molecules with increased 
electron-donor properties. We suggest that a metal ion would form one covalent bond 
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with a ligand, while another bond would be formed via coordination of metal ion by 
an electron-donor atom, which would provide a free pair of electrons. This would 
help to produce more stable complexes. Dipyrromethenes could be considered as 
possible ligands, but their instability and multi-steps synthesis are inconvenient. 
When developing site-specific therapeutic or diagnostic radiopharmaceuticals, 
many important factors must be considered. It is essential that a metallic radionuclide 
upon interaction with a chelating agent should form an in vivo stable complex with 
high specific activities and with defined metal to ligand stoichiometry. These 
requirements narrow the choice to only a few ligand backbones. The detailed 
understanding of the coordination chemistry of new ligand systems with non-
radioactive rhenium or ground4 isotope 99Tc is important. This knowledge helps to 
subsequently extent these reactions at the trace level in order to label the chelating 
agents with 99mTc. In addition, the ability of the ligand to form radiopharmaceutical 
complexes under conditions suitable for routine formulation is also an essential 
consideration. 
Thiol groups are known to bind to technetium with high affinity. N,S-
Bidentate ligands are particularly attractive as potential technetium and rheniurn 
chelators. They have nitrogen as part of a heterocycle and sulphur donor atom as part 
of the thione or thiol group. There exists continuing interest to study such bidentate 
chelating agents. A wide range of different N,S bidentate and NxS4-x tetradentate 
chelating agents have been synthesised over the past years and tested for their 
capacity to complex technetium (Volkert and Jurisson, 1996). 
" The most stable arrangement of nucleons within nucleus is called the ground state. 
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Reports on compounds containing a 2-pyrrolylthione moiety have appeared in 
the literature (Murase et al., 1991; Kost et al., 1974, Sato and Sunagawa, 1967). 
However, their potential chelating ability was never addressed. 
It bas been reported that 2,2'-dipyrrolylthione forms a complex with mercuric 
chloride (Clezy and Smythe, 1969), although no structures or characteristics of such 
complexes were provided. 
Recently it bas been reported that unsubstituted 2,2'-dipyrrolylthione was used 
as starting material for the synthesis of 5, l 5-diphenylporphyrin via the Raney-Nickel 
induced hydrodesulphurisation, thereby obtaining 2,2'-dipyrrolylmethane - a key 
intermediate in porphyrin synthesis (Brückner et al., 1998). The anticipated 
hydrodesulphurisation, however, did not occur. Instead of the expected product, a 
Ni(Il)-2-pyrrolylthione complex was isolated from the reaction. This finding 
prompted a close look at 2-pyrrolylthiones as N,S-donor chelating agents for 
transition metals. Description of the Ni(II), Co(ll), and Hg(II) complexes with 
unsubstituted 2,2'-dipyrrolylthione can be found in literature (Brückner et al., 2000). 
Thus, the use of 2-pyrrolylthiones (Figure 26) was suggested as potential 
ligands for transition metals, including technetium and rhenium. First of all, they 
contain N,S donor atoms, the combination of which can be found in bis-bidentate or 
tetradentate ligands. The photochemical and 
spectroscopie properties of the thione group can be 
advantageous for biological applications. Finally, 
there are many possibilities to modify the periphery 
of pyrrolylthiones, which may be useful to study the 
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Figure 26. General formula 
for 2-pyrrolylthiones 
biological behaviour of the ligand and its metal complexes as a function of different 
substituents. 
2-Pyrrolylthiones represent a rather unknown class of compounds. There are 
few groups that have studied pyrrolylthiones and reported on their physical and 
chemical properties. Previous studies (Clezy and Smythe, 1969; Bruchner et al., 
2000) were performed using 2,2'-dipyrrolylthiones, which can be considered as a 
particular example of 2-pyrrolylthiones, where two usually symmetric pyrroles are 
bound together via a thione group. 
Few methods of 2,2'-dipyrrolythione synthesis are described in the literature. 
The most convenient synthetic pathway to prepare 2,2'-dipyrrolylthiones proceeds 
through the reaction of initially substituted or unsubstituted pyrrole molecules with 
thiophosgene (Clezy and Smythe, 1969). The 2-position of the pyrroles must be free 
to allow for the interaction with thiophosgene. The optimal conditions for the 
reaction depend primarily on the nature of the substituents in the pyrrole molecule. 
Although it seems plausible to use pyrrolic Grignard derivatives for 
''coupling"-type syntheses of 2-pyrrolylthiones, the experiments with such activated 
pyrrolic compounds lead to no avail. The possible formation of a tripyrrolic 
substance was reported in such reactions (Clezy and Smythe, 1969) due to the high 
electron-acceptor activity of the thione group, which affects the basicity of the 
pyrrolic nitrogen. It is worth noting that analogous compounds are never formed in 
the reaction of comparable pyrroles with phosgene (Clezy and Nichol, 1965; 
Ballantine et al., 1966). To avoid the formation of tripyrrolic compounds, it is 
suggested to carry out the reaction directly from pyrrole. 
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Sorne 2-pyrrolylthiones and dipyrrolylthiones can be obtained from their 
ketone analogues by converting the carbonyl group into the thiocarbonyl moiety. 
This reaction would be possible using sulphuration agents such as tetraphosphorus 
Figure 2 7. 2,4-bis( 4-methoxyphenyl)- l ,3-dithia-
2,4-diphosphetane-2,4-disulphide 
3.1. Synthesis of 2-pyrrolylthiones 
decasulphide (Scheeren et al., 
1973) or milder Lawesson's 
reagent (Figure 21) (Shabana et 
al., 1981). 
The parent unsubstituted or substituted 2-pyrrolylketones la-c served as the 
precursors for the synthesis of lipophilic 2-pyrrolylthiones. 2-Pyrrolylketone la is 
commercially available and was used as received. Compounds lb,c were obtained 
using the method suggested in the literature (Pesson et al., 1966) from the appropriate 
pyrrole activated as its Grignard derivative (Scheme 1). 







a: R1=R1=R3=H, R= -C,,Jls 
b: R1=R1=R3=H, R= -C,,J/4(0CH3) 
c: R1=R2=R3=H, R= -C,,J/3(0CH3)? 
Subsequently, compounds 1 were converted into the corespondent thiones 2 
(Scheme 2). Conversion of the carbonyl group into the thione group was achieved by 
treatment with Lawesson's reagent. 1,2-Dimethoxyethane is the solvent of choice for 
this process. The reaction must be conducted under a nitrogen atmosphere and 
shielded from light. The reaction is complete in 1-12 hours. The final compound was 
extracted from the reaction mixture with chloroform and washed with water. The 
yields are good (45-50%). 
Altematively, the conversion of carbonyl groups into the thiocarbonyl 
moieties was accomplished with P.iS10 (Scheme 2) using a slightly modified method 
described in the literature (Lumbroso and Liégeois, 1984; Bruckner, 1993). Benzene 
was used as a solvent. In this case, the reaction was complete in 40 minutes. 
Unreacted P.iS10 was separated from the reaction mixture by filtration. We prefer to 
use P.iS10 as a sulphuration agent for 2-pyrrolylketones because of its better 
availability, high reactivity, easy work-up of reaction mixtures, and very good yields 
of desired 2-pyrrolylthiones (up to 65 %). 
Final products were purified using column chromatography to give compound 




~ a: R1=R2=R3=H, R= -CJ/s 
b: R1=R2=R3=H, R= -CJ[,(OCH3) 
c: R1=R2=R3=H, R= -CJ/3(0CH3)? 
Scheme 2. Conversion of2-pyrrolylketones into 2-pyrrolylthiones 
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2b as a bright red crystalline solid and 2c as red oil, which subsequently crystallised. 
Compound 2a has been described in the literature (Lumbroso and Liégeois, 1984) as 
oil, but repeated purification by column chromatography gave a dark red crystalline 
solid with low melting point (33-36°C). 
Thione 2d was prepared as suggested in the literature (Clezy et al., 1974) with 
good yield (55%). This route can be used to obtain other dipyrrolylthiones of 
symmetric structure (Scheme 3). 
Synthesised 2-pyrrolylthiones 2 are quite stable in solid state but oxidise fairly 
easily in solution, particularly when exposed to light. 
Because solubility in water could change the physical, chemical and 





Scheme J. Synthesis of the symmetric dipyrrolylthiones 
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analogues of the lipophilic compounds were also prepared. A simple method to 
change the lipophilicity of the compounds is through the addition of one or more 
hydrophilic substituents to the pyrrolic ring, for example via sulphonation. Several 
sulphonating agents exist and are used in chemical synthesis (Fieser and Fieser, 
1967). 
The sulphonation of 2-pyrrolylthiones using pyridine-sulphur trioxide was not 
successful after reaction time of 24 hours. This signifies that pyridine-sulphur 
trioxide is too mild a reagent for these compounds. In contrast, the sulphonation of 
all compounds 2a-d goes smoothly with 1,4-dioxane-sulphur trioxide as a 
sulphonating agent (Scheme 4). Electrophilic substitution takes place in 4-position of 
aromatic pyrrolic ring resulting in a sulphonated compound. 
a: R1=R3=H, R= -C<lfs 
b: R1=R3=H, R= -C,,H~(OCH3) 
c: R1=R3=H, R= -C,,Ff3(0CH3)i 
d: R1=R3=H, R= -CP2(S03'{a)NH 
d': R1=R3=H, R= -CP3'VH 
Scheme 4. Sulphonation of2-pyrrolylthiones 
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Ja-d' 
1,4-Dioxane-sulphur trioxide was synthesised using a literature method 
(Bordwell and Rondestvedt, 1950). Sorne difficulties were encountered during 
product separation. In our bands, filtration of the product at first was not successful. 
Although we observed large quantity of the precipitate before filtration, most of the 
precipitate was re-dissolved during the washing step. Reducing the volume of the 
reaction mixture under vacuum resulted in more stable white precipitate, which was 
easily collected by filtration. A yield of 89% of the theoretically possible quantity 
was achieved by repeating this procedure (evaporating-filtration) several times. 1,4-
Dioxane-sulphur trioxide is very unstable under atmospheric conditions and is easily 
hydrolysed in water. Nevertheless, it can be stored in tightly closed vials sealed with 
Parafilm in the freezer for at least two years. This compound was further used for 
sulphonation of 2-pyrrolylthiones. 
A large excess of sulphonating agent (sometimes up to four equivalents) is 
required when 1,4-dioxane-sulphur trioxide is pre-dissolved in 1,4-dioxane for further 
use. We found that sulphonation is more efficient when a two-fold excess of 1,4-
dioxane-sulphur trioxide is added gradually as a solid to a substrate dissolved in 1,4-
dioxane. The reaction takes place at room temperature in an inert atmosphere and is 
usually complete in 10 min. Nitrogen atmosphere is crucial to prevent the hydrolysis 
of 1,4-dioxane-sulphur trioxide and to inhibit the oxidation of 2-pyrrolylthiones. 
Progress of the reaction is obvious from the colour change, which occurs when the 
sulphonating agent is added. The reaction mixture becomes yellowish-red and looks 
thicker, like oil, which can be due to increasing of density and/or liquid surface 
tension. Completion of the reaction was monitored using TLC. The parent thiones 
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move on silica-gel plates in chlorofonn, white water-soluble compounds remain at the 
origin. Sulphonated ligands migrate in methanol almost with the front of the sol vent. 
The reaction was terminated, when there was no initial pyrrolylthione detected in the 
reaction mixture. There was still a little amount left of the initial dipyrrolylthione 2d, 
but an addition ofnew portions of the sulphonating agent, increasing the reaction time 
or heating up to 60°C did not improve the yield. 
After the reaction was complete the solvent was evaporated and the product 
was re-dissolved in water. Aqueous solutions of sulpho-2-pyrrolylthiones are very 
acidic with pH less than 1. Acidity of these mixtures was adjusted using 0.1 N 
aqueous NaOH to the pH values shown in Table 1. It is essential to conduct 
neutralisation carefully, avoiding rapid pH shift into basic conditions past the titration 
point. Otherwise, at pH ~ 8 pyrrolylthione solution changes its colour rapidly from 
red to brown, which probably reflects product transformation in basic medium. This 
color change is reversible: once a weak acid solution is added to the mixture to move 
equilibrium to acidic conditions, the mixture becomes red again. No further 
observations were made to find out if this color shift is permanent or the reversion 
will become impossible with time. Thus, it is important to keep acidity of a 
sulphonated 2-pyrrolylthione solution below pH 5. 
Table J. The final pH of the 2-pyrrolylthiones' 
solution after neutralisation 
2a 2b 2c 2d 
pH 4.6 4.6 4.3 3.6 
Next, sulphonation by-
products and other impurities were 
precipitated from aqueous solutions 
by adding acetone. Acetone was 
added gradually until a white 
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precipitate appears. A light brown precipitate was observed only in the case of 
dipyrrolylthione 2d. The volume of the added acetone was roughly equal to 4 
volumes of the initial solution. The red supematant obtained after centrifugation was 
stripped of solvent to give the water-soluble 2-pyrrolylthiones. 
Each of 2-pyrrolylthiones 2a-c yielded a single main product of sulphonation. 
Purification of these compounds was straightforward. Reversed-phase column 
chromatography with water as eluent gave pure sulphonated 2-pyrrolylthiones Ja-c in 
good yields (40-56 %). There are some side products fonned during the synthesis of 
Jb,c, which are perhaps disulphonated analogues or 5-substituted isomers, but their 
yields are too low to perform routine analyses. Separation of the main component 
from the by-products is easily accomplished on reversed-phas~ (C1s or Phenyl) silica 
gel due to considerably different chromatographie mobilities of these compounds. 
Two reaction products were recovered when 2,2'-dipyrrolylthione 2d was 
used as a substrate. They were identified as di- and monosulphonated 2,2'-
dipyrrolylthiones 3d and Jd', respectively. The major product is disulphonated 
compound Jd, which was obtained in 43% yield. The quantity of separated 
monosulphonated 2,2'-dipyrrolylthione Jd' was much lower (12% yield) but 
sufficient to allow for chemical analyses and syntheses of Tc complexes. The 
retention time of these products differ significantly, allowing for separation hy 
reversed-phase chromatography. Dried samples of the synthesised water-soluble 
sulpho-2-pyrrolylthiones were used to study their physical and chemical properties. 
Ail synthesised sulphonated compounds Ja-d' are hrightly coloured in various 
shades of red. They are highly soluble in water and decompose at high temperature 
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without melting. Synthesised sulpho-2-pyrrolylthiones are strong acids. Because 
sodium hydroxide bas been used to neutralise them during purification, the final 
products were obtained as sodium salts. Elemental analyses, NMR spectroscopy and 
crystallographic data suggest that all synthesised compounds were recovered as 
hydrates with one to three molecules of water retained in the ligand structure. 
3.2. Analysis of the spectroscopie data 
The tautomeric nature of the dipyrrolylthiones has been discussed previously 
(Clezy and Smythe, 1969). 2-Pyrrolylthiones preserve the same tautomeric structure 
(Scheme 5). The IR spectra of the synthesised lipophilic compounds recorded in 
chloroform show characteristic weak SH absorption near 2550 cm·1, corresponding to 
the structure of the thiol isomer 2' (Silversten et al., 1991; Dyer, 1970). However, 
these pyrrolylthiones have a maximum of medium intensity, which is assigned to the 
C=S stretching frequency (1250-1020 cm-1) (Silversten et al., 1991). The thione 
group is less polar than the ketone group and has a considerably weaker bond. As a 
consequence, the band is not intense and appears at lower frequencies, where it is 
Sclleme 5. Tautomeric structures of2-pyrrolylthiones 
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much more susceptible to coupling effects. Therefore, identification presents a 
challenge. A medium-intensity absorption of C=S group occurs at the same region as 
C-0 and C-N stretching, which suggests that considerable intramolecular interaction 
may occur between these vibrations. The IR spectra of the water-soluble 2-
pyrrolylthiones 3 were recorded in KBr pellets. No absorption was found around 
2550 cm·1• However, a high intensity maximum is present around 1210-1212 cm·1, 
which is assigned to the thione structure. Therefore, it is likely that the ligands in 
solid state exist mainly in the thione form with minor contributions of the other 
tautomer. The dynamic tautomeric thione-thiol transition exists in solution. 
Lipophilic 2-pyrrolylthiones 2 have characteristic UV-visible spectra with 
intensive absorption around 376-406 nm, attributable to intraligand 7t-7t ·transitions, 
that can be used for their quantitative detection. UV-visible spectrum of the novel 
sulpho-2-pyrrolylthiones 3 is similar in shape to that of compounds 2. The very 
strong absorption of 3 at 375-397 nm is somewhat red-shifted as compared to the 
lipophilic analogues. The extinction coefficients are high (lg & > 4) and close to the 
extinction coefficients of lipophilic compounds. In general, the extinction 
Table 2. Extinction coefficients & for the synthesised 2-pyrrolylthiones (À.max, nm (lg &)) 
a 
Compounds 2 392 (4.26) 













coefficients of the water-soluble 2-pyrrolylthiones are slightly higher than those of 
the lipophilic compounds with the exception of the dipyrrolylthiones 3d,d' (Table 2). 
These data are in agreement with a comparable study of 2-pyrrolylketones, wherein 
the peak position was observed to be a function of substituents in the pyrrolic ring 
(Ballantine, 1966). 
Nuclear Magnetic Resonance (NMR) spectra of the 2-pyrrolylthiones show 
pyrrolic and aromatic CH protons at 6.5-8 ppm, which is in good agreement with 
published data for pyrrolic and aromatic compounds in general (Silversten et al., 
1991). The pyrrolic NH proton was observed around 9.8 ppm for lipophilic 
compounds as a single broad peak. This data is in good accordance with 
experimental results for other 2-pyrrolylthione containing compounds. (Lumbroso 
and Liégeois, 1984; Murase et al., 1991) A broad peak of the same shape was found 
at 11. 7 ppm for hydrophilic ligands, which was also assigned to the NH proton. The 
shift of almost 2 ppm can be explained by intramolecular hydrogen bonding between 
the NH proton and sulpho-substituent. This proton would have a resonance peak 
corresponding to the strong acidic nature of the sulpho-group, which is even more 
shifted towards high frequency than for pyrrolic NH proton. lt is known that 
sulphonic acids show a peak around 10-12 ppm (Silversten et al., 1991). Correlated 
spectroscopy5 (COSY) and Nuclear Overhauser Effect spectroscopy6 (20 and 
selected lD NOESY) were performed to prove the position of the sulpho-group in the 
5 COSY is useful to determine existence of neigbbouring protons in pyrrolic ring. A COSY spectrum 
yields througb bond correlations via spin-spin coupling. 
6 NOESY helps to determine protons, which are close in space but not closely connected by chemical 
bonds. A NOESY spectrum yields through space correlations via dipole-dipole coupling known as 
Nuclear Overhauser Effect {NOE). 
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pyrrolic ring of the sulphonated 2-pyrrolylthiones. Systematic study of the spectra 
con.finns that two protons in the substituted pyrrolic ring cannot be adjacent, which 
can be taken as affirmative of the sulpho-group to be positioned at forth carbon in 
pyrrolic ring. 
The results of other analytical methods must be considered to identify the 
chemical structure of synthesised 2-pyrrolylthiones, since little is known about NMR 
spectra for this class of compounds. 
3.3. Crystallographic study 
Single crystal X-ray diffraction studies were performed for selected ligands. 
Crystal data and selected experimental details are listed in Table 3. The complete 
results including selected bond lengths and angles are collected in Supporting data 
(Part 2). 
3,4-Dimethoxyphenyl-2-pyrrolylketone le is a new compound, which was 
not described previously. An X-ray diffraction study was perfonned for le to 
establish its structure. A pale grey-green block crystal with dimensions of 
0.76x0.36x0.21 mm was grown by slow evaporation of the solvent (chlorofonn). 
The resolved structure is the expected pure ketone (Figure 28). The bond lengths 
around the carbonyl Cl-C2 and Cl-C7 are l.453(4) A and 1.479(4) A, respectively. 
The length of 01-Cl bond is somewhat shorter (1.231(3) À), which is due to its 
double order. The pyrrolic part of the molecule is found to be in plane with the 
carbonyl group with a deviation not exceeding 7°. The C7-C10 axis of the phenolic 
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ring is lying in the same plane, 
while the phenolic ring itself 
is found to be at an angle of 
ca. 36. 7° to the plane. The 
torsion angle 010-C 10-C 11-
011 is 0.3°. The two 
methoxy-groups are at a 
trans-position with respect to 
each other. The methoxy-
group, which is cis to the 
carbonyl, is almost in the 
phenyl ring plane with a 
deviation of only 2.4°, while 
another one rises from the 
plane at 10.1°. The pyrrolic 
NH hydrogen binds to the 
carbonyl oxygen of another 
C13 
Figure 28. ORTEP drawing and numbering scheme 
for 3,4-dimethoxyphenyl-2-pyrrolylketone le 
SI 
Figure 29. ORTEP drawing and numbering scheme for 
p-methoxyphenyl-2-pyrrolylthione 2b 
molecule forming relatively weak hydrogen bonds of2.37 A. 
The single crystal X-ray diffraction study of compound 2b results in a thione 
structure, with the C=S bond readily visualised (Figure 19). Monoclinic crystals of 
2b with P21/c space group are forrned via the pyrrolic hydrogen-sulphur bonds. 
Overall the crystal structure is similar to the one above of the ketone. The 
thiocarbonyl Sl=Cl bondis longer than the analogous carbonyl Ol=Cl bond of le 
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Table J. Crystal dara for selected ligands. 
Compound le 2b 3b 
Form Block Block Block 
Colour Pale grey-green Darkred Intense violet-pink 
Dimensions (mm) 0.76x0.36x0.21 0.58x0.52x0.18 0.57x0.53x0.27 
Empirical formula C1;l/uN03 C12H11NOS Cr2H1~a01S2 
Molecular weigbt 231.244 217.278 373.368 
Crystal system Ortborbombic Monoclinic Orthorbombic 
Space group Pca2 1 P21/c Pnma 
a(Â) 18.972(8) 11.8386(1) 6.763(3) 
b (À) 9.065(3) 11.9453(1) 7.540(6) 
c (À) 6.867(2) 7.5061(1) 31.641(15} 
/J(o) 98.676(1) 
V(À3) 1181.0(7) 1049.33(2) 1613.5(15) 
z 4 4 4 
Dcak. (Mg/m3} 1.3006 1.3753 1.5370 
µ(mm-1) 0.766 2.490 3.587 
Extinction coefficient 0.0205(19) 0.0275(19) 0.0146(12) 
~ (Rwb) 0.0616 (0.1485) 0.0402 (0.1118) 0.0286 (0.0817) 
.. R = tllFol - IF,11 / tlFol; b R.., = [~[ w(Fo 2 - F, 2)2] / t[ w(Fo 2) 2]] l/2 
as expected due to the larger sulphur atom radii as compared to oxygen. The double-
bond S l =C 1 has a length of 1.6686(15) A, which is more than the single bonds 
Cl-C2 and Cl-C7 that are 1.426(2) A and 1.4782(19) A, respectively. This is in 
good agreement with crystal data reported for 2,2'-dipyrrolylthione containing 
complexes (Bruckner et al., 2000). 
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A block crystal of intense violet-pink colour with dimensions of 
0.57x0.53x0.27 mm was used to collect the data for compound 3b (Suppot1ing data, 
Part 2). lts resolved structure is illustrated in Figure 30. The sulphonated analogue 
3b of the general formula C12H16'VNa01S2 was found to be a sodium sait of the 
ligand, which is logical considering the method of synthesis and purification, and this 
is in good accordance with elemental analyses. The ligand itself bas a negative 
charge of -1. Sodium atoms are accommodated between water molecules forming an 
infinite chain in which each Na+ ion is surrounded by 6 water oxygens, and each 
water molecule is bridging two 
Na+ ions. In the lattice, the 
motive shown (see picture in 
Supporting Data, page S44) is 
repeated indefinitely in both 
directions. This chain is an 
associated cation disordered 
between negative ligand 
molecules. The angles around 
the thione carbon are almost 
perfect: 119.79(17)0 , 
120.42(17)0 , and 119.78(15)0 • 
The pyrrolic ring is lying in the 
same plane as the thiocarbonyl 
group while the phenolic ring is 
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Figure JO. ORTEP drawing and numbering scheme for 
p-methoxyphenyl-4-sulpho-2-pyrrolylthione Jb. The 
associated cation omitted for clarity. 
51 
rotated around the Cl-C7 axis with a deviation of about 35-40° from the plane. 
This rotation takes part in the crystal formation. lt is of interest to note that 
the main planes of the two disordered molecules remain roughly parallel, whereas the 
phenolic rings adopt an orientation of -70° apart (Figure 30). The methoxy-group is 
not linear and is bent at 122.08( 19)0 , which is normal for sp2 hybridisation. The 
sulpho-group has tetrahedron configuration with angles of ca. 112°. The pyrrolic 
nitrogen is protonated and participates in hydrogen bonding of the system. 
This case is a good demonstration of the fact, that X-ray diffraction data alone 
cannot identify unequivocally position of the sulpho-group in the pyrrolic ring. 
Aromatic nature of the structure together with similarity of carbon and nitrogen atoms 
for the technique might suggest forth position as well as fifth. Consideration ofNMR 
studies results is very important to establish true structure of the sulphonated 2-
pyrrolylthiones. 
3.4. Reactions with small transition metals ions 
Compounds 2 and 3 are potential ligands for transition metals, including such 
large ions as Tc and Re. The presence of N,S donor atoms in their molecular structure 
should facilitate formation of ligand-to-metal bonds. A series of screening 
experiments were performed to evaluate the potential of the sulphonated 2-
pyrrolylthiones as chelators in neutral medium. To accomplish this, a range of 
transition metal complexes with ail synthesised water-soluble compounds 3 was 
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prepared. 
Cadmium (Cd), cobalt (Co), copper (Cu), nickel (Ni), and zinc (Zn) were 
selected and their complexes with ligands 3a-d were successfully synthesised 
(Scheme 6). Reactions were performed in neutral medium to mimic synthetic 
conditions for 99mTc. Formation of complexes was complete in a few minutes after 
simply adding the ligand solution to the previously dissolved metal sait. 
Meta! acetates and metal chlorides were used for reactions. The reaction with 
the acetates occurs rapidly, which is not the case for the chloride salts. The yields are 
also significantly higher for complexes made from the acetate salts. This can be 
explained by the difference in dissociation constants (pKa) between hydrogen 
chloride and acetic acid (-2.2 and 4. 7 respectively). 
Either water or methanol was used as a solvent for complexation reactions. In 
some instances, we obtained the complexes as precipitates (for example, Ni and Cu 
complexes with 3a in aqueous solution). In other cases, we had to monitor the course 
of the reaction using spectrophotometry. 
Ali 2-pyrrolylthiones display a characteristic absorption in the UV-visible 
spectrum around 380 nm. These peaks became broader and progressively shifted 
toward higher wavelengths upon addition of metal salts to the ligand solutions. The 
shape and the peak maximum depend on several factors, including valency and 
oxidation state of the central metal ion, as well as geometric structure of the complex. 
The results agree with experimental data obtained earlier for 2,2'-dipyrrolylthione 
complexes (Bruckner et al., 2000). 
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The resulting complexes were purified by either, normal or reversed-phase 
chromatography, or by using both methods if the sample was not pure enough after 
the first run. The purified compounds were characterised using spectroscopie 
methods and elemental analyses. 
NMR spectra of the water-soluble complexes are in good agreement with 
those of the ligands themselves. Aromatic and pyrrolic CH protons can be seen 
where expected white acidic proton disappears from 11. 7 ppm, which serves as an 
additional confirmation of the complex formation. Curiously, two peaks still appear 
at 11.86 and 11.99 ppm for Cd complex with ligand Ja. The ligand itself shows the 
only peak in this region at 11.81 ppm. Similar situation exists for Cu complex with 
the same ligand Ja: this complex has a peak at 11.92 ppm. We suggest that these 
signais arise not from unprotonated NH pyrrolic group but rather from acidic -SOJf[ 
protons. We believe that Na+ ions were substituted for Et' in the aqueous solution of 
the reaction mixture and the resulting compound is not a sodium sait anymore but a 
sulphonic acid or a mixture ofboth. 
NMR data collected for Co and Cu complexes do not give good spectra. This 
NaS~03 








~ ~ R 
R1 I 
s n 
4,5,6, 7 ,8a-d 
Scheme 6. Reaction of 2-pyrrolylthiones with transition metals. M =Cd (4a-d), Co (5a-d), 
Cu (6a-d), Ni (7a-d), Zn (8a-d); n=l,2. 
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could be an indicative oftheir +2 oxidation states, which are paramagnetic. Bruckner 
describes formation of Co(ill) complex with unsubstituted dipyrrolylthione 2d in 
basic conditions starting from Co(II) acetate (Bruckner et al., 2000) explaining this 
transformation as oxidation of Co(ll) by aerial oxygen during reaction. Nevertheless, 
we strongly support the idea that Co(ll) complexes were formed with ligands 3a-d. 
The reaction conditions in these experiments are very diff erent from those described 
in reference above. First, the complexation was performed in neutral medium. 
Secondly, reaction time is only few minutes in case of the ligands 3a-d, comparing to 
12 hours cited in the paper mentioned. 
Consistent elemental data for every complex was impossible to obtain. This 
can be due to high sait formation and/or formation of complexes as mixtures that 
cannot be separated. The elemental analyses that were successful show formation of 
1: 1 or 1 :2 complexes. Mass-spectra of these compounds exhibit peaks with the 
corresponding mlz ratio. Interestingly, mass spectrum of some complexes (i.e. Sb, 
6b) exhibit 1 :2 peaks even if their elemental analysis shows formation of 1: 1 
compounds. This cannot be explained until additional analyses are performed, for 
exarnple, X-ray crystallography. 
Ali the sulpho-pyrrolylthione complexes are forrned in aqueous solutions. 
Our data suggest that water, along with methanol (if used), is always present in the 
coordination spheres of sulphonated complexes, filling up the space that would 
otherwise be taken (or not taken) by a second pyrrolylthione. This rnight explain why 
we have obtained sulphonated nickel complexes 7a-d with a ratio of metal:ligand 1: 1, 
as opposed to 1:2 in case oflipophilic nickel 2,2'-dipyrrolylthionates (Bruckner et al., 
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2000). 
We believe that sulpho-group does not participate in complex formation. This 
suggestion came from observation that sulpho-group does not undergo changes in its 
structure: if starting ligand was used as a sodium sait (Ja-d), the resulting complex 
will be most likely a sodium sait also (complexes 4-8a,b,d; 7c), if starting ligand was 
in a sulphonic acid fonn (Je), the resulting complex will be also a sulphonic acid 
(complexes 4-6,8c). Thus, one can consider sulphonated 2-pyrrolylthiones Ja-d as 
monoanionic ligands in regards to transition metals at described conditions. 
Although exact structures of the synthesised metal complexes cannot be 
established unequivocally from the provided limited picture, we found that most of 
the fonned complexes have a ratio metal:ligand 1: 1 with a few exeptions, where 1 :2 
ratio can be suggested (Table./). Defining the general reactivity for each metal ion 
and establishing complete structures of the resulting metal complexes is a separate 
subject and was beyond the scope ofthis study. 
Table 4. Suggested metal-to-ligand ratio in synthesised transition metal complexes 
Cd Co Cu Ni Zn 
Ja 1:2 1:1 1:1 1:1 1:1 
Jb 1:1 1:1 1:1 1:1 1:1 
Je 1:1 1:2 1:1 1:1 1:1 
Jd 1:2 1:2 1:1 1:1 1:2 
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3.5. Reactions with technetium and rhenium 
The metastable 99mTc-compounds could only be synthesised in solutions in 
minute concentrations (-10-9 M). It makes establishing the structure of these 
compounds by direct methods difficult. We have to assume that such complexes have 
the same chemical structure as their more stable 998Tc (or stable Re) analogues despite 
the fact that a ligand is added to the reduced 99mTc0-1 - in great excess. One way to 
establish the identity of new 99mTc-complexes is to compare their chromatographie 
properties with those of 99Tc-analogues. 
In order to gather structural information on the technetium complexes, we 
obtained various 99Tc and Re analogues with lipophilic and hydrophilic ligands on a 
macroscopic scale. 
The general procedure that was developed for the reaction of 2-
pyrrolylthiones 2,3 with Tc04 - and Re04 - in aqueous ethanol or water solution 
involved the use of a reducing agent in the form of a saturated solution of stannous 
chloride SnC/2 in O. IN aqueous HCI. The formation of oxo- and hydroxy-metal 
polymers as side products may occur, particularly in the case of Re, due to relative 
difficulty to reduce Tc(VII) and Re(VII) to lower oxidation states and easy acidic 
hydrolysis of the respective moieties. 
We explored another reduction method, wherein formamidine sulphinic acid 
(FSA) was used as a reducing agent (Fritzberg et al., 1977). This procedure was 
examined for the reduction of the perrhenate ion in a neutral solution. However, 
treatment of the perrhenate at 60°C for 24 h with FSA did not result in the reduction 
of Re04-, which was probably due to the low reduction capability of FSA. 
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Accordingly, SnC/i was retained in this study to reduce technetium and rhenium ions. 
Reduced pertechnetate and perrhenate react smoothly with ligands 2 fonning 
l :2 stable, soluble complexes 9,10 with very few side products (Scheme 7, 1). The 
yields are good and vary from 40% to 90% of the theoretically expected quantities. 
The complexation reaction is complete in half an hour for Tc complexes but can take 
up to 24 hours for Re compounds. In most cases the reaction mixture was heated to 
60°C, but reactions will also proceed at room temperature. The reaction was carried 
out in a nitrogen atmosphere to inhibit hydrolysis and aerial oxidation to unwanted 
species, which is particularly important for rhenium complexes. The colour of the 
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Scheme 7. Syntbesis of technetium and rhenium complexes 
a: Ri = R3 = H, R = -CJls 
b: Ri= R3 = H, R = -CJ{.(OCH3) 
c: R1 = R3 ""'. H, R = -CJ[3(0CH3)i 
d: Ri= R3 = H, R = -C.Jl2(S03Na)NH 




9: Rl = H, M = 99Tc, X= -OC2Hs 
10: Rl = H, M = Re, X= -OC2Hs 
11: Rl= S03Na, M = 99Tc, X =-OH 
12: Rl = S03Na, M =Re, X= -OH 
reagents. The degree of complexation was monitored using TLC on silica gel. The 
orange-yellow spots of unreacted lipophilic ligands move in chlorofonn near to the 
solvent front. Brown-coloured lipophilic complexes move in methanol white the 
polymers and reduced metal oxides always remain at the origin of the chromatogram. 
Synthesised lipophilic 99 Tc (9a-d) and Re (lOa-d) compounds were isolated 
and characterised in tenns of their identity and purity. Ali complexes were purified 
by suitable methods such as normal phase chromatography, re-precipitation from 
organic solvents, etc. Sometimes a combination of these methods was used to 
achieve an adequate degree of purification. The complexes are brown crystalline 
solids. Rhenium complexes decompose at high temperature without melting. Ali 
complexes are soluble at different degree in organic solvents such as chloroform, 
ethyl acetate, acetone, and ethanol. 
99Tc complexes with 2-sulphopyrrolylthiones 3 were prepared by mixing three 
components of the reaction. Stannous chloride was the reducing agent of choice. 
Reactions were carried out in water (Scheme 7, Il). Reduced pertechnetate reacted 
fairly smoothly with ail ligands to form stable complexes 11. The complexation was 
complete in 15 minutes at 60°C. The course of the reaction was followed using TLC 
on normal and reversed-phase silica gel. Purification by either normal or reversed-
phase chromatography gave 99Tc complexes in good yields (75-95%). A few side 
products were detected in quantities not sufficient for their characterisation. 
Compounds 1 la-c were purified using normal phase chromatography with methanol 
as an eluent. The one step purification is easy and effective. Compounds 1 ld,d' are 
considerably less soluble in organic solvents but they are highly soluble in water. 
59 
These two crude products were purified using reversed-phase chromatography with 
water and methanol as eluents. 
Optimal reaction conditions for the complexation (such as solvent, 
temperature and time of reaction) were found for each system "chelating agent -
metal ion". 
We attempted to obtain Re complexes with ligands 3 using either FSA or 
SnC/z to reduce the perrhenate. FSA was found to be inactive, white SnC/z reduces 
the perrhenate quite effectively. No immediate changes were observed after mixing 
the initial reactants at room temperature in inert atmosphere. A brown precipitate 
starts to appear after heating at 60°C for 15 minutes. The precipitate was separated 
by centrifugation and washed with water giving products 12 with low yields varying 
from 12 to 25%. The product does not dissolve well in methanol and other organic 
solvents, which makes chromatographie purification and spectroscopie analyses in 
solution problematic. Ail attempts to purify the material on a reversed-phase column 
failed. TLC analysis ofboth precipitate and supematant suggests that the compound, 
which forrns the precipitate, is still present in the soluble fraction. Further 
purification of the product isolated from the supematant was unsuccessful. lt is 
unclear why the yields of the reactions are so low (as compared to the S)nthesis of the 
99Tc complexes) and why Re complexes are almost insoluble in water. This could be 
due to the formation of non-stoichiometric compounds or polymers with possible 
participation of tin ions. Another possibility is that the sulpho-group at 4-pyrrolic 
position is lost during complexation, which would lead to final products similar to 
lipophilic compounds 10. It remains unclear why such de-sulphonation might occur 
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in this case; steric interference could be one of the causes. Nevertheless, it is obvious 
that the behaviour of rhenium is completely different from that of technetium in 
reactions with sulphonated compounds J. 
We suggest that the metal binding of these new Tc and Re complexes occurs 
at the pyrrolic nitrogen and the sulphur, leaving a pendant uncoordinated pyrrolic 
(ligands 2d;Jd,d') or phenolic (ligands 2a-c;Ja-c) ring. We have shown that the 
periphery of the ring can be modified to change the solubility of the subsequent Tc 
and Re complexes, white the central metal core remains the same. 
Ali synthesised complexes were characterised by mass- and UV-visible 
spectroscopy, 1 H NMR, and 13C NMR. Elemental analyses were performed when 
possible (i.e. for non-radioactive rhenium compounds). 
The mass spectrum (SIMS, thioglycerol as matrix) of some water-soluble Tc 
complexes (for exarnple llc,d,d') did not contain the molecular ion peak but rather 
signais of the ligand. Similar problems with mass-spectroscopy for Tc complexes 
have been reported earlier (Schoster and Zeisler, 1997). 
The UV-visible spectra of the 99Tc and Re complexes show a broad peak 
approximately at 430 nm, which is indicative of complex formation. Two minor 
bands are present for some complexes (e.g. 9b, lOd, 12c), which can be found at 509 
nm and 628-696 nm and correspond to mono- and diprotonated oxo-group 
respectively. Overall, the UV-visible spectra of synthesised compounds differ from 
those of pure ligands. The cbaracteristic peaks of the complexes are shifted towards 
longer wavelengths and are considerably broader. The absence of maxima at 244 and 
289 nm, wbich are characteristic for Tc04-, confirms that the reduction was complete 
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and that other Tc products were formed. 
Elemental analysis and NMR data suggest that synthesised complexes are 
isolated as solvates that have one or two molecules of methanol (or ethanol, 
depending on the solvent used) in the crystal structure. These results are consistent 
with the data discussed above for synthesised small transition metals complexes, 
which also mostly exist as solvates. The 1 H NMR spectra for compounds 9,10,11 a-c 
show no peak at 9-11 ppm, which corresponds to the pyrrolic NH hydrogen. Only 
one NH hydrogen peak should be observed for the metal complexes with 2,2'-
dipyrrolylthione 9,10,lld-d' around 11.8 ppm. This confirms the complex formation 
between metal ion and ligand molecule and its stability in solution. 
Infrared (IR) spectra for Re complexes show strong bands at 900-1000 cm·1, 
which is the range observed generally for oxo-groups (Barraclough et al., 1959; 
Bélanger and Beauchamp, 1997). Interpretation of the spectra and peaks assignement 
are quite difficult in these regions because of high population of various bands, 
including strong absorbtion resulting from bending vibrations of aromatic rings of the 
ligands. Hydrophilic complexes have somewhat different IR spectra in this region 
comparing to lipophilic analogues. In case of sulphonated ligands, the reaction 
conditions could lead to dioxo compounds of the type [Re02(monoanionic ligand)2r, 
which can be distinguished by a strong O=Re=O band at 789-825 cm·1 in their IR 
spectra (Bélanger and Beauchamp, 1996). At general, stretching modes of dioxo 
compounds shift to lower frequency (768-895 cm-1) if comparing to monooxo groups 
(Nugent and Mayer). A strong band should be observed at 956-962 cm·1 for Tc=O 
core (Tisato et al., 1994). 
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A single crystal X-ray diffraction study was performed for the bis-(p-
methoxyphenyl-2-pyrrolylthionato)rhenium lOb. The results show the formation of a 
trinuclear three-layered structure wherein rhenium atoms are connected by oxygen 
bridges forming a [ O=Re-O-Re-O-Re=Ot7 axis and six bidentate ligands are 
coordinated around Re atoms in equatorial planes (Figure 31). Such complex 
structure is uncommon for rhenium. Only two similar examples can be found in the 
literature (Banbery et al., 1990; Carrondo et al., 1980), which also report the 
formation of a trinuclear rhenium complex with O=Re-O-Re-0-Re=O axial 
backbone. The bilayered rhenium complexes with heterocyclic nitrogen-containing 
ligands are described in the literature more often (Bélanger and Beauchamp, 1997; 
Fortin and Beauchamp, 1998; Bélanger and Beauchamp, 1999; Hansen et al., 2000). 
Fractional atomic coordinates from the crystallographic study of 
[Re304(C12H1oNOS)6t1[Re04r1·2CH3CH20H have been deposited with the 
Cambridge Crystallographic Data Center. Selected bond lengths and angles are 
presented in Table 5 ( complete list can also be found in Supporting data, Part 2). The 
structure of the complex is illustrated in Figure 31. 
The complex has an overall positive charge of + l and is associated with an 
anion. We have established that the anion is Re04-. lt seems unlikely that the 
perrhenate ion could have survived in the presence of SnC/i, but it is an ion, which 
does not lend itself to reduction easily even when an excess of the reducing agent is 
present. To our knowledge, a few similar cases, where Re04- acts as a counter-ion to 
a main molecular cation, were described in the literature (Carrondo et al., 1980; 




Figure 31. ORTEP drawing and numbering scbeme for Re complex lOb. Ellipsoids correspond to 
30% probability 
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imagines the [O=Re-O-Re-O-Re=Ot1 backbone as a structure containing three Re(V) 
centres, each ofwhich coordinates two 2-pyrrolylthione ligands forming one covalent 
and one coordination bond with each centre. The coordination around each Re atom 
is octahedral, which is characteristic of cf sp3 hybridisation. Each molecule of the 
complex is also associated with two molecules of ethanol. These data confirm 
previously suggested solvatation 
from the results of NMR 
spectroscopy and elemental 
analyses. 
The complex contains a 
near linear [ O=Re-0-Re-0-
Re=Ot1 core; the central -0-Re-
0- part of the molecule is 
perfectly linear ( 180°) and the 
deviation from the linearity is 
within 2.4° for the terminal parts 
of the structure. Also, the various 
lengths of the Re-0 bonds 
suggest their different orders. 
Thus, the two terminal bonds are 
the shortest with a mean length of 
1.6655(9) A, whereas the bonds 
on the other side of the terminal 





Dimensions (mm) 0.27x0.12x0.04 
Formula weight 2262.556 
Crystal system Monodinic 
Space group C2/c 
a(A) 34.6651(2) 





Deale. (Mg/m3) 1.9274 
µ(mni1) 13.923 
~(R.., ") 0.0619 (0.1710) 
il R = tllFol - IFcll / tlFol; 
b R.., = ~[ w(F/ - F/)2] I t[ w(F/)2]] 112 
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rhenium atoms are the longest with a mean of 2.082(6) A. The lengths of the bonds 
on either side of the central rhenium atom are l.779(6) A. Therefore, the oxygen 
bridges of this structure are asymmetric. These data are similar to those reported for 
other trinuclear Re complexes. (Banbery et al., 1990; Carrondo et al., 1980) 
The ligands of the terminal Re atoms are almost parallel and overlay one over 
another with an inter-planar distance of ca. 7.7 A. Bath ligands at each terminal are 
somewhat pushed from the Re=O bond to the centre of the molecule, thereby fonning 
a kind of umbrella. The deviation is no more than 9.5° from the plane and can be 
attributed to the electronic configuration of the Re=O double bond. This explains the 
fact that the terminal rhenium atoms exhibit distortion from regular octahedral 
geometry. The ligands of the central Re atom are ideally planar, lying almost 
perpendicular to the O=Re-O-Re-0-Re=O axis at an angle of 90.8°. These central 
ligands are in a tra11s-configuration to the tenninal ones. They do not overlay 
terminal ligands exactly but are displaced counter-clockwise by 6°. Such placement 
can be defined as favourable in order to accommodate sterically crowded ligands and 
to stabilise the system. 
An interesting observation can be made from the ORTEP drawings 
(Supporting data, Part 2, page S66-S67). These two pictures represent the same 
molecule, in which the phenolic ring on the top right-hand side is disordered over two 
orientations (Cl47-Cl52 vs. Cl37-Cl42). This is an unusual disorder, which was 
found also in crystals of the ligand molecule Jb (Figure 30). 
A complicated structure of this compound partially explains its mass-
spectrum. For example, the mass-spectrum of bulle compound lOb contains peaks 
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corresponding to the fragments [ReO(ligand)it and [Re02(1igand)2r and can be 
explained as a gain or loss of the bridge oxygen atom. The presence of the peaks with 
masses corresponding to the complexes of type metal-ligand2 and metah-ligan<4 
simultaneously (9c) also become not controversial. They can be considered as parts 
of the large layered structure with a higher molecular mass. The combustion analysis 
data are close enough to those calculated for the mononuclear 1 :2 compound. 
Surnmarising all obtained analytical and spectroscopie data, we could suggest 
that lipophilic Re complexes can be described most likely by the following schematic 
formulae: Re v 0( OC2H5)(monoanionic ligand)2. The crystals of the trimer could then 
be a product resulting from slow hydrolysis to Rev O(OH)(monoanionic ligand)i and 
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following condensation by formation of an oxo bridge. 
We suggest that these results can be extrapolated to the complete family of 
newly synthesised Re complexes lOa-d, since other characteristics of the compounds 
in this series look pretty much similar. Because the chemistry of 99 Tc is close in 
many aspects to that of Re and considering existence of high mass molecular ions in 
mass spectra of Tc complexes (e.g. 9a), similar structures for the 99 Tc complexes 9a-d 
can also be suggested. But this will have to be confirmed eventually using X-ray 
crystallography methods. 
3.6. Labelling with technetium-99m 
The chemistry at the microscopie level differs from the chemistry at the 
macroscopic level. Even when a 99mrc complex is identified using spectroscopie and 
chromatographie methods, the synthetic route and the mechanism of reaction for 
99mTc complexes giving high yield, high radiochemical and chemical purity at the 
trace level, may be different from those for corresponding "cold" 99 Tc complexes. 
Ali ligands 2,3 were successfully labelled with 99mTc-pertechnetate (Scheme 
8). Stannous tartrate Sn(C~406) was selected as a reducing agent. Direct labelling 
was carried out in aqueous ethanol or water solution for lipophilic and hydrophilic 
compounds, respectively. Around 1 mCi of Tc04 - was used for each synthesis, which 
means that Tc04 - was present in solution in nanomolar concentrations. Since the 
ligand to metal ion ratio is significantly higher than in the synthesis of 99Tc 
complexes, the reactions were complete in a few seconds. Crude complexes were 
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purified using normal phase silica gel Seppak cartridges. 
The chemical identities of products were confinned by comparing 
chromatographie mobilities to those of analogous 99Tc compounds. The labelling 
efficiency varied from 78 to 96% (based on chromatographically separated 99mTc 
complexes). 
Resulting water-soluble final products contained free ligand as an impurity. 
Since the latter does not produce any phannacological effect and is not detectable 
during imaging, further purification is not mandatory for biological studies. Such a 
situation is common in the preparation of radiopharmaceuticals for nuclear medicine. 
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Scheme 8. Labelling with 99mTc 
a: Ri= R3 = H, R = -C6"s 
b: R 1 = R3 = H, R = -C6".4(0CH3) 
c: Ri= R3 = H, R = -CJl3(0CH3)i 
d: R 1 = R3 = H, R = -C4H2(S03Na)NH 
d':Ri = R3 = H, R = -C,.H3NH 
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2,13: Ri=H 
3,14: Ri= -S03Na 
13: X= -OC2Hs 
14: X=-OH 
The radiochemical purity of synthesised compounds was detennined using 
thin layer chromatography (TLC) on commercially available paper strips impregnated 
with silica gel. In order to do this, we followed standard procedures available in 
nuclear medicine, which are used for quality control of technetium 
radiopharmaceuticals. Thereby, the absence of free pertechnetate and the reduced but 
uncomplexed technetium in preparation used for injection was assured. The 
radiochemical purity of the complexes exceeded 90% in all cases. 
3. 7. Biodistribution and pharmacokinetic studies 
Water-soluble compounds were prepared for injection in physiological saline 
solution, while lipophilic compounds were fonnulated using a water-based emulsion 
containing Cremophor-EL and propanol. The radioactive concentrations of these 
final solutions were adjusted according to specifications for biological studies and 
steri lised. 
Biodistribution studies were perfonned on Balb/c mice bearing EMT6 
mammary adenocarcinoma on each thigh. Complexes 13a,d and 14 were tested for 
their biodistribution pattern and in vivo stability. (Selected results can be found in 
Supporting Data, Part J.) 
After six hours following the injection of the radiopharmaceuticals, the blood 
radioactivity levels for the lipophilic complexes remain high. In contrast, their water-
soluble analogues are mostly cleared from the blood. 
lt is worth noting that sulphonation of 2-pyrrolylthiones lowers blood and 
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plasma radioactivity retention, as well as radioactivity uptake by the liver, spleen, and 
lungs. On the other band, kidney uptake of the complexes increases with the level of 
ligand sulphonation, showing the highest value for complexes with the 
dipyrrolylthione 3d. 
After six hours post-injection, renal uptake of the sulphonated 
radiopharmaceuticals 14d,d' is still considerably high, which suggest that these 
compounds were trapped within the kidneys. 
It should be noted that there is a major difference between the overall biodistribution 
of the compounds tested and that of pertechnetate, which is indicative of the strong 
binding of technetium to the ligands and in vivo stability of the synthesised 
complexes. However, there is still a significant accumulation of the lipophilic drugs 
(13a,13d) in thyroid, even though it is twice less than an accumulation of the free 
pertechnetate. It is likely that lipophilic complexes undergo partial decomposition 
after administration. This would release technetium species, which could be oxidised 
to free pertechnetate allowing for accumulation of radioactivity in the thyroid. For 
hydrophilic complexes thyroid accumulation is much less and comparable with that 
of kidney. Partial desintegration of the complexes might occur, which would explain 
the thyroid uptake. The results show clearly that hydrophilic complexes are much 
more stable than lipophilic analogues. 
The biodistribution study conducted shows that 2-pyrrolylthiones are good 
chelating agents for 99mTc. Their biological behaviour is mostly influenced by their 
lipophilicity. Variations in the ligand periphery change the biological properties of 
the complexes. Because there was a significant kidney uptake of the sulphonated 
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Tobie 7. Percent of the injected dose per gram of tissue (average (standart error of the mean)) 
Compound Brain Tumor Thyroid Blood Kidneys Spleen lungs Plasma Skin Muscle Fat li ver Stomach 
Tc04- 0.03 0.72 436.27 1.29 1.30 0.41 0.83 2.56 2.74 0.18 0.38 1.48 8.54 
(0.00) (0.08) (37.72) (0.12) (0.10) (0.03) (0.07) (0.37) (0.04) (0.02) (0.08) (0.08) (1.07) 
0.30 2.40 206.05 11.00 5.38 3.31 5.21 17.28 1.03 0.45 0.93 16.53 
(0.03) (0.03) (54.53) (0.61) (0.45) (0.26) (0.52) (1.21) (0.18) (0.06) (0.25) (0.78) 
14a 0.03 1.43 81.94 1.53 21.80 0.87 1.69 2.27 1.19 0.34 0.94 4.87 1.93 
(0.00) (0.17) (10.36) (0.11) (1.88) (0.06) (0.45) (0.20) (0.09) (0.04) (0.21) (0.41) (0.31) 
........ 14b 0.06 1.45 62.41 2.09 17.39 0.98 1.39 2.89 1.26 0.36 0.87 4.22 2.01 N 
(0.00) (0.37) (7.20) (0.11) (1.31) (0.04) (0.13) (0.25) (0.06) (0.03) (0.04) (0.19) (0.41) 
14c 0.04 1.91 61.21 1.94 18.08 0.95 2.42 1.94 1.53 0.44 0.94 2.93 1.15 
(0.00) (0.09) (5.55) (0.06) (1.57) (0.02) (0.81) (0.06) (0.14) (0.09) (0.09) (0.08) (0.13) 
13d 0.27 2.34 200.37 8.02 6.97 3.38 5.27 9.32 1.60 0.46 1.17 15.04 
(0.01) (0.29) (10.79) (0.39) (0.42) (0.47) (0.82) (0.40) (0.24) (0.01) (0.16) (0.86) (0.00) 
14d' 0.04 2.14 25.10 1.45 18.67 0.93 1.61 2.13 3.90 0.47 0.82 3.33 0.96 
(0.00) (0.20) (2.01) (0.09) (0.99) (0.05) (0.12) (0.12) (0.25) (0.03) (0.04) (0.10) (0.09) 
14d 0.05 2.21 53.83 2.02 24.49 1.93 2.47 3.42 1.98 0.52 1.00 8.29 1.50 
i0.01! i0.13! {6.04~ {0.08! {2.24) {0.06! {0.24! {0.24! {0.13! {0.04~ {0.10~ {0.53! {0.12~ 
complexes, we studied their phannacokinetics in more detail. Rapid accumulation 
and slow clearance of these compounds from renal tissue prompted us to compare 
their properties with those of the conventional kidney imaging radiophannaceutical 
99mTc-dimercaptosuccinate (99mTc-DMSA, Succimer Injection). Although 99mTc-
DMSA is the renal radiophannaceutical currently used, it present some disadvantages 
in terms of clinical applications. The long time to reach optimal renal uptake results 
in the fact that the best contrast imaging is achived several hours postinjection. The 
slow excretion leads to the subsequent build-up of a considerable radiation dose. A 
new radiopharmaceutical that could reach peak uptake rapidly and clear quickly 
would represent a significant advantage for patients. 
The water-soluble complexes of 99mTc 14d,d' with mono- and disulphonated 
dipyrrolylthiones were administered to a group of 3 male Sprague and Dawley rats 
and scintigraphie images (Figure 32) were taken with y-camera. The kidney images 
are better resolved with compound 14d (Figure 32, B) than with 14d' (Figure 32, C), 
where the liver is still apparent. The kidneys are well visualised with both, 14d and 
99mTc-DMSA (Figure 32, A): the outer area of the cortex appears as a dark band 
delineating the kidneys whereas the medulla is greyish. However, the innermost part 
of the kidneys (kidney pelvis, calyx area), where the urine is collected, is well defined 
with the 99mTc-DMSA, which is not the case for 14d. 
Analysis of the activity curves (Figure 34) suggests that the kidney activity 
reaches a plateau more rapidly with compound 14d as compared to 99mTc-DMSA, 
which is an advantage of the new complex. 
Comparison of the biodistribution at 1 hour post-injection (Figure 33) for the 
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tested compounds shows that 99mTc-DMSA is more rapidly cleared from the blood, 
followed by 14d and 14d' (heart area was used as a measure of blood radioactivity). 
As far as the overall kidney uptake is concemed, 99mTc-DMSA shows the highest 
activity followed by 14d and 14d', which show similar values. For kidney uptake, 
only the left kidney was considered because the right kidney lies under the liver. The 
best excretion rate, as evaluated by measuring the activity found in the bladder, was 
obtained with l 4d. 
The renal retention is greater in the cortex that in the medulla for the newly 
synthesised drugs, particularly for compound 14d. This may be due to the binding of 
the radiopharmaceuticals to the proximal or distal convoluted tubules, which are 
primarily located in the renal cortex. 
A B 
bladder 






A- with 99mTc-DMSA; B - with complex 14d; C- with complex 14d' 
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It is established that 99mTc-DMSA is excreted in the urine via glomerular 
filtration and tubular secretion. W e suggest that compound l 4d and 14d' are also 
excreted via glomerular filtration and tubular secretion. Glomerular filtration is a 
passive diffusion of substances through glomeruli. It is selective only with respect to 
the molecular size of the substances filtered. Tubular secretion is an active transport 
mechanism mediated by a carrier system. A saturation of the carriers might occur 
when concentration of the substances competing for the transport is high. 
When glomerular filtrate enters the proximal tubule, the non-ionised forms of 
weak electrolytes may readily diffuse back into the circulation whereas the ionised or 
charged forms are trapped in the tubular urine and excreted. The extent to which the 
organic acids or bases are eliminated in the urine following secretion is dependent on 
their degree of ionisation within the tubular urine: the more ionised the compound is 
45 
40 - DMSA i:=:J 14d 
>- 35 "O - 14d' 0 














Heart Leftkidney Bladder 
Figure 33. Biodistribution at 1 hour post-injection 
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- the less reabsorbtion it undergoes. We believe that little or no reabsorption occur 
for complexes 14d and 14d', because they are salts of highly ionised acids. 
It is possible that the affinity of 14d to the carrier system is higher than 
affinity of 99mTc-DMSA and that protein binding of 14d is lower comparing with 
99mTc-DMSA. 
The overall pharmacokinetics suggests that compound 14d is comparable and 
in certain aspects superior to 99mTc-DMSA as a potential kidney scanning agent. Due 
to the very limited scope of animal studies that have been undertaken so far, the 
clinicat advantages of this compound are not obvious. Our proposed next step would 
be to study biodistribution and pharmacokinetics of the compounds 14d and 14d' 
using other animal models. A series of specific biological test should be performed 
also to establish precisely protein binding rate for these novel potential 
radiopharmaceuticals and to determine extension to which these compounds are 
excreted by tubular secretion mechanism. 
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Figure 14. Activity curves for compounds 14d, 14d', and 99mTc-DMSA. 
Results are presented in counts per second and in percents of radioactivity of the whole body. 
Analysis of the activity curves suggest that the kidney activity reaches a plateau more rapidly with 





We have synthesised several lipophilic 2-pyrrolylthiones featuring 
methoxyphenyl substituents. 
These compounds, along with 2,2'-dipyrrolylthione and phenyl-2-
pyrrolylthione, were used as precursors for the synthesis of a series of new water-
soluble analogues, i.e. sulphonated 2-pyrrolylthiones. 
The chemical properties of these compounds were studied, particularly as 
potential chelating agents for transition metal ions, including technetium and 
rhenium. It was found that physical and chemical properties of the potential ligands 
are highly dependent on substituents in the outer periphery of the molecule. For 
instance, the solubility of lipophilic compounds in organic solvents and their 
chromatographie mobility change significantly from one ligand to another within the 
series. As for the synthesised sulphonated analogues, their solubility in water ranges 
from highly hydrophilic to amphiphilic. Thus, we have shown that the desired degree 
of solubility of 2-pyrrolylthiones can be achieved through the introduction of selected 
substituents. 
A number of small-ion-radii transition metals were used in reactions with 2-
pyrrolylthiones. Ail resulting complexes were stable and easy to synthesise using 
developed procedure. Despite the fact that all the sulphonated 2-pyrrolylthiones are 
highly soluble in water, the resulting metal complexes have different lipophilicity. 
Sorne of the nickel and copper complexes are not readily soluble in water but instead 
dissolve in methanol. 
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Technetium and rhenium complexes with 2-pyrrolylthiones were successfully 
prepared. 99Tc and non-radioactive rhenium complexes were used to establish the 
chemical structures of the new compounds and to characterise them as well as to 
study their properties. A general complexation procedure was developed using 
stannous chloride as a reductant. 
The resultant complexes are chemically stable compounds and can be kept for 
months in sealed vials. Rhenium complexes are more sensitive to air oxidation but 
they still can be stored for up to a few months without significant decomposition. 
We found that the new 2-pyrrolylthiones, either lipophilic or water-soluble, 
are good ligands for a wide range of transition metals, rhenium and technetium. We 
have shown that the periphery of these ligands can be modified easily in order to add 
various specific properties to the final complexes. The suitability of these novel 
ligands as chelators for radiometals, such as the isotopes of technetiurn and rhenium, 
was confirmed. 
ln order to obtain new radioactive complexes, ail synthesised 2-
pyrrolylthiones were labelled directly with technetium-99m. 
It was found that the biodistribution pattern of the new 99mTc-complexes 
greatly depends on their lipophilicity. Graduai chemical changes in the ligand 
periphery allow for fine-tuning of the biological properties of the corresponding 
technetium complexes. 
Selected 99mTc-compounds were tested in rats to study their biodistribution 
and pharmacokinetics. One of the newly synthesised complexes (14d) showed 
promise as a radiopbarmaceutical agent for kidney imaging. An overall 
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pharmacokinetic study showed that this novel compound is comparable to 99mTc-
DMSA in tenns of delineating a rat's kidney and is more favourable in terms of 
radiation doses absorbed: it reaches the maximum kidney uptake rapidly and clears 
quickly, which is a significant improvement. Due to the very limited scope of animal 
studies that have been undertaken so far, the clinicat advantages of this compound are 
not obvious. Our proposed next step would be to study biodistribution and 
phannacokinetics of the compound 14d using other animal models. A series of 
specific biological test should be performed also to establish protein binding rate for 
this novel potential radiophannaceutical and to determine extension to which this 
compound is excreted by tubular secretion mechanism. 
Finally, we have discovered that novel 2-pyrrolylthiones could provide a new 
versatile class of radiopharmaceuticals for medical imaging, wherein the periphery of 
the molecule can be modified with various substituents, including biomolecules, 
while preserving the same central core. 
Future research with various substituted 2-pyrrolylthiones, including testing of 
radioactive metal complexes in different animal models, could identify other new 
compounds with specific properties that might be useful in nuclear medicine. 
The substituted pyrrolylthione ligands might well be used in various 
biological, medical, and other applications wherein chelators have an important role. 
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CHAPTER 3: Experimental 
4.1. Chemistry 
4.1.1. Materia/s and methods 
Metting points were detennined on a Fisher-Johns Melting Point Apparatus 
and are uncorrected. 
The ultraviolet - visible spectra were detennined with a Hitachi U-2000 
spectrophotometer. 
Silica gel for preparative column chromatography was Silica gel 60 from EM 
Science, 0.063-0.200 nm particle size (70-230 mesh ASTM). 
Reversed-phase silica gel for preparative column chromatography was C18 
Bonda-Pac from Waters, 37-55 µm particle size, 125 A pores. 
TLC glass plates coated with C 18-silica gel were TECHW ARE, RPSF 
reversed phase hydrocarbon impregnated in silica gel W /UV254, layer thickness 250 
µm, 5x20 cm, from Analthech. Silica gel coated polyester was POLYGRAM SIL 
G/UV 254 for TLC, layer thickness 200 µm, particle size 5-1 7 µm, pore size 60 A, 
20x20 cm, from MACHEREY-NAGEL (Gennany). 
Infrared spectra were carried out with help of Mr. Alain Desponts of 
Department of Chemistry of the Université de Sherbrooke using KBr pellets for 
hydrophilic compounds and CHC/3 solution for lipophilic compounds. 
Ali the commercial reagents used were of reagent grade or higher, and were 
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used as received without further purification. 
NMR data were recorded on a Bruker Ac-300 300 MHz nuclear magnetic 
resonance spectrometer by Dr. Normand Pothier from Department of Chemistry of 
the Université de Sherbrooke and on a 600 MHz apparatus by Ms. Sylvie Bilodeau 
and Dr. Phan Viet Minh Tan of the Université de Montréal. Results are given in parts 
per million (ppm) on the scale relative to tetramethylsilane (TMS) as internai or 
extemal standard. 
Elemental analyses were performed at Guelph Chemical Laboratories 
(Guelph, ON, Canada) and at the Department of Chemistry, Université de Montréal 
(Montreal, PQ, Canada). 
FAB (negative mode), SIMS, and MALDI mass spectrometry were done at 
the Department of Chemistry, University of British Columbia (Vancouver, BC, 
Canada) and by Mr. Michael Evans of the Department of Chemistry, Université de 
Montréal (Montreal, PQ, Canada). Either thioglycerol, 3-nitrobenzylalcohol (NBA) 
or glycerol-methanol mixture was used as matrices. 
High performance liquid chromatography (HPLC) of products was done using 
a Waters Liquid Chromatograph fitted with a Waters RCM module. The 
chromatograph was equipped with a Nova-Pac Radial-Pac C1s cartridge of 
8mmx 1 OOmm or 8mmx200mm size (particle size about 4 µm with pore size 60A) to 
purify water-soluble compounds. They were eluted with a linear gradient running 
from 100 % of water or aqueous sodium phosphate buffer pH 5.0 (lOmM) to 100 % 
of methanol (HPLC grade, Fisher Scientific) over a period of 30 minutes with a flow 
rate of 1 ml/minute. The chromatograph was equipped with a Nova-Pac Silica 
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cartridge of 8mmx 1 OOm.m size (particle size about 4 µm with pore size 60Â) to purify 
lipophilic compounds. These were eluted with a linear gradient running from 100% 
chloroform to 100% methanol (both HPLC grade from Fisher Scientific) over 30 
minutes with a flow rate of 1 ml/minute. Compounds were detected using an UV-Vis 
detector. 
Radioactive doses were measured in an Accucal 2001 dose calibrator from 
Nuclear Pharmacy Inc. (Albuquerque, NM, U.S.A). 
Scintigraphie images were recorded with a Starcam 4000i XRT Gamma 
camera, General Electric (Saint Albans, UK) equipped with a parallel medium energy 
high resolution collimator. Image analysis was performed on a Genie PNR model 
nuclear medicine dedicated computer General Electric (Saint Albans, UK). 
The X-ray diffraction data were collected by Ms. Francine Bélanger-Gariépy 
of the Université de Montréal on a Bruker AXS SMART 2K/Platform diffractometer 
with graphite-monochromated Cu Ka radiation. Computations were carried out with 
SHELXS97, SHELXL96, and SHELXTL computer programs. Fractional atomic 
coordinates from the study have been deposited with the Cambridge Crystallographic 
Data Centre. 
4.1.2. Safety: hazard compounds and reactions 
Caution: 998Tc is a weak ~-emitter (t112 2.2x105 yrs, ~- 0.3 MeV). 99mTc is a 
y-emitter (t112 6 h, y 140 keV). Ail studies using these radioisotopes were carried out 
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in laboratories approved for the use of radioactivity. Appropriate shielding screens 
used and radiation safety procedures were followed at all times. 
Caution: Sulphur trioxide S03 is a highly hygroscopie volatile corrosive 
compound. Lawesson's reagent, thiophosgene, and phosphorus decasulphide P~1o 
are volatile and poisonous compounds. Gloves and appropriate masks should be 
wom for handling these chemicals in a well-ventilated fume hood. 
4.1.3. Synthesis of the precursors 
p-Methoxyphenyl-2-pyrrolylketone (1 b) 
This compound was prepared as described in the literature (Pesson et al., 
1966). 
MW=201.22 
M.P. = 107-108°C (lit. l 10-l l 1°C) 
3,4-Dimethoxyphenyl-2-pyrrolylketone (1 c) 
The procedure above was adapted for the synthesis of dimethoxyphenyl-2-
pyrrolylketone. The Grignard derivative was prepared by slow addition of a pyrrole 
solution (0.7 ml, 0.01 mol) in dry ether (4 ml) to an etheral solution (5 ml) of 
ethylmagnesium bromide (from 0.24 g, 0.01 mol Mg; l .50ml, 0.02 mol ethyl 
bromide) with stirring. The reaction mixture was heated to reflux for 30 minutes 
under nitrogen, then cooled. The Grignard reagent was added dropwise to a stirred 
solution of 3,4-dimethoxybenzoylchloride (2 g, 0.01 mol) in dry ether (5 ml) at 0°C. 
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The stirring was continued for 3 h at room temperature and the mixture was allowed 
to stand overnight. The reaction mixture was treated with saturated solution of 
NH4C/. Organic phase was separated, and the aqueous phase was extracted 
repeatedly with toluene. Organic extracts were combined and dried over MgS04• 
The solution was concentrated and chromatographed on silica gel using toluene as an 
eluent. The solvent was evaporated to dryness yielding 3,4-dimethoxyphenyl-2-
pyrrolylketone as a pale yellow-green crystalline solid (2.13 g, 9.2 mmol, 92% yield). 
MW=231.25 
M.P. = 82-83°C 
LS-MS (IE), m/z = 231 (MJ 
UV-Vis (CHC/3) À.max (lg E): 318 (4.20), 243 (3.88). 
The single crystal X-ray diffraction data: C1JH13N03, Mr = 231.244, orthorhombic, 
space group Pca2 1, a= 18.972(8) A, b = 9.065(3) A, c = 6.867(2) A, V= 1181.0(7) 
A3, Z = 4, D:c = l.3006 Mglm3• Cell parameters from 25 reflections: 8 = 19.00-
24.000, µ=O. 766 mm.·1, T=293(2) K, block, pale grey-green, O. 76x0.36x0.2 l mm. 
1,4-dioxane-sulphur trioxide 
1,4-Dioxane-sulphur trioxide was obtained using a method described by 
Bordwell and Rondestvedt. (Bordwell and Rondestvedt, 1950) 
Briefly: 40g of sulphur trioxide were distilled into the cooled ethylene 
dichloride (lL). The resulting solution was cooled in an ice bath and the equivalent 
quantity of the 1,4-dioxane was added dropwise to the stirred sulphur trioxide 
solution. The 1,4-dioxanesulfotrioxide complex precipitated as fine granules and was 
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separated by filtration in a yield of 89%. This compound is unstable under 
atmospheric conditions and is susceptible to hydrolysis. 
4.1.4. Synthesis of 2-pyrrolylthiones 
Phenyl-2-pyrrolylthione (2a) 
The compound was obtained using a method described in the literature. 
(Lumbroso and Liégeois, 1984) 
MW= 187.18 
M.P. = 33-36°C (lit. < 40°C) 
UV-Vis (CHCIJ), Àmax (lg &): 527 (2.29), 392 (4.26), 316 (3.98), 
(lit. (MeOH), Àmax (lg &): 536 (2.33), 390 (4.75), 310 (4.41)). 
LR-MS, m/z: 187 (M}. 
p-Methoxyphenyl-2-pyrrolylthione (2b) 
This compound was obtained using a method suggested in the literature. 
(Pesson et al., 1966) 
A stirred solution of p-methoxyphenyl-2-pyrrolylketone ( 4.02 g, 0.02 mol) in 
benzene (100 ml) was refluxed for 30 min under nitrogen. Tetraphosphorus 
decasulphide (4.44 g, 0.01 mol) was added in portions to the stirred solution over 30 
min. The mixture was then allowed to react in an ultrasonic bath for 40 min. After 
removal of excess of P~1o by filtration, the solution was reduced under vacuum and 
the residue was chromatographed on silica gel. The column was eluted with toluene 
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and the first bright scarlet fraction was collected to yield p-methoxy-2-pyrrolylthione 
as a bright red solid (2.81 g, 0.013 mol, 65% yield). 
MW=217.29 
M.P.=97°C 
1H NMR (CDC/3): 3.87 (s, 3H), 6.38-6.41 (m, lH), 6.74-6.76 (m, un, 6.88-6.90 (m, 
lH), 6.92-6.93 (m, lH), 7.27-7.28 (m, lH), 7.75-7.77 (m, lH), 7.79-7.80 (m, lH), 
9.81 (s, lH) ppm. 
13C NMR (CDC[J): 55.38, 112.66, 113.17, 117.21, 129.57, 131.04, 139.20, 141.41, 
162.37, 212.21 ppm. 
IR spectra (CHC/3): 3784, 3403, 2977, 2838, 2550, 1599, 1527, 1503, 1389, 1337, 
1303, 1257, 1173, 1107, 1036, 961, 836 cm·1• 
UV-Vis (CHC/3), À.max (lg e): 529 (2.69), 376 (4.38), 287 (3.57). 
LR-MS, m/z: 217 (M}. 
Calculated for C12H11NOS: C, 66.34; H, 5.11; N, 6.45; S, 14. 73; 
found: C, 66.56; H, 5.18; N, 6.40; S, 14.42. 
The single crystal X-ray diffraction data: C12H11NOS, Mr = 217.278, monoclinic, 
space group P21/c, a = 11.8386(1) A, b = 11.9453(1) A, c = 7.5061(1) A, f3 = 
98.676(1)0 , V= 1049.33(2) A3, Z = 4, Dx = 1.3753 Mg/m·3• Cell parameters from 




The method above gave 3,4-dimethoxyphenyl-2-pyrrolylthione with 45% 
yield. The compound was obtained as bright red oil, which subsequently crystallised. 
It is unstable at room temperature and is slowly oxidised by atmospheric oxygen. 
MW= 247.31 
MP =88-90°C 
1H NMR (CDC'3): 3.90 (s, 3H), 3.95 (s, 3H), 6.40-6.43 (m, lH), 6.76-6.78 (m, lH), 
6.85-6.88 (m, lH), 7.29-7.31 (m, lH), 7.37-7.38 (m, lH,), 7.40-7.42 (m, lH,), 9.79 (s, 
lH) ppm. 
13C NMR (CDC'3): 56.04, 109.72, 112.77, 117.29, 122.58, 129.65, 139.28, 215.53 
ppm. 
IR spectra (CHC/3): 3783, 3403, 2969, 2840, 2581, 1593, 1513, 1461, 1415, 1383, 
1331, 1266, 1170, 1142, 1109, 1036 cm-1• 
UV-Vis (CHC/3), Âmax (lg E): 529 (2.59), 390 (4.29), 298 (3.59), 264 (3.90). 
LR-MS, m/z: 247 (M}. 
Calculated for C13H 13N02S: C, 63.14; H, 5.30; N, 5.66; S, 12.96; 
found: C, 63.24; H, 5.29; N, 5.30; S, 12.85. 
2,2 '-Dipyrrolylthione (2d) 
2,2'-dipyrrolylthione was obtained as suggested in the literature (Clezy et al., 
1970). 
MW= 176.24 
M.P. = 86-90°C (lit. = 96-98°C) 
UV-Vis (CHC'3), À.max (lg E): 404 (4.70), 302 (3.64), 
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{lit. {CHC/3), Àma:< {lg E): 406 (4.56), 303 (3.47)). 
4.1.5. Su/phonation of the 2-py"olylthiones 
The general procedure. Solid 1,4-dioxane-sulphur trioxide (2 mmol) was 
gradually added to a stirred solution of 2-pyrrolylthione (1 mmol) in 1,4-dioxane (25 
ml) under nitrogen atmosphere. The reaction mixture was allowed to stand for 10 
min at room temperature. Next, the solvent was evaporated in a vacuum and the 
residue was redissolved in water (about 5 ml). The pH was brought to 3.6-4.6 upon 
addition of lM solution of NaOH. 
Acetone ( 40 ml) was added and the resulting precipitate was separated by 
centrifugation. The red supematant was evaporated to dryness. The solid product 
was redissolved in water and chromatographed on reversed-phase silica gel with 
water as an eluent. Evaporation resulted in red crystalls, which were identified as 
sodium sait hydrate of the sulphonated 2-pyrrolylthione. Single sulphonated 
derivatives resulted in ail cases except 2,2' -dipyrrolylthione where two products of 
sulphonation were found. 
Ail synthesised sulphonated 2-pyrrolylthiones are highly soluble in water. 




1HNMR (DMF-d7): 6.75-6.76 (m, lH), 7.45-7.48 (m, 2H), 7.50-7.60 (m, 2H), 7.66-
7.69 (m, 2H), 11.81 (s, lH) ppm. 
13C NMR (DMF-d1): 116.19, 128.30, 128.81, 130.69, 130.82, 138.00, 162.60, 214.80 
ppm. 
IR spectra (KBr): 3364, 3121(v(N-H));1615 (8(C-H)ar.); 1591, 1531, 1458 (v(C-C)); 
1408, 1367 {vas.(S{=O)i)); 1320 {v(C-N)); 1211 (v{C=S)); 1155 (v5.(S{=0)2)); 1113; 
1082 (ar.); 1059; 1041; 1026 (ar.), 968, 941, 852; 768, (y(C-H), P-ring); 700, 667 
(ô(C-H)); 644, 629, 617. 
UV-Vis (H20), À.max (lg &): 513 (2.11), 382 (4.34), 320 (4.05), 215 (4.07). 
LR-MS (SIMS), m/z: 266 (M}. 
Calculated for C11HsNNa03S2 x H20: C 42.99, H 3.28, N 4.56, S 20.86; 
found: C 42.32, H 2. 73, N 4.41, S 20.44. 
p-Metlaoxyphenyl-1-( 4-sulpho)pyrrolylthione, sodium sait (Jb) 
Yield 40%. 
MW=373.37 
1H NMR (DMF-d1): 3.92 (s, 3H), 6.80-6.81 (m, lH), 7.04-7.14 {m, 2H), 7.56-7.57 
(m, lH), 7.74-7.92 (m, 2H), 11.71 (s, lH) ppm. 
13C NMR (DMF-d1): 55.63, 113.61, 115.55, 129.72, 131.13, 131.27, 137.49, 139.94, 
141.11, 213.22 ppm. 
IR spectra (KBr): 3570 (hydrogen bonds); 3283 (v(N-H)); 1597, 1531, 1504, 1460 
(v(C-C)); 1408, 1367 (vas_(S(=0)2)); 1310 (v(C-N)); 1250 (vas.(C-0-C)); 1159 
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(v5.(S(=0)2)); 1117 (ar.); 1057; 1041; 1024 (ar., v5.(C-0-C)), 950, 941, 860, 837 785 
(y(C-11), ,8-ring); 671, 635 (y(C-H)); 580. 
UV-Vis (H20), Â.max (lg E): 511 (2.35), 375 (4.40), 221 (4.03). 
LR-MS (SIMS), m/z: 296 (M}. 
Calculated for C12H10NNa0~2x 3H20: C 38.60, H 4.32, N 3.75, S 17.17; 
found: C 38.75, H 3.63, N 3.69, S 17.38. 
3,4-dimethoxyphenyl-2-(4-sulpho)pyrrolylthione, sodium sait (3c) 
Yield 56%. 
MW=367.37 
1H NMR (DMF-d1): 3.89 (s, 3H), 3.94 (s, 3H), 6.85-6.86 (m, lH), 7.08-7.11 (m, lH), 
7.34-7.37 (m, lH), 7.43-7.44 (m, lH), 7.57-7.58 (m, lH), 11.71 (s, lH) ppm. 
13C NMR (DMF-d1): 55.77, 55.89, 110.70, 113.48, 115.74, 122.60, 129.53, 129.67, 
137.28, 139.94, 148.94, 152.69, 213.25 ppm. 
IR spectra (K.Br): 3443 (hydrogen bonds,v(N-11)); 3125 (v(N-11)); 1595, 1531, 1512, 
1462, 1454 (v(C-C)); 1420, 1366 (vas.(S(=O)z)); 1331 (v(C-N)); 1265 (vas.(C-0-C)); 
1210 (v(C=S)); 1138 (v5.(S(=0)2)); 1043, 1016 (v5.(C-0-C)); 941, 862, 762, 663, 635 
(y(C-11)); 478. 
UV-Vis (H20), Â.max (lg E): 508 (2.56), 382 (4.64), 264 (4.01), 221 (4.34), 197 (4.54). 
LR-MS (SIMS), m/z: 326 (M}. 
Calculated for C1P12NNaOsS2 x H20: C 42.50, H 3.84, N 3.81, S 17.45; 
found: C 42.55, H 3.40, N 3.69, S 19.45. 
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The single crystal X-ray diffraction data: C12H1€NNa01S1, Mr = 373.368, 
orthorhombic, space group Pnma, a= 6.763(3) A, b = 7.540(6) A, c = 31.641(8) A, V 
= 1613.5(15) A3, Z = 4, Dx = 1.5370 Mg/m-3• Cell parameters from 25 reflections: () 
= 20.00-25.00°, µ = 3.587 
0.57x0.53x0.27 mm. 
-1 mm, T=293(2) K, block, intense violet-pink, 
2,2'-(4-Su/pho)dipyrro/ylthione, sodium sait (Jd') 
This compound was obtained as a side product in sulphonation reaction of 
2,2'-dipyrrolylthione 2d with 12% yield. 
MW= 314.31 
1H NMR (DMF-d7): 6.37-6.39 (m, lH), 7.00-7.07 (m, 2H), 7.37-7.43 (m, 2H), 11.47 
(s, lH), 11.63 (s, lH), ppm. 
13C NMR (DMF-d7): 111.67, 112.90, 115.62, 126.92, 128.92, 139.62, 195.26 ppm. 
IR spectra (/Œr): 3587, 3512 (hydrogen bonds); 3329, 3132 (v(N-H)); 1631 (ô(C-H)); 
1622 (ô(N-H)); 1529, 1462, 1404, 1350 (v(C-C)); 1298, 1252 (v(C-N)); 1211 
(v(C=S)); 1169 (v(S(=0)2)); 1121; 1099, 1059, 1028; 991, 945, 916, 879, 841, 752, 
708, 677, 667, 631 (y(C-H)); 586, 575, 542. 
UV-Vis (H20), À.max (lg E): 397 (4.03), 224 (3.44). 
LR-MS (SIMS), m/z: 255 (M). 
Calculated for CrJ-hN2Na03S2 x 2H20: C 34.39, H 3.53, N 8.91, S 20.40; 
found: C 35.06, H 2.94, N 8.93, S 19.84. 




1H NMR (DMF-d1): 7.33-7.37 (m, 2H), 7.43-7.44 (m, 2H), 11.71(s,2H) ppm. 
13C NMR (DMF-d1): 110.06, 112.90, 127.19, 136.38, 138.20, 195.72 ppm. 
IR spectra (KBr): 3468, 3122 (v(N-H)); 2951, 1631 (ô(C-H)); 1536, 1413, 1351 (v(C-
C)); 1218 (v(C=S)); 1162 (v(S(=O)i)); 1112; 1048, 939, 916, 834, 817(y(C-H)). 
UV-Vis (H20), À.max (lg e): 389 (4.44), 222 (3.76). 
LR-MS (SIMS, thioglycerol), m/z: 335 (M}. 
Calculated for CcPrJ/2Na20~3x3H20: C 24.89, H 2.78, N 6.45, S 22.15; 
found: C 24.62, H 2.32, N 5.76, S 20.84. 
4.1.6. Synthesis of the cadmium, cobalt, copper, nickel, and zinc 
complexes with sulpho-2-pyrrolylthiones. 
The general procedure. A solution of sulphonated 2-pyrrolylthione (3 mmol) 
in water (l ml) was added to a solution of metal sait (acetate, 3.3 mmol) in water (1 
ml). The colour of the reaction mixture changed rapidly. 
Cd and Co complexes: The reaction mixture was chromatographed on reverse 
phase with water as an eluent. The resulting product was collected and the solvent 
was evaporated. The residual solid was dissolved in methanol (- 2 ml) and then 
chromatographed on a normal phase column with methanol as an eluent. The single 
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main fraction was collected and evaporated to dryness giving the resulting complex in 
good yield (48-95 %). Synthesised complexes were than analysed. 
Cu complexes 6a,6b and Ni complexes 7a,7b,7c: These complexes precipitate 
from the reaction mixture. A solvent was evaporated and the residual solid was re-
dissolved in methanol and chromatographed on Si02• A yellow fraction was 
collected and dried to give a metal complex generally in good yields (45-93 %). Pure 
products were analysed. These compounds are poorly soluble in water and 
moderately soluble in methanol. 
Cu complexes 6c,6d: The colour of the reaction mixture changed from red to 
brown upon addition of the metal sait. Reversed-phase chromatography gave the 
desired products in good yields (68-82 %). 
Ni complex 7d: The colour of the reaction mixture changed from red to brown 
upon addition of the metal sait. Normal phase chromatography followed by reversed-
phase chromatography produced the complex in moderate yield (58 %). 
Zn complexes: A crude product was purified either on reverse phase with 
water as an eluent or on normal phase silica gel with methanol as an eluent. Single 
fractions of desired products were collected and evaporated to dryness. The yields 
were good (70-87 %). 
In general, metal complexes of the d series are poorly soluble in methanol and 
other organic solvents. Water as solvent was used to dissolve these compounds for 
purification and analysis. Accordingly, reversed-phase chromatography was often 
used to purify such complexes. 
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1 :2 Complex of cadmium with phenyl-2-(4-sulpho)pyrrolylthione (4a) 
Fine orange-brown powder with a metallic shine resulted. Yield 95 %. 
1H NMR (DMF-d1): 6.72-6.96 (m, 2H), 7.40-7.70 (m, lOH), 7.84-7.89 (m, 2H), 11.86 
(bs, lH), 11.99 (bs, lH) ppm. 
UV-Vis (H20), À.max (relative intensity): 390 (l), 315 (0.61). 
LR-MS (FAB, NBA), m/z: 645.5 (M}. 
Calculated for Cd(C22H1sN2Na0<>84)x3H20: C 36.65, H 2.94, N 3.89, S 17.79, Na 
3.19; 
fowid: C 37.81, H 2.87, N 3.94, S 16.38, Na 
3.61. 
1: 1 Complex of cobalt with phenyl-2-( 4-sulpho)pyrrolylthione (Sa) 
Dark red-brown powder with a metallic shine was obtained in 48 % yield. 
1H NMR (DMF-d1): 6.57 (s, lH), 6.88 (s, lH), 7.10-7.13 (m, 2H), 7.22-7.24 (m, 2H), 
7.56-7.67 (m, 4H), 7.81-7.94 (m, 4H) ppm. 
UV-Vis (H20), À.max (lg &): 451(4.54),318 (4.79). 
LR-MS (F AB), m/z: 322.9 (M) 
Calculated for Co(C11H1N03S2)x2H20: C 36.67, H 3.08, N 3.89, S 17.80; 
fowid: C 38.00, H 3.24, N 3.91, S 17.85. 
1: 1 Camp/ex of copper with phenyl-2-( 4-sulpho)pyrrolylthione (6a) 
Fluffy brown powder was collected in 77 % yield. 
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1H NMR (DMF-d7): 6.92 (s, lH), 7.35 (s, lH), 7.55-7.64 (m, 3H), 7.86-7.88 (m, 2H), 
l l.92 (m, lH) ppm. 
UV-Vis (H20), À.max (lg E): 450 (4.00), 347 (4.20). 
LR-MS (FAB, NBA), m/z: 352.4 ~+Na). 
Calculated for Cu(OCH3)(C11H1NNa03S2): C 37.65, H 2.63, N 3.66; 
found: C 38.ll, H 2.78, N 3.37. 
1:1 Complex of nickel with phenyl-2-(4-su/pho)pyrrolylthione (7a) 
A violet colloid resulted from the reaction. It dissolves well in methanol and is only 
moderately water-soluble. Dry complex is dark violet-bleu. Yield 47 %. 
1H NMR (DMF-d1): 6.89 (s, lH), 7.61 (m, 3H), 7.90 (s, 2H), 8.04 (s, lH) ppm. 
13C NMR (DMF-d7): 129.l l, 132.38, 137.31 ppm. 
UV-Vis (H20), À.max (lg E): 525 (3.78), 390 (4.36), 316 (4.50). 
LR-MS (FAB), m/z: 325.l (M} 
Calculated for Ni(OH)(C11H1NNa03S2): C 36.30, H 2.22, N 3.85, S 17.62, Ni 16.12; 
found: C 36.27, H 3.13, N 3.54, S 17.37, Ni 16.35 
1:1 Complex of zinc with phenyl-2-(4-sulpho)pyrro/ylthione (Ba) 
A compound of red-wine colour resulted. Yield 68 %. 
1H NMR (D20): 7.26-7.54 (m, 5H), 7.65-7.68 (m, 2H) ppm. 
UV-Vis (H20), À.max (relative intensity): 501(0.009),382 (1), 312 (0.63). 
LR-MS (F AB, NBA), m/z: 329.4 (M + ). 
Calculated for Zn(OCH3)(C11H1NNa03S2): C 37.47, H 2.62, N 3.64; 
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found: C 40.23, H 3.02, N 3.41. 
1: 1 Complex of cadmium with p-methoxyphenyl-2-( 4-sulpho)pyrrolylthione ( 4b) 
Light-brown compound was collected in 77 % yield. 
1H NMR (DMF-d7): 3.57-3.59 (m, 3H), 6.81-7.16 (m, 3H), 7.38-7.92 (m, 3H) ppm. 
UV-Vis (HzO), À.max (lg E): 390 (3.70). 
Calculated for: Cd(C12HcNNa0~2): C 33.46, H 2.11, N 3.25, Na 5.34, S 14.89, Cd 
26.10; 
found: C 30.00, H 2.07, N 2.63, Na 5.20, S 15.30, Cd 
26.01. 
1: 1 Complex of cobalt with p-methoxyphe11yl-2-( 4-sulpho)pyrrolylthione (Sb) 
Dark red-brown compound with a metallic shine was obtained. Yield 78 %. 
1H NMR (D20): 3.08-3.65 (m, 3H), 7.33-6.68 (m, 6H) ppm. 
UV-Vis (H20), À.max (lg E): 384 (3.64). 
LR-MS (FAB), m/z: 353.8 ~(1:1)), 671.8 (M+(l:2)+Na). 
Calculated for: Co(OH)(C12HcNNa0~2): C 36.56, H 2.56, N 3.55, Na 5.83, S 16.26, 
Co 14.95; 
found: C 39.35, H 3.42, N 2.72, Na 6.44, S 16.81, 
Co 14.90 
1: 1 Complex of copper with p-methoxyphenyl-2-( 4-sulpho)pyrrolylthione (6b) 
Very fine brown powder was collected. Yield 45 %. 
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1H NMR (D20): 3.57 (s, 3H), 7.39-6.91 (m, 6H) ppm. 
UV-Vis (MeOH), À.max (relative intensity): 458 (0.49), 381 (1). 
LR-MS (FAB), m/z: 358.l ~(1:1)), 675.7 ~(1:2)+Na). 
Calculated for: Cu(OH)(C12HCJf{Na0~2): C 36.14, H 2.53, N 3.51, Na 5.76, S 16.08, 
Cu 15.93; 
found: C 40.18, H 3.23, N 3.24, Na 5.96, S 17.09, 
Cu 16.08. 
1: 1 Complex of nickel with p-methoxyphenyl-2-( 4-sulpho)pyrrolylthione (7b) 
Dark brown solid was obtained in 49 % yield. 
1H NMR (DMF-d7): 3.46 (br.s, 3H), 6.93 (br.s, lH), 7.19-7.21 (m, 2H), 7.71 (br.s, 
lH), 7.97-8.00 (m, 2H) ppm. 
UV-Vis (MeOH), À.max (lg &): 607 (3.37), 531(3.69),406 (4.20), 357 (4.09). 
LR-MS (SIMS, thioglycerol+methanol), m/z: 377 ~+Na). 
Calculated for: Ni(OH)(C12HCJNNa04S2)x3H20: C 32.17, H 3.60, N 3.13, Na 5.13, S 
14.31, Ni 13.10; 
found: C 33.14, H 4.07, N 3.13, Na 5.12, S 
14.25, Ni 12.89. 
1: 1 Complex of zinc with p-methoxyphenyl-2-( 4-sulpho)pyrrolylthione (8b) 
Solid compound of the red-wine colour with a metallic shine resulted. Yield 87 %. 
1H NMR (D20): 3.58-3.64 (m, 3H), 6.66-6.88 (m, 3H), 7.41-7.59 (m, 3H) ppm. 
UV-Vis (H20), À.max (lg &): 374 (3.87). 
99 
LR-MS (FAB, NBA), m/z: 365 ~(1:1)), 652.8 ~(1:2)). 
Calculated for: Zn(C12H~aO.iS2): C 37.56, H 2.36, N 3.65, Na 5.99, S 16.71, Zn 
17.04; 
found: C 40.98, H 3.29, N 3.11, Na 6.12, S 16.51, Zn 
17.23 
1: 1 Complex of cadmium with 3,4-dimethoxyphenyl-2-( 4-su/pho)pyrrolylthione ( 4c) 
A light-brown powder with a metallic shine was produced with 56 % yield. 
1H NMR (D20): 3.70-3.72 (m, 3H), 3.74-3.75 (m, 3H), 6.94-7.43 (m, 5H) ppm. 
UV-Vis (H20), À.max (relative intensity): 421(1),321(0.90),268 (0.51), 230 (0.97). 
LR-MS (F AB, NBA matrix), m/z: 438.8 (M}. 
Calculated for Cd(OH)(C1:#12NOsS2)x3H20: C 30.63, H 3.76, N 2.75, S 12.58, Na 
0.00; 
found: C 30.79, H 3.33, N 2.75, S 11.36, Na 
0.03. 
1 :2 Complex of cobalt with 3,4-dimethoxyphenyl-2-(4-sulpho)pyrrolyltllione (Sc) 
Dark brown powder with a metallic shine resulted. Yield 87 %. 
UV-Vis (H20), À.max (relative intensity): 383 (0.78), 322 (1), 268 (0.56), 231 (0.97). 
LR-MS (F AB, NBA), m/z: 384.9 (M). 
Calculated for Co(C1Jl/12NOsS2)zx4H20: C 39.85, H 4.12, N 3.57, Na 0.00, Co 7.52; 
found: C 30. 72, H 4.17, N 2.68, Na 0.10, Co 7 .50. 
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1: 1 Complex of copper with 3,4-dimethoxyphenyl-2-( 4-sulpho)pyrrolylthione (6c) 
Compound 6c was dried using an oil pump evaporator. A fine almost black powder 
with a metallic shine resulted. Yield 82 %. 
1H NMR (DMF-d7): 3.52 (m, 6H), 7.16-7.59 (m, 5H) ppm. 
UV-Vis (H20), À.max (relative intensity): 450 (shoulder), 323 (1), 235 (0.8). 
LR-MS (FAB, NBA matrix), m/z: 389.9 (M}. 
Calculated for Cu(OH)(C13H12NOsS2)x2H20: C 35.25, H 3.87, N 3.16, Na 0.00; 
found: C 35.45, H 4.10, N 3.12, Na 0.10. 
1:1 Complex of nickel with 3,4-dimet11oxyphenyl-2-(4-sulp/1o)pyrrolylthione (7c) 
Very fine black powder was obtained. Yield 93 %. 
MW=407.03 
1H NMR (DMF-d7): 3.98-4.00 (m, 6H), 7.01-7.59 (m, 5H), ppm. 
UV-Vis (MeOH), À.max (lg &): 609 (4.25), 535 (4.55), 502 (4.53), 422 (4.94), 322 
( 4.67), 281 ( 4. 78). 
LR-MS (SIMS, glycerol+methanol), m/z: 407 ~+Na). 
Calculated for Ni(C1J1111NNaOsS2): C 38.36, H 2.72, N 3.44, S 15.75, Ni 14.42; 
found: C 38.44, H 2.98, N 3.20, S 17.20, Ni 14.87. 
1:1 Complex of zinc with 3,4-dimethoxyphenyl-2-(4-sulpho)pyrrolylthione (Be) 
Thin dark-cherry layers of the compound Sc resulted. Yield 72 %. 
1H NMR (D20): 3.71-3.75 (m, 6H), 6.93-6.96 (m, 2H), 7.27-7.43 (m, 3H) ppm. 
UV-Vis (H20), À.max (relative intensity): 393 (0.72), 322 (0.98), 268 (0.57), 232 (1). 
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LR-MS (FAB, thioglycerol matrix), m/z: 389.8 (M1. 
Calculated for Zn(OH)(C1Y/12N05S2)x4H20: C 32.47, H 4.40, N 2.91, S 13.34, Na 
0.00; 
found: C 32.39, H 3.86, N 2.80, S 12.56, Na 
0.13. 
1:2 Complex of cadmium with 2,2'-(4,4'-disulpho)dipyrrolylt/1ione (4d) 
Thin dark red plates were collected. Yield 49 % 
1H NMR (D20): 7.03 (s, 4H), 7.19 (d, lH), 7.33-7.38 (m, lH), 7.43 (s, 4H), 11.51 (s, 
lH) ppm. 
UV-Vis (H20), À.max (relative intensity): 389 (1). 
LR-MS (F AB), m/z: 784.5(M1 
Calculated for Cd(CrJ/sN2Na20~3)ix6H20: C 22.08, H 2.26, N 5.72, Na 9.39; 
found: C 23.25, H 2.42, N 5.88, Na 9.02. 
1:2 Complex of cobalt with 2,2'-(4,4'-disulpho)dipyrrolylthione (5d) 
Black solid compound was produced in 57 % yield 
1H NMR (DMF-d1): 6.22-6.46 (m, lH), 7.18-7.52 (m, 3H), 11.52 (s, lH) ppm. 
UV-Vis (H20), À.max (relative intensity): 422 (1). 
Calculated for Co(CrJ/sN2Na20~3)2x6H20: C 23.36, H 2.40, N 6.05, Na 9.93; 
found: C 23.36, H 2.50, N 3.87, Na 9.16. 
1: 1 Complex of copper with 2,2 '-( 4,4 '-disulpho)dipyrrolylthione (6d) 
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Shiny black solid was obtained. Yield 68 %. 
1H NMR (D20): 7.03 (s, 4H), 7.19 (d, lH), 7.33-7.38 (m, lH), 7.43 (s, 411), 11.52 (s, 
lH) ppm. 
UV-Vis (H20), Àma."< (relative intensity): 469 (0.75), 419 (1). 
Calculated for Cu(OH)(CcPsN2Na20~3)xH20: C 22.62, H 1.69, N 5.86, Cu 13.30; 
found: C 23.18, H 1.79, N 5.41, Cu 11.94. 
1:1 Complexofnickel with 2,2'-(4,4'-disulpho)dipyrrolylthione (7d) 
Black compound resulted. Yield 58 %. 
1H NMR (D20): 7.18 (m, lH), 7.39 (s, 2H), 7.45 (m, 2H), 7.57 (s, 3H), 7.67 (m, lH), 
7.88 (s, lH), ppm. 
UV-Vis (H20), Àmax (relative intensity): 432 (1), 399 (0.92). 
LR-MS (SIMS, glycerol+methanol), m/z: 437 ~ + 2Na) 
Calculated for Ni(OCH3)(C9HsN2Na20~3)xH20: C 24.66, H 2.07, N 5.75, S 19.75. 
found: C 24.40, H 2.44, N 5. 76, S 20.35. 
1:2 Complex of zinc with 2,2'-(4,4'-disulpho)dipyrrolylthione (Bd) 
Thin plates oflight-brown colour were collected. Yield 70 %. 
1H NMR (DMF-d7): 7.04 {s, 2H), 7.20-7.35 (m, lH), 7.44 (s, lH), 11.52 (s, lH), ppm. 
UV-Vis (H20), Àmax (relative intensity): 389 (1). 
LR-MS (F AB), m/z: 458.1 ~ - 4S03 - + 2Na) 
Calculated for Zn(C~sN2Na20~3)2x4H20: C 24.13, H 2.02, N 6.25, S 21.47, Zn 
7.30; 
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found: C 24.46, H 2.01, N 5.74, S 18.50, Zn 
7.26. 
4.1.7. Synthesis of lipophi/ic technetium and rhenium complexes 
General procedure. A solution of SnC/2 (0.5 mmol) in 0.6 N HC/ (5ml) 
purged with nitrogen was added to a solution of a 2-pyrrolylthione (0.5 mmol) in 
EtOH (100 ml) in a nitrogen atmosphere. Next, a solution of KRe04 or K198Tc04 
(0.25 mmol) in water (10 ml) was added to the initial reactants. The reaction mixture 
was heated at 60°C for 15-30 minutes. The solvent was then evaporated and the 
residue was treated with a saturated aqueous solution of KHC03• The solid was 
separated by centrifugation and dissolved in an appropriate solvent for further 
purification by colurnn chromatography. 
Bis-(phenyl-2-pyrrolylthionato)rhenium (1 Oa) 
Repeated chromatography (CHC/3) on silica-gel gave bis-(phenyl-2-
pyrrolylthionato )rhenium in 40% yield. 
M.W. =619.77 
1H NMR (DMF-d1): 6.38-6.78 {m, lH), 7.06-7.30 {m, lH), 7.53-7.97 {m, 6H) ppm. 
13C NMR (DMF-d1): 121.73, 122.26, 127.91, 129.07, 130.35, 131.96, 132.25, 160.55 
ppm. 
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IR spectra (KBr): 3422, 3058, 2927, 1723, 1533, 1480, 1441, 1381, 1359, 1295, 1240, 
1197, 1183, 1159, 1135 1122, 1081, 1067, 1030, 999, 949, 896, 849, 817, 767, 699, 
671, 645, 620, 601, 577, 483 cm-1• 
UV-Vis (CHCIJ), À.max (lg e): 454.5 (4.32), 333.5 (4.75). 
LR-MS (SIMS, thioglycerol), m/z: 575 (~ - OC2H5). 
Rr(Si02, MeOH:CHC/1=1:49) = 1; (Si02, MeOH:CHC/1=0.5:99.5) = 0.1. 
Calculated for ReO(OC2H5)(C11HsNS)2: C, 46.51; H, 3.42; N, 4.52; S, 10.35; 
found: C, 46.63; H, 3.28; N, 4.31; S, 10.35. 
Bis-(p-methoxyp/ienyl-2-pyrrolylthionato)rhenium (1 Ob) 
Normal phase column chromatography (0-2% EtOH in CHC/3) followed by re-
precipitation from hexane gave bis-(p-methoxyphenyl-2-pyrrolylthionato)rhenium in 
69% yield. 
M.W. = 679.82 
1H NMR (CDC'3): 3.71-3.98 (m, 3H), 6.55-7.11(m,4H), 7.51-8.03 (m, 3H) ppm. 
13C NMR (CDC/3): 55.68, 68.18, 114.43, 122.51, 128.83, 130.61, 130.89, 132.46, 
162.44, 163.67 ppm. 
UV-Vis (CHC/3), À.max (lg e): 382 (4.53). 
LR-MS (SIMS, thioglycerol), m/z: 635 ~ - OC2Hs) 
Rr(Si02, MeOH:CHC/1=/ :49) = 0.95; (Si02, MeOH:CHC/1=0.5:99.5) = 0.1. 
Calculated for ReO(OC2Hs)(C12H1oNOS)2: C, 45.94; H, 3.71; N, 4.12; S, 9.43. 
found: C, 47.09; H, 3.63; N, 3.82; S, 9.32. 
The single crystal X-ray diffraction data: 
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group C2/c, a= 34.6651(2) A, b = l l.5694(1) A, c = 24.6839(2) A, f3 = 128.0350(4)0 , 
V = 7797.3(1) A3, Z = 4, Dx = l.9274 Mg/m-3• Cell parameters from 29416 
reflections: B = 2.28-72.86°' µ = 13.923 
0.27x0.12x0.04 mm. 
-1 
mm' T=293(2) K, plate, red, 
Bis-(3,4-dimethoxyphenyl-2-pyrrolylt/lio11ato)rhenium (1 Oc) 
Normal phase chromatography (2-20% EtOH in CHC/3) and reprecipitation from 
hexane afforded compound lOc in 75% yield. 
M.W. = 785.94 
1H NMR (CDC'3): 3.92-3.99 (m, 3H), 4.01-4.05 {m, 3H), 6.61-6.63 {m, lH), 6.70-
6.73 {m, lH), 7.10-7.13 (m, lH), 7.24-7.28 (m, lH), 7.40-7.42 {m, lH), 7.74 {s, lH) 
ppm. 
13C NMR (CDC/3): 55.86, 56.13, 109.87, 110.23, 112.89, 113.39, 120.03, 123.47, 
124.04, 126.94, 151.63, 158.76 ppm. 
IRspectra(.KBr):3409,3000,293l,2839,2595,2028, 1728, 1594, 1530, 1510, 1462, 
1378, 1329, 1268, 1250, 1216, 1169, 1144, 1087, 1062, 1022, 990, 951, 923, 908, 
871, 858, 808, 797, 765, 703, 664, 642, 613, 588, 544, 466 cm-1• 
UV-Vis (CHC'3), À.max (lg E): 432 (4.28), 352 (4.13), 268 (4.20), 243 (4.24). 
LR-MS (S™S, thioglycerol), m/z: 695 ~ - OC2Hs). 
Rr(Si02, MeOH:CHC/1=1:49)=0.9; (Si02, MeOH:CHCIJ=0.5:99.5) = 0.3. 
Calculated for 
ReO(OC2Hs)(C1Jl/12N02S)2x C2HsOH: C, 45.85; H, 4.49; N, 3.56; S, 8.16; 
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found: C, 46.73; H, 4.37; N, 3.56; S, 8.09. 
Bis-(2,2 '-dipyrrolylthionato)rhenium (1 Od) 
A crude compound was dissolved in acetone and approximately 3 cm3 of 
silica gel was added to the solution. The solvent was evaporated. A pure complex 
was obtained in 83% yield after column chromatography on Si02 using a mixture of 
chloroform:ethanol (95 :5) as an eluent. 
M.W. = 597.72 
1H NMR (DMF-d1): 6.23-6.25 (m, lH), 6.46-6.49 {m, lH), 6.55-6.59 (m, 2H), 7.18-
7.22 {m, 2H), 7.28-7.29 {m, lH), 7.38-7.39 (m, lH), 7.53-7.54 (m, 2H), 7.58 (s, lH), 
7.76 {s, lH), 11.73 (s, lH), 11.83 (s, lH) ppm. 
13C NMR (DMF-d1): 112.59, 118.62, 118.80, 119.12, 123.21, 123.57, 128.62, 155.11, 
155.59, 180.33 ppm. 
IR.spectra(KBr):3582,3396,3124,3087,2528, 1981, 1617, 1545, 1517, 1472, 1420, 
1393, 1340, 1303, 1275, 1257, 1201, 1132, 1104, 1072, 1043, 1005, 992, 928, 911, 
880, 816, 746, 702, 653, 597, 546, 467 cm·1• 
UV-Vis (EtOH:DMF=50:1), Â.max {lg E): 628 (2.11), 425 (4.0), 301 (3.34). 
LR-MS (SIMS, thioglycerol}, m/z: 553 ~ - OC2H5). 
Rr (Si02, MeOH) = 0.5-0.9. 
Calculated for ReO(OC2Hs)(Cc#1N2S)2: C, 40.19; H, 3.20; N, 9.37; S, 10.73; 
found: C, 40.72; H, 3.29; N, 9.10; S, 10.62. 
Bis-(phenyl-2-pyrrolylthionato)tech11etium (9a) 
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Compound 9a was obtained in 69% yield after purification on a normal phase silica 
gel column eluted with methanol. 
M.W. =486.50 
1H NMR (CDC/3): 6.31-6.86 (m, 3H), 7.32-7.89 (m, 5H) ppm. 
13C NMR (CDCIJ): 92.92, 95.99, 99.05, 107.41, 111.51, 119.79, 125.52, 128.75, 
129.36, 132.29 ppm. 
UV-Vis (CHC/3), Âmax (lg E): 307 (4.35). 
LR-MS (STh1S), m/z: 487 (MJ. 
Bis-(p-methoxyphenyl-2-pyrrolylthionato)technetium (9b) 
Compound 9b was purified by column chromatography (2-30% EtOH in CHC/3) 
followed by re-precipitation from hexane. Yield 41 %. 
M.W. = 546.55 
1H NMR (CDC/3): 3.81-3.94 (m, 3H), 6.23-8.04 (m, 7H) ppm. 
13C NMR (CDCIJ): 55.40, 113.57, 130.01, 131.17, 132.21 ppm. 
UV-Vis (CHCIJ), Âmax (lg E): 696 (3.01), 368 (4.27). 
LR-MS (STh1S), m/z: 547 (M). 
Bis-(3,4-dimethoxyphenyl-2-pyrrolylthionato)technetium (9c) 
Repeated purification by normal phase chromatography (eluent CHC/3:EtOH = 4: 1) 
and re-precipitation from hexane gave a fine black precipitate of compound 9c. It 
was isolated in 43% yield. 
M.W. = 606.61 
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1H NMR (CDCIJ): 3.78-4.23 (m, 6H), 6.34-7.70 (m, 6H) ppm. 
13C NMR (CDCIJ): 56.05, 56.32, 110.09, 110.99, 111.57, 112.94, 121.63, 123.31, 
123.75, 124.50, 126.04, 128.84, 130.89, 131.48 ppm. 
UV-Vis (CHC'3), À.max (lg e): 328 (4.23). 
LR-MS (SIMS, thioglycerol), m/z: 607 {M), 1213 (M+2) 
Bis-(2,2 '-dipyrrolylthionato)teclinetium (9d) 
Normal phase chromatography (0-30% MeOH in CHCIJ) gave pure 9d complex in 
89% yield. 
M.W. =464.46 
1H NMR (DMF): 6.28-6.53 (m, 2H), 7.17 (s, lH), 7.25-7.31 (m, lH), 7.51 (s, lH), 
8.35 (s, lH), l l.74 (s, lH) ppm. 
13C NMR (DMF): 109.97, 115.40, 120.48, 124.37, 127.45 ppm. 
UV-Vis (EtOH), À.max (lg e): 429 (4.03). 
LR-MS (SIMS), m/z: 465 (M). 
4.1.8. Synthesis of water-soluble technetium comp/er:es 
General procedure. The SnC/i (0.2 mmol) solution in 0.12N HCI (1 ml) was 
added to a solution of sulphonated 2-pyrrolylthione (0.2 mmol) in water (2 ml), which 
bas been purged previously with nitrogen. After 5 minutes the solution of KTc04 (0.1 
mmol) in water (2 ml) was added to a reaction mixture, which soon became dark 
brown. It was further heated for 15-30 minutes at 60°C. According to the 
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chromatographical dat~ no free ligand was detected in a solution at that time. Next, 
the solvent was evaporated and each complex lla-d was purified as described below. 
Bis(phenyl-2-( 4-sulpho)pyrrolylthionato)technetium, sodium sait (11 a) 
Normal phase chromatography (eluent MeOH) gave the compound lla as dark brown 
solid in 75% yield. 
M.W. =690.58 
1H NMR (D20): 6.95-6.96 (m, lH), 7.37-7.41 (m, 3H), 7.47-7.52 (m, lH), 7.64-7.68 
(m, 2H) ppm. 
13C NMR (D20): 112.64, 115.55, 120.47, 125.97, 128.68, 130.69, 193.13 ppm. 
UV-Vis (H20), Àma.'t (relative intensity): 421 (0.44), 337 (1). 
LR-MS (SIMS, thioglycerol): 649 (M} 
Bis(p-methoxyphenyl-2-( 4-sulpho)pyrrolylthionato)technetium, sodium sait (11 b) 
This compound was purified on a silica gel column, using methanol as an eluent. 
Yield 95%. 
M.W. = 750.63 
1H NMR (D20): 3.64-3.69 (m, 3H), 6.87-6.94 (m, 3H), 7.38-7.39 (m, lH), 7.66-7.69 
(m, 2H)ppm. 
13C NMR (D20): 57.25, 115.61, 118.72, 127.00, 131.08, 133.21, 164.59, 187.95 ppm. 
UV-Vis (H20), À.max (relative intensity): 380 (shoulder), 311 (1). 
LS-MS (SIMS, thioglycerol): 728 ~+Na} 
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Bis(3,4-dimethoxyphenyl-2-(4-sulp/1o)pyrrolylthionato)technetium, sodium sait 
(llc) 
Normal phase chromatography ( eluent: methanol) gave complex 1 lc in 86% yield. 
M.W. = 810.69 
1H NMR (D20): 3.64-3.66 (m, 6H), 6.75-6.79 (m, lH), 6.88 (s, lH), 7.19 (s, lH), 
7.22-7.26 (m, lH), 7.36-7.37 (m, lH) ppm. 
13C NMR (D20): 57.24, 57.51, 112.38, 113.09, 118.42, 126.09, 126.88, 129.46, 
130.95, 131.85, 149.39, 153.92, 177.47, 187.08, 196.87 ppm. 
UV-Vis (H20), À.max (relative intensity): 321 ( 1 ), 390 (shoulder). 
LS-MS (SIMS, thioglycerol): 790 ~+Na} 
Bis(2,2 '-( 4,4 '-disulp/1o)dipyrrolyltllionato )tec/1 netium, sodium sait (11 d) 
This compound was dissolved in water and purified on a reversed-phase (C 18) 
preparative column using water as an eluent. The main dark brown fraction was 
collected and dried. Yield 95%. 
M.W. = 872.62 
1H NMR (D20): 7.20 (d, 2H), 7.35 (d, 2H) 
13C NMR (D20): 115.34, 125.67, 128.55, 130.36, 175.27 ppm. 
UV-Vis (H20), À.max (relative intensity): 400 (0.55), 330 (1 ). 
Bis(2,2 '-( 4-sulpho)dipyrrolylthionato)technetium, sodium sait. (11 d') 
The crude compound was dissolved in methanol and purified on silica gel 
column (eluent EtOH). A brown fraction was collected and stripped of the solvent. 
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Compound lld' was obtained in 82% yield. 
M. W. = 668.54 
1H NMR (D20): 6.96-6.97 (m, lH), 7.35-7.53 (m, 3H), 7.66-7.69 (m, 2H) ppm. 
13C NMR (D20): 97.51, 126.53, 129.16, 129.54, 131.06, 133.47 ppm. 
UV-Vis (HiO), Àmax (relative intensity): 421 (0.59), 33 7 ( 1 ). 
4.1.9. Synthesis of water-soluble rhenium complexes 
General procedure. The SnC/2 (0.2 mmol) solution in 0.12N HCI (1 ml) was 
added to a solution of a sulphonated 2-pyrrolylthione (0.2 mmol) in water (2 ml), 
which had been purged previously with nitrogen. A.fier 5 minutes the solution of 
KRe0-1 (0.1 mmol) in water (2 ml) was added to a reaction mixture, which was further 
heated for 15 minutes at 60°C. A fine brown precipitate resulted. The end of the 
reaction was monitored using TLC. A precipitate was collected by prolonged 
centrifugation (2 hours). It was washed with water and dried. 
Bis(phenyl-2-(4-sulpho)pyrrolylthionato)r/1enium (12a) 
Yield 12%. 
M.W. = 751.83 
IR spectra (KBr): 3405, 2923, 1703, 1630, 1593, 1535, 1474, 1443, 1354, 1298, 1227, 
1176, 1155, 1046, 1025, 1006, 1000, 949, 892, 876, 818, 809, 796, 765, 717, 664, 
645, 627, 593, 506 cm-1• 
UV-Vis (HiO), Â.max (lg e): 509 (0.82), 458 (0.89), 393 (0.91), 380 (0.91), 362 (1). 
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LR-MS (MALDI), m/z: 736 ~-OH), 759 ~ - OH+ Na). 
Bis(p-methoxyp/1enyl-2-(4-sulpho)pyrrolylthionato)rhenium (12b) 
Yield 25%. 
M.W. = 811.89 
lR spectra (KBr): 3582, 2931, 1597, 1526, 1506, 1461, 1427, 1401, 1354, 1312, 1293, 
1272, 1165, 1150, 1046, 1026,941,917,883,839,810, 789, 776, 706,683,659,635, 
589, 503 cm·1• 
LR-MS (MALDI), m/z: 796 ~ - OH), 818 ~ - OH+ Na), 840 ~ - OH+ 2Na). 
Bis(3,4-dimethoxyplienyl-2-( 4-sulplio)pyrrolylthionato)rhenium (12c) 
Yield 21% 
M.W. = 871.94 
lR.spectra(KBr):3409,2443, 1638, 1550, 1522, 1424, 1388, 1342, 1273, 1255, 1144, 
1045, 942, 911, 875, 856, 825, 708, 659, 571, 559 cm·1• 
UV-Vis (H20), À.max (relative intensity): 696 (0.13), 509 (O. 72), 435 (1 ), 378 (0.90), 
362 (0.98). 
LR-MS (MALDI), m/z: 855 ~ - OH). 878 (~ - OH+ Na), 900 ~ - OH+ 2Na). 
Calculated for ReO(OH)(C13H12NOsS2)i: C 35.82, H 2.89, N 3.21; 
found: C 36.82, H 3.00, N 3.17. 
Bis(2,2'-(4-sulpho)dipyrrolylthionato)rhenium, sodium sait. (12d') 
Yield 18%. 
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M.W. = 729.79 
UV-Vis (H20), À.max (relative intensity): 425 (1) 
LR-MS (MALDn, m/z: 736 ~ - OH+ Na), 758 (W - OH+ 2Na), 779 ~ - OH+ 
3Na). 
Calculated for ReO(OH)(CcJ!f)l2Na03S2)ix6H20: C 24.52, H 2.86, N 6.35, S 14.54; 
found: C 25.17, H 3.09, N 5.14, S 13.86. 
4.1.10. Labelling of the 2-pyrro/ylthiones with 99mTc-isotope 
General procedure. Direct labelling was carried out at near physiological pH. 
Stannous tartrate Sn(CJ/406) was selected as a reducing agent. A lipophilic ligand (1 
mg) was dissolved in 10 ml of methanol. A water-soluble ligand (1 mg) was 
dissolved in 1 ml of distilled water. Next, 20 µg of saturated solution of stannous 
tartrate was added, followed by a solution of sodium pertechnetate Na99mTc04 in 
saline, as obtained from the generator ( 100-500 µL, according to measured 
radioactivity, usually approximately 3 mCi). Labelling was accomplished by 
incubation of a solution at 60°C for 15 minutes in a nitrogen atrnosphere. 
The solvent was evaporated in a vacuum. A residual solid was re-dissolved 
either in ethanol or water (for lipophilic and hydrophilic compounds respectively). A 
labelled product was purified using normal phase (Si02) Seppak cartridges. For the 
lipophilic compounds, the cartridges were pre-conditioned with chlorofonn. 
Chlorofonn, ethanol and acetone were used as eluents. For water-soluble 
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compounds, the cartridges were conditioned with water and methanol. Methanol was 
used as an eluent. A radioactive fraction corresponding to a 99mTc-pyrrolylthione 
complex was collected. 
Radiochemical purity. At this point, the radiochemical purity of the product 
was determined using thin layer chromatography (TLC) on commercially available 
paper strips impregnated with silica gel. In order to do this, we followed standard 
procedures used for quality control of radiopharmaceuticals in nuclear medicine. 
Specifically, a sample of a product was loaded on a paper strip and thoroughly 
dried. A strip was then immersed in a solvent in order to detect the main radioactive 
components that could be present in such a mixture ( e.g. complex, free pertechnetate, 
and reduced technetium). Afterwards, the strip was dried and eut into three equal 
pieces. These pieces were placed in a y-counter and the radiochemical purity of a 
product was calculated using the data obtained. 
For lipophilic compounds, the strip was first run in chloroform to detect a 
radioactive complex (Rr 0.5-1.0, usually >90% of total activity). Next, the strip was 
immersed in acetone to detect free pertechnetate. Reduced technetium bas Rr 0.0 in 
these solvents. 
For water-soluble compounds, the strip was first chromatographed in acetone 
to detect free pertechnetate (Rr 1.0), then in methanol and water (a Tc-complex, Rr 
1.0, usually >90% of total activity). Reduced technetium, again, remains at the origin 
of the chromatogram. 
Labelling e/flciency. The labelling efficiency was calculated based on the 
chromatographically purified complex. Briefly, a synthesised product was loaded on 
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an activated Seppak cartridge and eluted with an appropriate solvent (chlorofonn 
followed by methanol for lipophilic complexes and water followed by methanol for 
water-soluble compounds). Collected fractions and the cartridge itselfwere placed in 
a y-counter and the labelling efficiency of a product was calculated using the data 
obtained. The values were corrected for decay of the radioisotope. 
Formulation of the radiopharmaceuticals. In order to fonnulate solutions 
for injection to perform biodistribution tests, water-soluble compounds were 
redissolved in saline and their radioactive concentrations were adjusted according to 
specifications for biological studies. 
The lipophilic compounds were formulated for injection using an emulsion 
with either Cremophor-EL or Travamulsion (Sigma-Aldrich). Emulsions were 
prepared as follows. For Cremophor containing emulsion 10% of Cremophor-EL, 
3% of propanol and the balance of water (87%) were used. A complex was dissolved 
in propanol followed by the addition of Cremophor-EL. The mixture was vigorously 
shaken on a Vortex while water was added. For the Travamulsion mixture, the 
complex was dissolved in 0.5 ml of ethanol, followed by the addition of 
Travamulsion ( 4.5 ml). The mixture was shaken on a Vortex at the lime of addition 
and for 5 more minutes after the addition. The volume of the ethanol in the final 
emulsion must not exceed 10%. 
Finally, the solutions for injection were sterilised. 
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4.2. Biological tests 
Dr. Jacques Rousseau from our Department carried out the biodistribution and 
pharmacokinetics experiments. 
4.2.1. Biodistribution 
For biodistribution studies Balb/c mice bearing an EMT6 mammary 
adenocarcinoma on each thigh were injected in vivo with 100-200 µl (0.5 to 1 mCi) of 
carrier free 99mTc labelled 2-pyrrolylthones. Animais were sacrificed at 6 hours post-
injection. 
4.2.2. Pharmacokinetics 
A group of 3 male Sprague and Dawley rats were anaesthetised by intra-
muscular administration of a mixture of Ketamine Xylazine (lml/kg). A 26 gage 
Butterfly was introduced into the lateral tail vein and filled with heparinised 
physiological saline. The animais were injected with the proper radiopharmaceutical. 
Acquisition started in few minutes after injection. 
The camera was set to record a series of 32 images with an interval of 1 min. 
Animais were injected successively after the camera was started. Ail injections were 
finished within the first minute and a half. Following each injection the catheter was 
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flushed with 0.5 ml of physiological saline. Second dynamic acquisition was 
perfonned at a rate of one image every 10 minutes. The animais woke up 90 min 
after injection, when the study was terminated. 
For analysis, areas were traced around the organs of interest (right and left 
kidneys for the dynamic study, and heart, left kidney and bladder at 60 min post-
injection). The results were expressed as counts per seconds or as percent of the 
whole body activity at a given time. 
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J[,. = 231.244 
Orthorhombic 
Pca21 
a = 18.9î2 (8) Â 
b = 9.065 (3) A 
c = 6.86î (2) Â 
~/ = 1181.0 (i) Â3 
Z=4 
D:: = 1.3006 Mg m -3 
Dm not measured 
Cu Ko radiation 





Cell parameters from 25 reflections 
(} = 19.00-24.00° 
µ = O.î66 mm- 1 
T = 293 (2) K 
Block 
Pale grey-green 
O.î6 x 0.36 x 0.21 mm 
Data collection 
Nonius CAD-4 diffractometer 
;.; scan 
Absorption correction: 
by integration ABSORP in NRCVAX 
(Gabe et al. 1989) 
Tmm = 0.6686, Tmax = 0.8714 
2380 l measured reflections 
2228 independent reflections 
l ï 43 reflections w i th 
>2u(J) 
Refinement 
Refinement on r 
R[r > 20-(r)J = 0.0616 
wR(F2 ) = 0.1485 
S = l.Oïl 
2228 refiections 
15ï parameters 
H-atom parameters constrained 
w=l/[o-2 (F02 ) + (0.1015?) 2] 
where P = ( F0 2 + 2Fc2)/3 
(.:.l/u)max = 0.000 
Rint = 0.045 
Omax = 69.82° 
h = -23 - 23 
k=-11-11 
l = -8 - 8 
5 standard refiections 
frequency: 60 min 
intensity decay: no decay. variation l. ï% 
~Pmax = 0.155 e ..\ - 3 
• -3 
~Pmin = -0. 160 e A 
Extinction correction: SHELXL96 (Sheldrick, 
1996) 
Extinction coefficient: 0.0205 ( 19) 
Scattering factors from International Tables 
for Crystallography (Vol. C) 
Absolute structure: Flack ( 1983) 
Flack parameter = 0.1 (4) 
Table 1. S elected geometric parameters ( Â, 0 ) 
01-Cl 1.231 (3) C7-Cl2 1.410 (3) 
Cl-C2 1.453 (4) C8-C9 1.383 ( 5) 
Cl-Cï 1.479 (4) C9-Cl0 1.384 ('1) 
C2-N3 1.3ïl (4) Cl0-010 1.360 (3) 
C2-C6 1.385 ( 4) ClO-Cll 1.396 (4) 
N3-C4 1.354 (4) Cll-011 l.3ï3 (3) 
C4-C5 1.348 (5) Cll-Cl2 1.376 (4) 
C5-C6 1.396 (4) C13-010 l.420 (4) 
C7-C8 1.375 (4) Cl4-011 1.424 (4) 
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01-Cl-C2 120.4 (3) Cl2-C7-Cl 
01-Cl-C7 120.0 (3) C7-C8-C9 
C2-Cl-C7 119.6 (2) C8-C9-C10 
N3-C2-C6 106.2 (2) 010-Cl0-C9 
N3-C2-Cl 119.9 (3) 010-C 10-C 11 
C6-C2-Cl 133.8 (3) C9-Cl0-Cll 
C4-N3-C2 110.0 (3) Oll-Cll-Cl2 
C5-C4-N3 108.2 (3) 011-Cll-ClO 
C4-C5-C6 108.1 (3) Cl2-Cll-Cl0 
C2-C6-C5 107.6 (3) Cll-Cl2-Ci 
C8-C7-C12 119.2 (3) C 10-010-C 13 
CS-Ci-Cl 123.7 (2) Cll-011-Cl4 
Ol-Cl-C2-N3 5.1 (4) C l-C7-C8-C9 
C7-Cl-C2-N3 -lï6.3 (3) C7-C8-C9-Cl0 
0 l-Cl-C2-C6 -171.6 (3) C8-C9-C 10-010 
C7-Cl-C2-C6 7.0 (5) C8-C9-C 10-C 11 
C6-C2-N3-C4 -1.2 (3) 010-ClO-Cll-Oll 
Cl-C2-N3-C4 -178.7 (3) C9-C10-Cll-011 
C2-N3-C4-C5 1.1 (4) 0l0-C10-Cl 1-C 12 
N 3-C.t-C5-C6 -0.5 (4) C9-C10-Cll-Cl2 
N3-C2-C6-C5 0.9 (3) Oll-Cll-Cl2-C7 
Cl -C2-C6-C5 l îï.9 (3) Cl0-Cll-Cl2-C7 
C4-C5-C6-C2 -0.2 (4) C8-C7-Cl2-Cll 
Ol-Cl-Cï-C8 -142.5 (3) Cl-C7-Cl2-Cll 
C2-C l-Cï-C8 38.9 (4) C9-C 10-010-C 13 
01-Cl-Ci-Cl2 34.6 (4) Cl 1-C10-010-C13 
C2-Cl-Ci-Cl2 -144.l (3) Cl2-Cll-011-Cl4 
Cl2-Ci-C8-C9 0.9 (4) Cl0-Cll-Oll-Cl4 
Table 2. Hydrogen-bonding geometry ( Â, 0 ) 
D-H···A 
N3-H3· · ·Oli 
D-H 
0.86 



























1.0 ( 4) 
-2.0 (4) 







Data collection: CAD-4 software (Enraf-Nonius, 1989). Cell refinement: CAD-4 software (Enraf-
Nonius, 1989). Data reduction: NRC-2, NRC-2A (Ahmed et al. 19i3). Program(s) used to 
solvc structure: SHELXS9i (Sheldrick, 199i). Program(s) used to refine structure: SHELXL96 
(Sheldrick, 1996). '.\folecular graphies: SHELXTL (Bruker, 199i). Software used to prcpare 
material for publication: SHELXL96 (Sheldrick, 1996). 
References 
Ahmed, F. R., Hall, S. R., Pippy, M. E. & Huber, C. P. (19i3). NRC Crystallographic Computer 
Programs for the IBM/360. Accession Nos. 133-147 in J. A.pp/. Cryst. 6, 309-346. 
Enraf-Nonius ( 1989). CAD-4 Software. Version 5.0. Enraf-Nonius, Delft, The Netherlands. 
Flack, H. D. (1983). Acta Cryst. A39, 876-881. 
Flack, H. D. & Schwarzenbach, D. (1988). Acta Cryst. A44, 499-506. 
Gabe, E. J., Le Page, Y., Charland, J.-P., Lee, F. L. & White, P. S. (1989). J. A.pp/. Cryst. 22, 
384-38i. 
International Tables for Crystallography ( 1992). Vol. C. Tables 4.2.6.8 and 6.1.1. 4, Dordrecht: 
Kluwer Academic Publishcrs. 
Sheldrick, G. ~[. (1997). SHELXS97. Program for the Solution of Crystal Structures. üniversity 
of Gottingen, Gcrmany. 
Sheldrick, G. M. (1996). SHELXL96. Program for the Refinement of Crystal Structures. University 
of Gëttingen, Germany. 
SHELXTL (1997) Release 5.10; The Complete Software Package for Single Crystal Structure 
Determination. Bruker AXS Inc., Madison, WI 53719-1173. 
Spek, A. L. (1995). PLATON, Molecular Geometry Program, July 1995 version, University of 
Utrecht, Utrecht, Rolland. 
Space group confirmed by PLATON program (Spek, 1995). Data reduction performed using a 
locally modified version of the NRC-2 program (Ahmed et al. 1973). The structure was solved 
by direct rnethod using SHELXS97 (Sheldrick, 1997) and difmap synthesis using SHELXTL 
(Sheldrick, 1997) and SHELXL96 (Sheldrick, 1996). Alt non-H atorns anisotropie, H atoms 
isotropie. H atoms constrained to the parent site using a riding mode!; SHELXL96 defaults, 
C-H 0.93 ta 0.96 and N-H 0.86 Â. The isotropie factors, Uiso , were adjusted ta 50% higher 
value of the parent site (methyl, NH) and 20% higher (others). A final verification of possible 
voids was performed using the VOID routine of the PLATONprogram (Spek, 1995). 
Data collection: CAD-4 software (Enraf-Nonius, 1989). Cell refinement: CAD-4 software 
(Enraf-Nonius, 1989). Data reduction: NRC-2, NRC-2A (Ahmed et al. 1973). Program(s) 
used ta salve structure: SHELXS91 (Sheldrick, 1997). Program(s) used ta refine structure: 
SHELXL96 (Sheldrick, 1996). Molecular graphies: SHELXTL (Bruker, 1997). Software used 
ta prepare material for publication: SHELXL96 (Sheldrick, 1996). 
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Table Sl. Fraetional atomie eoordinates and equivalent isotropie displaeement parameters (A 2 ) 
Ueq = (1/3)E;E;Uiiaiaia;.a;. 
r y = U.,q 01 0.48586 ( 11) 0.0941 (2) -0.2345 (4) 0.0908 (8) 
Cl 0.42879 (15) 0.0648 (3) -0.1586 (5) 0.0679 (8) 
C2 0.38455 (15) -0.0513 (3) -0.2381 (5) 0.0633 (7) 
:-;3 0.40872 (14) -0.1365 (3) -0.3890 (4) 0.0770 (7) 
H3 0.4496 -0.1285 -0.4419 0.116 
C4 0.35869 (18) -0.2351 (3) -0.4424 (6) 0.0820 (9) 
H4 0.3631 -0.3056 -0.5400 0.098 
es 0.30144 ( 17) -0.2131 (3) -0.3297 (6) 0.0809 (9) 
115 0.2593 -0.2654 -0.3366 0.097 
CG 0.31641 (15) -0.0983 (3) -0.2009 (5) 0.0698 (8) 
H6 0.2861 -0.0601 -0.1071 0.084 
e:- 0.40420 (13) 0.1502 (3) 0.0119 (4) 0.0623 (7) es 0.36831 (15) 0.0892 (3) 0.1660 (5) 0.0667 (7) 
H8 0.3570 -0.0106 0.1640 0.080 
C9 0.34886 (15) 0.1 745 (3) 0.3241 (5) 0.0672 (7) 
H9 0.3254 0.1316 0.4286 0.081 
ClO 0.36430 ( 14) 0.3237 (3) 0.3268 (5) 0.0626 (7) 
Cll 0.40169 ( 13) 0.3869 (3) 0.1728 (5) 0.0623 (7) 
c12 0.42200 (13) 0.3011 (3) 0.0174 (5) 0.0636 (7) 
Hl2 0.•1475 0.3428 -0.0843 0.076 
C13 0.2978 (2) 0.3653 (4) 0.614•1 (5) 0.0875 (10) 
Hl3A 0.2556 0.3311 0.5522 0.131 
Hl38 0.2864 0.4434 0.7034 0.131 
H13C 0.3192 0.2854 0.6845 0.131 
010 0.34549 ( 11) 0.4185 (2) 0.4713 (3) 0.0800 (7) 
CH 0.4502 (2) 0.6055 (3) 0.0316 (6) 0.0888 (10) 
Hl-IA 0.4949 0.5585 O.Q108 0.133 
Hl48 0.4575 0.7077 0.0622 0.133 
Hl4C 0.4222 0.5976 -0.0843 0.133 
011 0.41461 (11) 0.5354 (2) 0.1889 (4) 0.0764 (6) 
Table S'2. Anisotropie displacement parameters (Â2 ) 
Un U22 U33 U12 U13 U23 
01 0.0756 (13) 0.0663 (11) 0.130 (2) -0.0112 (10) 0.0339 (14) -0.0173(14) 
Cl 0.0645 (15) 0.0463 (13) 0.093 (2) 0.0012 (10) 0.0099 (15) -0.0016 (14) 
C2 0.0637 (14) 0.0449 (11) 0.0813 (18) 0.0043 (10) 0.0046 (14) -0.0050 (12) 
N3 0.0836 (16) 0.0529 (12) 0.0945 (18) 0.0004 (11) 0.0199 (14) -0.0085 (13) 
C4 0.096 (2) 0.0578 (15) 0.093 (2) -0.0039 (15) -0.0003 (19) -0.0149 ( 16) es 0.0732 (17) 0.0691 (17) 0.100 (2) -0.0064 (14) -0.0047 (18) -0.0112 (18) 
C6 0.0618 (14) 0.0596 (14) 0.088 (2) 0.0040 (12) 0.0001 (15) -0.0063 (15) 
c:- 0.0561 (13) 0.0461 (12) 0.0849 (18) 0.0007 (10) 0.0016 (13) -0.0033 ( 14) 
es 0.0703 (15) 0.0465 (12) 0.0834 (19) -0.0044 (11) -0.0033 (15) 0.0035 (13) 
e9 0.0713 (16) 0.0555 (14) 0.0749 (18) -0.0082 (12) -0.0024 (14) 0.0046 (H) 
ClO 0.0582 (13) 0.0570 (14) 0.0726 (16) -0.0050 (10) -0.0024 (12) -0.0044 (13) 
Cll 0.0555 (12) 0.0460 (12) 0.0852 (18) -0.0040 (10) -0.0009 (14) -0.0042 (12) 
C12 0.0571 (13) 0.0506 (12) 0.0833 (18) -0.0033 ( 11) 0.0073 (13) -0.0007 ( 14) 
Cl3 0.096 (2) 0.081 (2) 0.079 (2) -0.0044 (18) 0.0191 (18) -0.0021 (19) 
010 0.0880 (15) 0.0676 (12) 0.0844 (15) -0.0135 (10) 0.0179 (11) -0.0145 (11) 
C14 0.111 (2) 0.0534 (15) 0.102 (2) -0.0229 (16) 0.018 (2) 0.0006 (17) 
011 0.0881 (13) 0.0475 (9) 0.0937 (H) -0.0135 (9) 0.0174. (13) -0.0090 (10) 
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Table 53. Geometric parameters ( Â, 0 ) 
01-Cl l.231 (3) C9-C10 1.384 (4) 
Cl--C2 l.453 (4) C9-H9 0.9300 
Cl-C7 1.479 (4) Ct0-010 1.360 (3) 
C2-N3 l.371 (4) ClO-Cll 1.396 (4) 
C2-C6 1.385 (4) Cll-011 1.373 (3) 
N3-C4 l.354 (4) Cll-Ct2 l.376 (4) 
N3-H3 0.8600 C12-H12 0.9300 
C4-C5 1.348 (5) Cl3-010 l.420(4) 
C4-H4 0.9300 C13-H13A 0.9600 
C5-C6 1.396 (4) C13-Hl38 0.9600 
C5-H5 0.9300 Cl3-Hl3C 0.9600 
C6-H6 0.9300 C14-0lt 1.424(4) 
C7-C8 1.375 (4) Cl4-Hl4A 0.9600 
C7-C12 1.410 (3) Cl4-H148 0.9600 
C8-C9 1.383 (5) Cl4-Hl4C U.9tiUU 
C8-H8 0.9300 
Ol-Cl-C2 120.4 (3) C8-C9-H9 119.9 
Ol--Cl-C7 120.0 (3) Cl0-C9-H9 119.9 
C2-Cl-C7 119.6 (2) 010-c10-c9 l 2·l.9 (3) 
'.'i3-C2-C6 106.2 (2) 010-c10-c11 115.2 (2) 
:-:3-C2-Cl 119.9 (3) C9-Cl0-Cll 119.9 (3) 
C6-C2-Cl 133.8 (3) Ol1-Cll-C12 124.5 (3) 
C4-N3-C2 110.0 (3) 011-C11-c10 115.6 (2) 
C4-N3-H3 125.0 C12-C11-C10 119.8 (2) 
C2-N3-H3 125.0 Cll-C12-C7 120.2 (3) 
C5-C4-i'3 108.2 (3) Cll-Cl2-Hl2 119.9 
C5-C4-H4 125.9 C7-Cl2-Hl2 lHJ.() 
N3-C4-H4 125.9 010-Ct3-Hl3A 109.5 
C4---C5-C6 108.l (3) 010-Ct3-Hl3B 109.5 
C4-C5-H5 125.9 Hl3A-Cl3-Hl38 109.5 
C6-C5-H5 125.9 010-C13-Hl3C 109.5 
C2-C6-C5 107.6 (3) H13A-Cl3-Hl3C 109.5 
C2-C6-H6 126.2 Hl38-Ct3-Ht3C 109.5 
C5-C6-H6 126.2 Cl0-010-Cl3 117.2 (2) 
C8-Ci-Cl2 119.2 (3) 011-Cl4-Hl4A 109.5 
CS-Ci-Cl 123.7 (2) 011-Cl4-Hl48 109.5 
C12-C7-Cl 117.0 (3) H14A-Ct4-H148 109.5 
C7-C8-C9 120.8 (2) 011-C14-H14C 109.5 
C7-CS-H8 119.6 H14A-Ct•l-H14C 109.5 
C9-CS-HS 119.6 H14B-C14-H14C 109.5 
C8-C9-Ct0 120.0 (3) Cll-011-Cl4 117.5 (2) 
Ol-Cl-C2-N3 5.1 (4) Cl-C7-C8-C9 177.8 (3) 
C7-Cl-C2-N3 -176.3 (3) C7-C8-C9-C10 1.2 (4) 
Ol-C1-C2-C6 -171.6 (3) C8-C9-C10-010 177.6 (3) 
C7-Cl-C2-C6 7.0 (5) C8-C9-Cl0-Cl 1 -2.2 (4) 
C6-C2-N3-C4 -1.2 (3) 010-c10-c11-011 0.3 (4) 
Cl-C2-N3-C4 -178.7 (3) C9-C10-Cll-011 -179.8 (3) 
C2-N3-C4-C5 1.1 (4) 010-c10-c1i-c12 -178.7 (2) 
N3-C4-C5-C6 -0.5 (4) C9-Cl0-Cl 1-Cl 2 1.1 (4) 
N3-C2-C6-C5 0.9 (3) 011-C11-C12-C7 -178.0 (3) 
Cl-C2-C6-C5 177.9 (3) Cl0-Cll-C12-C7 1.0 (4) 
C4-C5-C6-C2 -0.2 (4) CS-C7-Cl2-C11 -2.0 (4) 
Ol-Cl-C7-C8 -142.5 (3) Cl-C7-C12-Cll -179.1 (3) 
C2-C1-C7-C8 38.9 (4) C9-Cl0-010-Cl3 -9.9 (4) 
Ot-Cl-C7-C12 34.6 (-l) Cl 1-C10-010-Cl3 169.9 (3) 
C2-Cl-C7-Cl2 -144.l (3) Ct2-Cll-Oll-Cl4 1.4 (4) 









,\t[,. = 217.278 
Monodinic 
P2i/c 
a = 11.8386 ( 1) Â 
b = 11.9453(1) À 
c = 7 .5061 ( 1) A. 
J3 = 98.676 ( 1 )0 
V = 1049.33 (2) À3 
Z=4 
Dr= 1.3753 Mg m-3 
Dm not measured 
Cu J.:o: radiation 
À= 1.54178 Â 
Compound 2b 
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Cell parameters from 11189 refiections 
(} = 3. 70- 72.85° 
µ = 2.490 mm- 1 
T = 293(2) K 
Black 
Dark red 
0.58 x 0.52 x 0.18 mm 
Data collection 




multi-scan SADABS (Sheldrick, 1996) 
Tmin = 0.3850, Tmax = 0.7390 
12236 measured reflections 
2054 independent reflections 
Refinement 
Refincment on P-
R[ P. > 2cr(P-)j = 0.0402 
wR(F2 ) = 0.1118 
s = 1.079 
2054 reflections 
138 parameters 
H-atom parameters constrained 
w=l/(cr2 (F02 ) + (0.06i8P) 2 + 0.30i9Pj 
where P = {F02 + 2FJ)/3 
1985 reflections with 
>2cr(J) 
R;nc = 0.0402 
Omax = 72 .84 ° 
h = -14 - 14 
k = -14 - 14 
l= -8 - 7 
108 standard reflections 
intensity decay: none 
(L1/cr)max = 0.000 
• -3 L1Pma.x = 0.294 e A 
• -3 ÂPmin = -0.330 e A 
Extinction correction: SH ELX L96 (Shcldrick, 
1996) 
Extinction coefficient: 0.0275 ( 19) 
Scattering factors from International Tables 
for Crystallography (Vol. C) 
Table l. Selected geometnc paramcters (:Î, 0 ) 
Sl-Cl 1.6686 ( 15) Ci-CS 1.396 (2) 
Cl-C2 1.426 (2) C7-C12 1.403 (2) 
Cl-C7 1.4782 (19) C8-C9 1.386 (2) 
C2-N3 1.3779 (18) C9-C10 1.391 (2) 
C2-C6 1.399 (2) Cl0-010 1.3605 ( 17) 
N3-C4 1.338 (2) ClO-Cll 1.393 (2) 
C4-C5 1.381 ( 3) Cll-Cl2 l.3i7 (2) 
C5-C6 1.390 (2) 010-Cl3 1.424 (2) 
C2-Cl-Ci 118.60 (13) C8-C7-Cl 122.48 (13) 
C2-Cl-Sl 121.35 (11) C12-C7-Cl 119.82 (13) 
C7-Cl-Sl 120.04 (11) C9-C8-C7 121.40 ( 13) 
N3-C2-C6 105.82 (13) C8-C9-Cl0 119.66 ( 14) 
N3-C2-Cl 121.46 (13) 010-Cl0-C9 124.57 ( 14) 
C6-C2-Cl 132.70 (14) 010-ClO-Cll 115.64 ( 13) 
C4-N3-C2 110.46 (14) C9-Cl0-Cll 119.78 (13) 
N3-C4-C5 108.48 (14) C12-Cll-Cl0 119.97 (13) 
C4-C5-C6 107.12 (15) Cll-Cl2-C7 121.31 (14) 
C5-C6-C2 108.11 (14) Cl0-010-C13 117.67 (12) 
C8-C7-C12 117.70 (13) 
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Cï-Cl-C2-N3 -lï4.12 (13) Sl-Cl-Cï-Cl2 
Sl-Cl-C2-N3 6.7 (2) Cl2-C7-C8-C9 
Cï-C l-C2-C6 8.1 (3) Cl-C7-C8-C9 
S 1-C l-C2-C6 -lïl.08 (14) C7-C8-C9-Cl0 
C6-C2-N3-C4 -0.28 ( 17) C8-C9-C 10-010 
Cl-C2-N3-C4 -lï8.60 (14) C8-C9-Cl0-Cll 
C2-N3-C4-C5 -0.30 ( 19) 010-Cl0-Cll-Cl2 
N3-C4-C5-C6 0.8 (2) C9-Cl0-Cll-Cl2 
C4-C5-C6-C2 -0.92 (19) Cl0-Cll-Cl2-C7 
N3-C2-C6-C5 O.ï4 (1 ï) C8-C7-Cl2-Cll 
C l-C2-C6-C5 lï8.79 (16) Cl-C7-Cl2-Cll 
C2-Cl-C7-C8 36.9 (2) C9-Cl0-010-C 13 
Sl-Cl-C7-C8 -143.89 ( 13) Cll-Cl0-010-Cl3 
C2-Cl-C7-Cl2 -143.50 ( 15) 
Table 2. Hydrogen-bonding geometry ( Â. 0 ) 
D-H···.4 
N3-H3· · ·Sl' 
D-H 
0.86 
















176.40 ( 14) 
-13.1(2) 
168.10 ( 15) 
D-H···A 
132.9 
Data collection: SMART (Bruker, 1999). Cell refinement: SAINT (Bruker, 1999). Data reduction: 
SAINT (Bruker, 1999). Program(s) used to solve structure: SHELXS91 (Sheldrick. 1997). 
Program(s) used to refine structure: SHELXL96 (Sheldrick, 1996). Molecular graphies: SHELXTL 
(Brukcr, 1997). Software used to prepare material for publication: SHELXL96 (Sheldrick, 1996). 
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Data reduction processing was carried out by the use of the program SAINT (Bruker, 1999), 
which applied Lorentz and polarization corrections to three-dimensionally integrated diffraction 
spots. The program SADABS (Sheldrick, 1996) was utilized for the scaling of diffraction 
data, the application of a decay correction, and an empirical absorption correction based on 
redundant retlections. The space group was confirmed by XPREP routine in SH ELXTL program 
(Sheldrick, 1997). The structure was solved by direct method using SHELXS9i (Sheldrick. 1997) 
and difmap synthesis using SHELXL96 (Sheldrick, 1996). AU non-H atoms anisotropie, hydrogen 
atoms isotropie. H atoms constrained to the parent site using a riding mode!; SHELX L96 
defaults, C-H 0.93 to 0.96, N-H 0.86 Â. The isotropie factors, Uiso , were adjusted to 50% 
higher value of the parent site ( methyl and NH) and 20% higher ( others). A final verification of 
possible voids was performed using the VOID routine of the PLATONprogram (Spek, 1995). 
Data collection: SMART (Bruker, 1999). Cell refinement: SAINT (Bruker, 1999). Data re-
duction: SAINT (Bruker, 1999). Program(s) used to solve structure: SHELXS97 (Sheldrick, 
1997). Program(s) used to refine structure: SHELXL96 (Sheldrick, 1996). Molecular graph-




Table Sl. Fraetional atomic eoordinates and equivalent isotropie displaeement parameters (IÎ 2 ) 
Ueq = (l/3)E;EjUiia1aia;.aj. 
r 'li : Ueq 
St 0.69294 (3) 0.96827 (4) -0.00753 (6) 0.0522 (2) 
Cl O.ï3243 (12) 0.91650 (12) 0.1989 (2) 0.0349 (3) 
C2 0.65056 (12) 0.89250 (12) 0.3149 (2) 0.0341 (3) 
N3 0.53491 (10) 0.90014 (11) 0.25519 (19) 0.0395 (3) 
H3 0.5050 0.9178 0.1473 0.059 
C4 0.-1756i (14) 0.87621 (14) 0.3888 (2) 0.0444 (4) 
H4 0.3965 0.8i63 0.3802 0.053 
es 0.55197 (14) 0.85136 (15) 0.5415 (2) 0.0452 (4) 
HS 0.5338 0.8310 0.6533 0.054 
C6 0.661H (13) 0.862·16 (13) 0.4967 (2) 0.0400 (-1) 
H6 0.7294 0.8518 0.5742 0.048 
Ci 0.85'158 (12) 0.89605 ( 12) 0.26610 (19) 0.0332 (3) 
es 0.89195 (12) 0.80525 (12) 0.3ï65 (2) 0.0354 (3) 
H8 0.8389 0.7532 0.4045 0.042 
C9 1.00643 ( 12) 0.79106 (12) 0.4454 (2) 0.0364 (3) 
H9 1.0297 0.7302 0.5193 0.044 
ClO 1.08636 ( 12) 0.86825 (13) 0.4036 (2) 0.0353 (3) 
Cll l.05160 ( 13) 0.95607 ( 13) 0.2858 (2) 0.0376 (4) 
Hll l.1053 1.0059 0.2532 0.045 
Cl2 0.93771 ( 13) 0.96911 (12) 0.21 ï8 (2) 0.0366 (4) 
Hl2 0.9154 1.0275 0.1383 0.044 
010 1.20008 (9) 0.86421 (11) 0.46760 (16) 0.045ï (3) 
C13 1.23672 (15) O.ï9024 (li) 0.6136 (3) 0.0536 (5) 
H13A 1.1902 0.8012 O.i065 0.080 
Hl3B 1.3151 0.8054 0.6610 0.080 
Hl3C 1.2295 0.7143 0.5i18 0.080 
Table S2. Anisotropie displacement parameters (Â2 ) 
U11 U22 U33 U12 U13 U23 
51 0.0393 (3) 0.0775 (4) 0.0385 (3) 0.00640 (18) 0.00165 (18) O.Oli98 (19) 
Cl 0.0328 (ï) 0.0363 (7) 0.0347 (8) 0.0010 (G) 0.0021 (6) 0.0008 (5) 
C2 0.0286 (7) 0.0358 (ï) 0.0370 (8) 0.0006 (5) 0.0018 (5) 0.0003 (5) 
:"-13 0.0301 (6) 0.0467 (7) 0.0404 (7) 0.0016 (5) 0.0009 (5) 0.0013 (5) 
C4 0.0336 (8) 0.0458 (9) 0.0551 (10) -0.0014 (6) 0.0110 (ï) 0.0003 (ï) 
es 0.0442 (9) 0.0476 (9) 0.0459 (9) 0.0013 (7) 0.0137 (7) 0.0058 (ï) 
C6 0.0354 (8) 0.0458 (8) 0.0382 (8) 0.0020 (6) 0.0037 (6) 0.0036 (6) 
Ci 0.0303 (7) 0.0381 (7) 0.0310 (7) 0.0012 (5) 0.0041 (5) 0.0003 (5) 
Cs 0.0321 (7) 0.0375 (7) 0.0368 (8) -0.0022 (5) 0.0060 (6) 0.0033 (6) 
C9 0.0347 (7) 0.0386 (7) 0.0356 (8) 0.0037 (6) 0.0048 (6) 0.0052 (6) 
ClO 0.0289 (7) 0.0450 (8) 0.0321 (7) 0.0011 (6) 0.0051 (5) -0.0037(6) 
Cll 0.0335 (8) 0.0431 (8) 0.0374 (8) -0.0050 (6) 0.0090 (6) 0.0018 (6) 
C12 0.0376 (8) 0.0389 (8) 0.0338 (8) 0.0003 (6) 0.0067 (6) 0.0059 (5) 
010 0.0281 (5) 0.0636 (8) 0.0446 (7) -0.0004 (4) 0.0027 (4) 0.0075 (5) 
Cl3 0.0356 (8) 0.0750 {12) 0.0476 (10) 0.0057 (8) -0.0022(7) 0.0096 (8) 
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Table S3. Geometric parameters (À, 0 ) 
Sl-Cl 1.6686 (15) C8-C9 1.386 (2) 
C1-C2 1.426 (2) C8-H8 0.9300 
Cl-Ci 1.4782 (19) C9-C10 1.391 (2) 
C2-N3 1.3779 (18) C9-H9 0.9300 
C2-C6 1.399 (2) Cl0-010 l.3605 (li) 
N3-C4 1.338 (2) C10-C11 1.393 (2) 
N3-H3 0.8600 Cll-Cl2 1.377 (2) 
C4-C5 1.381 (3) Cll-Hll 0.9300 
C4-H4 0.9300 C12-Hl2 0.9300 
C5-C6 1.390 (2) 010-Cl3 l.·124 (2) 
C5-H5 0.9300 C13-Hl3A 0.9600 
C6-H6 0.9300 Cl3-Hl38 0.9600 
Ci-CS 1.396 (2) Cl3-Hl3C 0.9600 
C7-Cl2 1.403 (2) 
C2-C1-Ci 118.60 (13) C9-C8-H8 119.3 
C2-Cl-51 121.35 (11) Ci-C8-H8 119.3 
Ci-Cl-51 120.04 (11) C8-C9-C10 119.66 {1·1) 
N3-C2-C6 105.82 (13) C8-C9-H9 120.2 
N3-C2-Cl 121.46 (13) Cl0-C9-H9 120.2 
C6-C2-Cl 132.70 (14) 010-C10-C9 124.57 (14) 
C4-N3-C2 110.46 (14) 010-ClO-Cl l 115.64 ( 13) 
C4-N3-H3 124.8 C9-Cl0-Cll 119.78 (13) 
C2-N3-H3 124.8 Cl2-Cl 1-ClO 119.97 (13) 
N3-C4-C5 108.48 (14) C12-Cll-Hll 120.0 
N3-C4-H4 125.8 ClO-Cll-Hll 120.0 
C5-C4-H4 125.8 C11-Cl2-Ci 121.31 (14) 
C4-C5-C6 lOi.12 (15) Cll-Cl2-H12 119.4 
C4-C5-H5 126.4 Ci-Cl2-Hl2 119.4 
C6-C5-H5 126.4 Cl0-010-C13 117.67(12) 
C5-C6-C2 108.11 (14) 010-Cl3-Hl3A 109.5 
C5-C6-H6 125.9 010-Cl3-Hl3B 109.5 
C2-C6-H6 125.9 Hl3A-Cl3-Hl3B 109.5 
C8-C7-Cl2 117.iO (13) 010-C13-Hl3C 109.5 
C8-C7-Cl 122.48 ( 13) Hl3A-C13-Hl3C 109.5 
Cl2-Ci-Cl 119.82 (13) Hl38-Cl3-Hl3C 109.5 
C9-C8-Ci 121.40 (13) 
C7-Cl-C2-N3 -174.12 (13) 51-Cl-C7-Cl2 35.67 (19) 
51-Cl-C2-N3 6.7 (2) Cl2-C7-CS-C9 3.8 (2) 
C7-Cl-C2-C6 8.1 (3) C1-C7-C8-C9 -176.60 (14) 
Sl-Cl-C2-C6 -171.08 (14) Ci-C8-C9-C10 -0.3 (2) 
C6-C2-N3-C4 -0.28 (17) C8-C9-Cl0-010 178.09 (1-1) 
Cl-C2-N3-C4 -178.60 (14) C8-C9-C10-C11 -3.l (2) 
C2-N3-C4-C5 -0.30 (19) 010-c10-c11-c12 -178.16 (14) 
N3-C4-C5-C6 0.8 (2) C9-Cl0-Cl l-Cl2 2.9 (2) 
C4-C5-C6-C2 -0.92 (19) ClO-Cl 1-Cl 2-Ci 0.7 (2) 
:'113-C2-C6-C5 0.74(17) C8-Ci-Cl2-Cl 1 -4.0 (2) 
Cl-C2-C6-C5 178.79 (16) Cl-C7-C12-C1 l 176.40 (14) 
C2-Cl-C7-C8 36.9 (2) C9-C10-010-Cl3 -13.1 (2) 
51-Cl-C7-C8 -143.89 (13) Cll-C10-010-C13 168.10 (15) 













.rt.-fr = 373.368 
Orthorhombic 
Pnma 
a = 6.763 (3) A 
b = ï.540 (6) A 
c = 31.641 (8) Â 
- • 3 V= 1613.5 (ln) A 
Z=4 
D,. = 1.5370 Mg m-3 
Dm not measured 
Cu Ko: radiation 
,\ = 1.54178 Â 
Compound 3b 
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Cel! parameters from 25 reflections 
8 = 20.00-25.00° 
µ = 3.587 mm- 1 
T = 293(2) K 
Block 
Intense violet-pink 
0.57 x 0.53 x 0.27 mm 
Data collection 
Nonius CAD-4 diffractometer 
w/20 scan 
Absorption correction: 
by intcgration ABSORP in NRCVAX (Gabe 
et al. 1989) 
Tmin = 0.1775, Tmax = 0.4530 
16409 measured refiections 
1655 independent reflections 
Re finement 
Refinement on f'1. 
R[F2 > 2u(F2 )] = 0.0286 
wR(F2 ) = 0.081i 
s = 1.107 
1655 reflections 
l 7ï parametcrs 
H-atom paramcters constraincd 
w=l/[u2 (F02 ) + (0.0536?)2 + 0.2229P] 
where P = (F02 + 2F~)/3 
1507 refiections with 
>2u(l) 
Rïnt = 0.031 
Omax = 69.92° 
h = -8-+ 8 
k = -9 - 9 
l = -38 - 38 
5 standard reflections 
frequency: 60 min 
intensity decay: no dccay. variation 0.8% 
(Â/O')max = 0.010 
ÂPmax = 0.359 C À - 3 
- • -3 6Pmin - -0.266 CA 
Extinction correction: SHELXL96 (Shcldrick. 
1996) 
Extinction coefficient: 0.0146 (6) 
Scattering factors from International Tables 
for Cr'ljstallography (Vol. C) 
Table 1. Selected geometric parameters ( Â, 0 ) 
Na-02i 2.4455 ( 12) Cl-C2 l..l::iU (3) 
Na-02 2.4·155 ( 12) Cl-C7 1..;!12 (2) 
Na-02ii 2.4538 ( 12) C2-C3 1.383 (::i) 
Na-02iii 2.4538 (12) C2-N6 1.382 (3) 
Na-Oliv 2.4572 (12) C3-C4 lAll (3) 
Na-01 2.5129 (13) C4-C5 l.361 (3) 
=-ra-Naiv 3.4331 (15) C5-N6 1.335 (3) 
Na-Naiii 3.4331 (15) C7-C8 l.3!lllll 
01-Naiii 2.4571 ( 12) C7-Cl2 l.390ll 
02-Naiv 2.-1538 (12) C8-C9 l.3!1011 
Sl-CI l.646 (2) C9-Cl0 l.390ll 
S4-042 l.4534 ( 12) Cl0-010 1.373 (2) 
S4-042v 1.4534 (13) ClO-Cll l.3900 
S4-041 1.4578 (13) Cl1-Cl2 l.J!JUO 
S-l-C4v 1.743 (2) 010-Cl3 l.3::i8 (3) 
S4-C-i 1.743 (2) 
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02i-Na-02 81.90 (6) 042v-S4-041 112.17 (5) 
02i-Na-02ii 165.09 (4) 042-S4-C4v 112.3!! ( 12) 
02-Na-02ii 96.32 (5) 042v -S4-C4v 102.·13 (12) 
02i-Na-02iii 96.32 (5) 041-S4-C4v 105.72 (!J) 
02-Na-02iii 165.09 (4) 042-S4-C4 lU2.43 (12) 
02ii_Na-02iii 81.57 (6) 042v-S4-C4 l 12.38 ( 11) 
02i-Na-01iv 74.40 (3) 04l-S4-C4 105.72 (9) 
02-Na-Oliv 74.40 (3) C4v-S4-C4 l l.5 (2) 
02ii_Na-01iv 90.83 (3) C2-Cl-C7 119.79 (17) 
02iii _Na-O l iv 90.83 (3) C2-Cl-Sl 120.42 (17) 
02i-Na-Ol 120.42 (3) C7-Cl-Sl 119.78 (15) 
02-Na-OI 120.42 (3) C3-C2-N6 106.·I (2) 
02"-Na-01 73.27 (3) C3-C2-Cl 133.2 (2) 
02iii_Na-Ol 73.27 (3) N6-C2-Cl 12034 (19) 
Oliv_:'fa-01 158.76 (4) C2-C3-C4 1U6.!! (4) 
02i-Na-Naiv 45.61 (3) C5-C4-C3 !!17 !J (2) 
O~-Na-Naiv 45.61 (3) C5-C4-S4 12.Ui3 (lfi) 
02ii_Na-Na1v 124.29 (3) C3-C4-S4 127 4 13) 
02iii-Na-i1faiv 124.29 (3) N6-C5-C4 lO!!lü ( l!J) 
01 iv -Nn-Naiv 46.99 (3) C5-N6-C2 110 45 (l!J) 
Ol-Na-Naiv 154.26 (4) C8-C7-Cl2 12U.U 
02i-Na-Naiii 139.00 (3) C8-C7-Cl l l!).06 ( 12) 
02-Na-Naiii 139.00 (3) Cl2-C7-Cl 120.92 (12) 
02ii-Na-Na1ii 45.42 (3) C9-C8-C7 120.11 
02iii-1'fa-Na iii 45.42 (3) C8-C9-Cl0 120.0 
Oliv -Na-Naiii 113.12 ( 4) 010-ClO-C!l 124 5·1 ( 13) 
01-Na-Naiii 45.64 (3) 010-ClO-Cl l l 13.69 (16) 
Naiv -Na-Naiii 160.10 (5) C!l-ClO-Cll 120.0 
Naiii_Ol-Na 87.37 (4) Cl2-Cl 1-ClO 120.ll 
Na-02-Naiv 88.97 (5) Cll-Cl2-C7 120.ll 
042-54-0·12'" ll l.46 ( 10) ClJ-010-ClO 122.08 (19) 
042-54-0•11 112.16 (5) 
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02i-Na-Ol-Naiii -130.53 (3) 042v -S4-C4-C3 -47.1 ( 12) 
02-Na-O 1-Naiii 130.53 (3) 041-S4-C4-C3 -169.8 (li) 
02ii_Na-Ol-Naiii 43.00 (3) C4v -S4-C4-C3 -78.2 ( l2) 
02iii_Na-Ol-Naiii -43.00 (3) C3-C4-C5-N6 -5.3 (10) 
Ol iv -Na-01-Naiii 0.0 S4-C4-C5-N6 178.6 (2) 
Naiv -Na-01-!'l/aiii 180.0 C4-C5-N6-C2 3.2 (3) 
02i-Na-02-Naiv 31.85 (2) C3-C2-N6-C5 U.2 ( 10) 
02ii-Na.-02-Na.iv -133.22 (4) Cl-C2-N6-C5 177.5 (2) 
oziii_Na-02-Naiv -52.28 (10) C2-Cl-C7-C8 144.06 ( l 7) 
01 iv -Na-02-Naiv -44.13 (2) Sl-Cl-C7-C8 -36.5 (2) 
Ol-Na-02-Naiv 152.49 (4) C2-Cl-C7-Cl2 -37.7 (3) 
Naiii_Na-02-Naiv -151.59 (7) Sl-Cl-C7-Cl2 l·ll.75 (14) 
C7-Cl-C2-C3 -8.5 (13) Cl2-C7-C8-C9 0.0 
S 1-C 1-C2-C3 172.l (12) Cl-C7-C8-C9 178.28 (17) 
C7-Cl-C2-N6 175.l (2) C7-C8-C9-CIO o.u 
Sl-Cl-C2-N6 -4.3 (3) C8-C9-Cl0-0 lO -163.9 (3) 
N6-C2-C3-C4 -3.3 (15) C8-C9-CIO-Cl l 0.0 
Cl-C2-CJ-C4 179.9(4) 010-ClO-Cl l-Cl2 lü!:i.5 (2) 
C2-C3-C4-C5 5.4 (15) C9-Cl0-Cll-Cl2 li.li 
C2-C3-C4-S4 -178.7 (6) CIO-Cl l-Cl2-C7 o.u 
042-S4-C4-C5 -112.0 (3) C8-C7-Cl2-Cl l li.li 
042v -S4-C4-C5 128.2 (3) Cl-C7-Cl2-Cll -178.24 (l7) 
04 l-S4-C4-C5 5.6 (3) C9-Cl0-010-Cl3 -149.4 (4) 
C4 V -S4-C4-C5 97.2 (3) Cll-Cl0-010-Cl3 45.8 (5) 
042-S4-C4-C3 72.6 (12) 
Symrnctry codes: (i) x, 2 -y, z; (ii) x - ~·y,~ - z; (iii) x - ~·~-y,' - z; (iv) ~ +x. ~-y,~ - z; 
(v) X,' - y, Z. 
Table 2. Hydrogen-bonding geometry ( Â, 0 ) 
D-H···A D-H ff ... A D ... A D-H. .A 
01-Hl· · ·042; 0.82 2.24 2.999 (2) 15·1.l 
02-H2A· · -042ii 0.82 2.04 2.845 (l) 165.7 
02-H2B· · ·04liii 0.82 2.01 2.833 (2) 176.8 
N6-H6· · .042iv 0.86 2.29 3.022 (2) l42.S 
Symmetry codes: (i) ~ + x, y - 1, ~ - z; (ii) ~ + x, y - 1, ~ - z; (iii) 1 + x, y - 1. z; (iv) 1 + x. y,::. 
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Data collection: CAD-4 software (Enraf-Nonius, 1989). Cell refinement: CAD-4 software (Enraf-
Nonius, 1989). Data reduction: NRC-2, NRC-2A (Ahmed et al. 1973). Program(s) used to 
salve structure: SHELXS97 (Sheldrick, 1997). Program(s) used to refine structure: SHELXL96 
(Sheldrick, 1996). Molecular graphies: SHELXTL (Bruker, 1997). Software used ta prepare 
material for publication: SHELXL96 (Sheldrick, 1996). 
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Space group confirmed by PLATON program (Spek, 1995). Data reduction performed using a 
locally modified version of the NRC-2 program (Ahmed et al. 1973). The structure was solved 
by direct method using SHELXS97 (Sheldrick, 1997) and difmap synthesis using SHELXTL 
(Sheldrick, 1997) and SHELXL96 (Sheldrick, 1996). Most atoms were displaced from the mirror 
and two models were observed for this complexe/The constraint AFIX 66 applied to phcnuyl 
ring was used to help congergence. Ail non-H atoms anisotropie, H atoms isotropie. H atoms 
constrained to the parent site using a riding mode!; SHELXL96 defaults, C-H 0.93 to 0.96, 
N-H 0.86 and 0-H 0.82 Â.. The isotropie factors, Uiao , were adjusted to 50% higher value of 
the parent site (CH3, NH,OH) and 20% higher (others). A final verification of possible voids was 
performed using the VOCD routine of the PLATON program (Spek, 1995). 
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Table S1. Fractional atomic coordinates and equivalent isotropie displacement pammeters (.-i ~} 
Ucq = (l/3)I:ï!:jU'JaiaJa;.aj· 
Occupancy :r y ;: Ucq 
:"a 0.72210 (ll) 1/4 0.74063 (2) 0.04139 (19) 
01 0.42033 (12) 1/4 0.69429 (2) 0.0506 (-l) 
Hl 0.3904 (6) 0.1674 (4) 0.67869 ( 13) 0.076 
02 0.98904 (7) 0.03743 (4) 0.728284 (13) 0.0-153 (2) 
H2A l.04-10 (3) -0.0015 (6) 0.70713 (7) 0.068 
H28 l 0.9786 (12) -0.0464 (3) 0.74464 (9) 0.068 
Sl 0.50 0.59191 (9) 0.81257 (11) 0.96292 (2) 0.0517 (2) 
54 -0.14359 (6) 3/4 0.827640 (12) 0.02936 ( 11) 
0-11 -0.0635 (2) 3/4 0.78487 (4) 0.0437 (3) 
0-12 -0.25712 (14) -0.90929 (13) 0.83659 {3) 0.0-129 (2) 
Cl 0.50 0.3504 (3) 0.7905 (3) 0.95933 (7) 0.0327 (8) 
C2 0.50 0.2546 (3) 0.7884 (3) 0.91834 (7) 0.0310 (8) 
C3 1 0.0630 (3) 0.754 (3) 0.90545 (6) 0.0300 (6) 
H3 0.50 -0.0433 0.7242 0.9227 0.036 
C4 o.so 0.0596 (3) 0.7732 (5) 0.861Ll (6) 0.0212 (7) 
es 0.50 0.2483 (4) 0.8019 (3) 0.84788 (7) 0.0398 (7) 
HS 0.50 0.2899 0.8099 0.8199 0.0·18 
N6 0.50 0.3634 (3) 0.8167 (3) 0.88198 (6) 0.039·1 (5) 
H6 0.50 0.4878 0.8406 0.8814 0.059 
C7 0.50 0.22905 ( 17) 0.7743 (3) 0.99851 (3) 0.0309 (6) 
es 0.50 0.30484 ( 18) 0.6807 (3) l.03270 (4) 0.0389 (6) 
H8 0.50 0.4280 0.6265 l.0307 0.047 
C9 0.50 0.1965 (2) 0.6680 (3) l.06992 (4) 0.0415 (6) 
H9 0.50 0.2472 0.6053 l.0928 0.050 
ClO l 0.01242 ( 19) 0.7489 (3) l.07294 (3) 0.0375 (-1) 
Cll 0.50 -0.06337 (18) 0.8426 (3) l.03874 (-l) 0.0362 (6) 
Hll 0.50 -0.1866 0.8968 l.0408 0.043 
Cl2 0.50 0.04493 ( 19) 0.8553 (2) l.00153 (·I) 0.0335 (5) 
Hl2 0.50 -0.0058 0.9180 0.9787 0.040 
010 0.50 -0.0852 (2) 0.7811 (5) l.11022 (5) 0.0•155 ( 10) 
Cl3 0.50 -0.2856 (4) 0.7825 (8) 1.11272 (9) 0.0576 (16) 
H13A 0.50 -0.3325 0.9024 1.1105 0.086 
H138 0.50 -0.3262 0.7332 l.1393 0.086 
H13C 0.50 -0.3398 0.7131 l.0901 0.086 
Table 82. Anisotropie displacement parameters ( Â 2 ) 
Un U22 U33 U12 U13 U2:i 
Na 0.0302 (4) 0.0505 (4) 0.0435 (4) 0.000 0.0017 (3) 0.000 
01 0.0638 (9) 0.0551 (9) 0.0328 (6) 0.000 -0.0011 (6) 0.000 
02 0.0511 (5) 0.0414 (5) 0.0435 (5) 0.0033 (5) 0.0129 (4) -0.0035 (4) 
51 0.0220 (3) 0.0839 (6) 0.0491 (3) -0.0008 (3) -0.0041 (2) 0.0000 (3) 
54 0.0289 (2) 0.0349 (2) 0.02428 (19) 0.000 -0.00192 (15) 0.000 
041 0.0510 (8) 0.0553 (8) 0.0249 (6) 0.000 0.0036 (5) 0.000 
042 0.0408 (5) 0.0454 (5) 0.0424 (5) 0.0139 (·I) -0.0043 (4) -0.0017 (4) 
Cl 0.0255 (9) 0.031 (2) 0.0358 (10) 0.0009 (8) -0.0034 (8) -0.0005 (9) 
C2 0.0255 (9) 0.038 (2) 0.0300 (9) -0.0007 (9) 0.0026 (8) 0.0015 (9) 
C3 0.0241 (8) 0.0385 {16) 0.0274 (7) 0.001 (6) 0.0025 (6) -0.001 (6). 
C4 0.0255 (8) 0.008 (2) 0.0297 (8) -0.0001 (8) 0.0000 (7) -0.0002 (9) 
es 0.0317 (11) 0.058 (2) 0.0300 (10) -0.0035 (10) 0.0066 (8) 0.0034 (10) 
N6 0.0219 (8) 0.0609 (14) 0.0355 (10) -0.0044 (9) 0.0036 (7) 0.0024 (9) 
S41 
C7 0.0252 (9) 0.0363 (17) 0.0311 (9) -0.0023 (IO) -0.0041 (7) 0.0039 (11) 
CS 0.0278 (11) 0.0492 (13) 0.0397 (12) 0.0028 (10) -0.0085 (IO) 0.0012 (10) 
C9 0.0390 (12) 0.0543 (15) 0.0312 (11) -0.0001 (13) -0.0127 (IO) 0.0054 (11) 
CIO 0.0384 (10) 0.0480 (10) 0.0261 (7) -0.002 (9) -0.0040 (7) 0.001 (9) 
Cil 0.0319 (11) 0.0464 (15) 0.0302 (11) 0.0040 (11) -0.0034 (9) -0.0025 ( 11) 
C12 0.0294 (12) 0.0415 (14) 0.0298 (IO) 0.0024 (10) -0.0049 (9) 0.0023 (IO) 
OIO 0.0463 (9) 0.063 (3) 0.0275 (6) -0.0014 (11) 0.0000 (6) -0.0023 (9) 
Cl3 0.0537 (14) 0.074 (5) 0.0456 (12) 0.0062 (18) 0.0137 (11) 0.006-1 ( 1 ï) 
Table s.3. Geometric parameters ( Â, 0 ) 
:'.'Ja-02i 2.4455 (12) C2-N6 1.382 (3) 
Na-02 2.<l455 (12) C3-C4 !.·Hl (3) 
Na-02;; 2.4538 (12) C3-H3 0.9300 
Na-02ii1 2.4538 (12) C4-C5 1.361 (3) 
Na-Oliv 2.4572 (12) C5-N6 1.335 (3) 
Na-01 2.5129 (13) C5-H5 0.9300 
Na-Naiv 3.4331 (15) N6-H6 0.8600 
Na-Naiii 3.4331 (15) C7-C8 1.3900 
01-Naiii 2.4571 (12) C7-Cl2 1.3900 
01-Hl 0.8200 C8-C9 1.3900 
02-Naiv 2.4538 ( 12) C8-H8 0.9300 
02-H2A 0.8200 C9-Cl0 L.3900 
02-H2B 0.8200 C9-H9 0.9300 
SI-Cl 1.646 (2) C!0-010 1.373 (:.!) 
54-042 1.4534 (12) ClO-Cll 1.3900 
S4-042v 1.4534 (13) Cl1-Cl2 1.3900 
S-t-041 1.4578 ( 13) Cll-Hll 0.9300 
S4-C4V 1.743 (2) Cl2-Hl2 0.9300 
S4-C4 1.743 (2) 010-Cl3 1.358 (3) 
Cl-C2 L.450 (3) Cl3-Hl3A 0.9600 
Cl-Ci 1.492 (2) Cl3-Hl38 0.9600 
C2-C3 1.383 (5) Cl3-Hl3C 0.9600 
S42 
02i-Na-02 81.90 (6) 041-S4-C4 105.72 (9) 
02i-Na-02ii 165.09 (4) C4V-S4-C4 11.5 (2) 
02-Na.-02ii 96.32 (5) C2-Cl-C7 119.79 (17) 
02i-Na-02iii 96.32 (5) C2-Cl-Sl 120.42 ( 17) 02-Na.-02iii 165.09 (4) C7-Cl-Sl 119.78 (15) 
02ii-Na-02iii 81.57 (6) C3-C2-N6 106.4 (2) 
02i-Na--01iv 74.40 (3) C3-C2-Cl 133.2 (2) 
02-Na-Oliv 74.40 (3) N6-C2-Cl 120.34 (19) 02ii_Na-01iv 90.83 (3) C2-C3-C4 106.8 (4) 
02iii-Na-01iv 90.83 (3) C2-C3-H3 l26.6 
02i-Na-Ol 120.42 (3) C4-C3-H3 l26.6 
02-Na.-Ol 120.42 (3) C5-C4-C3 107.9 (2) 
02ii_Na-OL 73.27 (3) C5-C4-S4 l24.63 ( 16) 02iii_Na-Ol 73.27 (3) C3-C4-S4 l2ï.4 (3) 
Oti'"-Na-01 158.76 (4) N6-C5-C4 108.16 (19) 
02i-Na-Naiv 45.61 (3) N6-C5-H5 l25.9 
02-Na-Naiv 45.61 (3) C4-C5-H5 l25.9 02ii_Na-Naiv 124.29 (3) C5-N6-C2 110.45 (19) 02iii_Na-Naiv 124.29 (3) C5-N6-H6 l24.8 01iv_Na-Naiv 46.99 (3) C2-N6-H6 l24.8 
01-Na-Naiv 154.26 (4) C8-C7-Cl2 l20.0 
02i-Na-Na'Îi 139.00 (3) C8-C7-Cl ll9.06 (l2) 
02-Na-Naiii 139.00 (3) Cl2-C7-Cl l20.92 ( l2} 02ii_Na-i.'\alii 45.42 (3) C9-C8-Ci 120.0 021ii_Na-Naiii 45.42 (3) C9-C8-H8 120.0 
01 iv -Na-Naiii 113.12 (4) C7-C8-H8 120.0 
01-Na-Naiii 45.64 (3) C8-C9-Cl0 120.0 
Na•v-Na-Naiii 160.10 (5) C8-C9-H9 120.0 
Naiii_Ol-Na 87.37 (4) Cl0-C9-H9 120.0 
Naiii_Ol-Hl 111.7 010-c10-c9 124.54 (13) 
Na-01-Hl 123.5 010-c10-c1 l l 13.69 ( l6} 
Na-02-Naiv 88.97 (5) C9-Cl0-Cll l20.0 
Na-02-H2A 134.4 Cl2-Cll-Cl0 120.0 
Naiv -02-H2A 105.6 (2) Cl2-Cll-Hll 120.0 
Na-02-H28 109.9 ClO-Cll-Hl l l20.0 
:O-:aiv -02-H28 107.8 (5) Cll-Cl2-Ci 120.0 
H2A-02-H28 106.2 Cl l-Cl2-Hl2 120.0 
042-S4-042v 111.46 (10) C7-Cl2-Hl2 l20.0 
042-54-041 112.16 (5) Cl3-0l0-Cl0 122.08 (19) 
042v-S4-041 112.17 (5) OIO-Cl3-Hl3A 109.5 
042-S4-C4v 112.38 (12) 010-Cl3-Hl3B L09.5 
042v -S4-C4v 102.43 (12) Hl3A-Cl3-Hl3B l09.5 
041-S4-C4v 105.72 (9) 010-Cl3-Hl3C 109.5 
042-S4-C4 102.43 (12) Hl3A-Cl3-Hl3C 109.5 















.\fr = 2262.556 
Monoclinic 
C2/c 
a = 34.6651 (2) ..\. 
b = 11.5694 ( l) Â 
c = 24.6839 (2) Â 
;3 = 128.0350 (4) 0 
V = 7797 .3 ( 1) Â 3 
Z=4 
Dr = 1.9274 Mg m-3 
Dm not measured 
Cu Ka radiation 
,\ = 1.54178 ..\ 
Compound 1 Ob 
S48 
3 
Cell parameters from 29416 reflections 
0 = 2.28- 72.86° 
µ = 13.923 mm- 1 
T = 293(2) K 
Plate 
Red 
0.27 x 0.12 x 0.04 mm 
Data collection 




multi-scan SADABS (Sheldrick, 1996) 
Tmin = 0.3i00, Tmax = 0.6900 
4574i measured reflections 
7583 independent reflections 
Re.finement 
Refinement on f'Z 
R[F'Z > 20"(f'Z)] = 0.0619 
wR(F2 ) = O.lilO 
s = 1.156 
7583 reflections 
-186 parameters 
H-atom parameters constrained 
S49 
6201 reflections with 
>20'(1) 
Rint = 0.0627 
Omax = 72.91° 
h = -42 - 42 
k = -14 - 14 
l = -24 - 29 
318 standard reflections 
intensity decay: none 
w=l/(0'2(F02) + (0.1012P) 2 + 59.7091P] 
where P = (Fo2 + 2Fe2)/3 
(tl/O')max = 0.003 
~Pmax = 2.248 e Â-3 
ilPmin = -1.598 e Â - 3 
Extinction correction: none 
Scattering factors from International Tables 
for Crystallography (Vol. C) 
Table 1. Selected geometric parameters (A, 0 ) 
Rel-01 1.667 (8) C141-C142 L.3900 
Rel-N113 2.064 (8) 0143-Cl43 L.4lï (16) 
Rel-N 133 2.066 (3) Cl47-Cl48 1.3900 
Rel-02 2.082 (6) Cl47-C152 1.3900 
Rel-Slll 2.384 (3) Cl48-Cl49 l.3900 
Rel-Sl31 2.406 (2) Cl49-Cl50 l.3900 
02-Re2 l.ii9 (6) Cl50-0153 U65 ( 14) 
Sl 11-Cl 11 l.704(10) Cl50-Cl51 1.3900 
Cl 11-Cl12 L.3il ( 11) Cl51-C152 1.:3900 
Clll-Cllï 1.481 (9) 0153-Cl53 1.415(18) 
Cll2-Nl13 1.404 ( 11) Re2-02i L.iï9 (6) 
Cl12-Cll6 1.431 (12) Re2-N213' 2.088 (7) 
Nll3-Cl14 1.327 ( 11) Re2-N213 :!.088 (7) 
Cl14-Cl 15 1.412 (13) Re2-S211' 2.418 (2) 
Cl 1.5-Cl 16 1.339 ( 12) Re2-S211 2.418 (2) 
Cl 17-Cll8 1.3900 S211-C211' 1.711 (9) 
Cl17-Cl22 1.3900 C211-C212 L.386 (9) 
Cl 18-Cl 19 1.3900 C211-C217 l.486 (8) 
Cl19-Cl20 1.3900 C211-S211' 1.710 (8) 
Cl20-0123 1.3581 C212-N213 l.420 (9) 
Cl20-Cl21 1.3900 C212-C216 l.421 ( 10) 
Cl21-C122 l.3900 N213-C214 L.329 ( 10) 
0123-C123 1.4273 C214-C215 1.-118(12) 
Sl31-Cl31 1.7145 C215-C216 l.348 ( 11) 
Cl31-Cl32 1.3889 C217-C218 l.3900 
Cl31-Cl37 1.473 (8) C217-C222 1.3900 
Cl31-Cl47 1.544 (12) C218-C219 1.3900 
Cl32-Nl33 1.4073 C219-C220 1.3900 
Cl32-Cl36 1.4396 C220-0223 l.366 (7) 
Nl33-C134 1.3392 C220-C221 l.3900 
Cl34-Cl35 1.4341 C221-C222 1.3900 
Cl35-Cl36 1.3705 0223-C223 1.435 ( 11) 
C137-Cl38 1.3900 Rell-011 1.664 ( 10) 
C13ï-Cl42 1.3900 Rell-Ollü 1.664 ( 10) 
Cl38-Cl39 1.3900 Rell-012ii 1.712 ( 11) 
Cl39-Cl•l0 1.3900 Rell-012 l.ïl2 ( 11) 
Cl40-0143 1.352 (12) 021-C22 l.466 (19) 
C140-C141 1.3900 C22-C23 1.46 (2) 
sso 
Ol-Rel-N113 97.9 (4) 01-Rel-Nl33 99.5 (3) 
Nll3-Rel-Nl33 162.6 (2) Cl32-Cl31-C137 120.9 (6) 
01-Rel-02 lï8.2 ( 4) Cl32-Cl31-C147 123.9 (8) 
'.'Jll3-Rel-02 80.ï (3) Cl32-Cl31-5131 118.ï 
Nl33-Rel-02 81.96(19) Cl37-C131-5131 11 ï.5 (6) 
Ol-Rel-5lll 98.3 (4) Cl47-Cl31-5131 114.5 (ï) 
~113-Rel-Slll 81.6 (2) Cl31-Cl32-Nl33 120.8 
Nl33-Rel-Slll 95.79 (10) Cl31-Cl32-Cl36 131.û 
02-Rel-5111 82.66 (17) Nl33-Cl32-Cl36 107.6 
Ol-Rel-5131 96.4 (4) Cl34-Nl33-Cl32 109.2 
Nl 13-Rel-Sl31 96.0 (2) Cl34-Nl33-Rel 1:31.81 (Ï) 
Nl33-Rel-Sl31 82.12 (8) Cl32-Nl33-Rel 118.86 (ï) 
02-Rel-5131 82.56 (17) Nl33-Cl34-Cl35 107.9 
5111-Rel-Sl31 165.22 (9) Cl36-Cl35-Cl34 109.2 
Re2-02-Rel 177.6(3) Cl35-Cl36-Cl32 106.0 
Clll-5lll-Rel 99.5 (3) Cl38-Cl37-Cl42 120.0 
Cl 12-Cl 11-Cl l ï 124.0 (8) Cl38-Cl37-Cl31 123.ï (8) 
Cl 12-Clll-Sl 11 119.9 (7) Cl42-Cl37-Cl31 116.2 (8) 
Cl 1ï-Cl11-5111 116.l (6) Cl37-Cl38-Cl39 120.0 
Clll-Cll2-N113 119.2 (9) Cl40-Cl39-Cl38 120.0 
Cl 11-Cl 12-Cl 16 133.8 (9) 0143-Cl40-Cl41 115.5 (11) 
Nll3-Cll2-Cll6 106.9 (8) 0143-Cl40-Cl39 124)) ( 11) 
Cll4-Nll3-Cll2 108.0 (8) C141-Cl40-Cl39 120.0 
C114-N113-Rel 132.4 (7) Cl40-Cl41-C142 120.0 
C 112-N 113-Rel 119.6 (6) Cl41-Cl42-Cl3ï 120.0 
Nl 13-Cll4-C115 109.3 (9) Cl40-0143-Cl43 119.3 ( lï) 
Cll6-Cll5-Cll4 108.6 (9) Cl48-Cl47-Cl52 120.0 
Cl15-Cl 16-Cll2 107.l (9) Cl48-Cl47-Cl31 124.6 ( 13) 
Cll8-Cll 7-Cl22 120.0 Cl52-Cl47-Cl31 115.2 ( 13) 
Cl 18-Cl lï-Clll 120.8 (4) Cl49-Cl48-Cl47 120.0 
Cl22-Cll 7-Clll 119.l (4) Cl48-Cl49-C150 120.0 
Cl lï-Cll8-C119 120.0 0153-Cl50-Cl51 121.2 (15) 
Cl20-Cll9-Cll8 120.0 0153-Cl50-Cl49 118.8 (15) 
0123-Cl20-Cll9 122.2 Cl51-Cl50-Cl49 120.0 
0123-Cl20-Cl21 117.8 Cl50-C151-Cl52 120.0 
C119-Cl20-Cl21 120.0 Cl51-Cl52-Cl47 120.0 
Cl22-Cl21-Cl20 120.0 Cl50-0153-Cl53 123 (3) 
Cl21-Cl22-Cl li 120.0 02-Re2-02; 179.996 (2) 
Cl20-0123-Cl23 117.9 02-Re2-N213i 90.8 (3) 
Cl31-Sl31-Rel 99.47 (6) 02;-Re2-N213; 89.2 (3) 
S51 
02-Re2-N213 89.2 (3) N213-C214-C215 110.6(8) 
02i-Re2-N213 90.8 (3) C216-C215-C214 lOï.:3 (8) 
N213i-Re2-N213 180.0 C215-C216-C212 lOï.9 (8) 
02-Re2-S2111 89.34 (19) C218-C2lï-C222 120.0 
021-Re2-s2111 90. ï (2) C218-C2 l 7-C2 ll 119.9 (4) 
N2131-Re2-S2 l P 98.37 (18) C222-C217-C211 120.0 (4) 
N213-Re2-S2lli 81.63 (18) C219-C218-C217 120.0 
02-Re2-S211 90.66 (19) C218-C2 l 9-C220 120.0 
02i-Re2-S21 l 89.3 (2) 0223-C220-C22 l 115.3 (5) 
N2131-Re2-S211 81.63 ( 18) 0223-C220-C219 124.ï (5) 
N213-Re2-S211 98.3ï ( 18) C221-C220-C219 120.0 
S211 1-Re2-S21 l 180.0 C222-C22 l-C220 120.0 
c211 1-s211-Re2 99.0 (3) C221-C222-C217 120.0 
C212-C211-C21i 121.9 (7) C220-0223-C223 118.5 (8) 
C212-C211-S21P 120.9 (6) 011-Re 11-011 ii llï.6(13) 
C21ï-C211-5211i lli.2 (5) 011-Rell-012ii 108.8 (11) 
C211-C212-N213 118.8 (7) Ollii_Rell-012;; 108.ï ( 11) 
C21 l-C212-C216 133.5 (8) 011-Rell-012 108.ï (11) 
N213-C212-C216 107 .3 (7) Ollii_Rell-012 108.S ( 10) 
C214-N213-C212 106.9 (7) 012ii_Rel 1-012 103.3 (18) 
C214-N213-Re2 133.6 (6) C23-C22-021 108 (2) 
C212-N213-Re2 119.4 (5) 
Ol-Rel-02-Re2 28 ( 16) Cl 16-Cl 12-Nl 13-Cll4 1.4 ( 12) 
N l 13-Rel-02-Re2 -12 (8) Cl 11-C 112-N 113-Rel 3.4 ( 12) 
N 133-Rel-02-Re2 168 (8) Cl 16-C 112-N 113-Rel -lïï.4(ï) 
Slll-Rel-02-Re2 -95 (8) 01-Rel-Nll3-Cll4 -83.5 ( 10) 
Sl31-Rel-02-Re2 85 (8) Nl33-Rel-Nl13-Cll4 96.5 ( 12) 
01-Rel-Slll-Clll -95.9 (5) 02-Rel-N113-Cll4 95.3 (10) 
N 113-Rel-Sl 11-Cll 1 1.0 ( 4) Sl ll-Rel-Nll3-C114 lï9.2 ( 10) 
Nl33-Re1-Slll-Clll 163.7 (4) Sl31-Rel-Nll3-Cl14 13.9 ( 10) 
02-Rel-Slll-Clll 82.6 (4) 01-Rel-N113-Cll2 94.9 (8) 
5131-Rel-Slll-Clll 82.6 (5) Nl33-Rel-N113-Cll2 -85.l (10) 
Rel-Sl l l-Clll-Cll2 0.4 (9) 02-Rel-Nll3-Cll2 -86.3 (7) 
Rel-Slll-Cl 11-Cll 7 -178.9 (6) Slll-Rel-Nl13-Cll2 -2.4 (7) 
Cl 1i-Cl11-Cl 12-Nl 13 176.8 (8) Sl31-Rel-Nll3-Cll2 -167.ï (Ï) 
Slll-Clll-Cll2-Nl13 -2.4 (13) C112-N 113-Cl 14-Cl 15 -2.1 (13) 
Cl l ï-Clll-Cl 12-Cll6 -2.1 (18) Rel-N113-Cl 14-Cll5 lî6.4 (8) 
Slll-Clll-Cll2-C116 178.7 (11) N 113-Cl 14-Cl 15-C 116 2.2 ( 16) 
Cl 11-Cl 12-Nl 13-C 114 -177.8 (10) C114-C115-Cll6-Cll2 -1.2(15) 
S52 
C 111-C 112-Cl 16-Cll5 178.9 (12) Slll-Rel-Nl33-Cl34 9.87 (10) 
N 113-Cll2-Cll6-Cl15 0.0 (14) Sl31-Rel-Nl33-Cl34 175.l 
Cl 12-Cl ll-Cl lï-Cll8 -37.9 (ll) Ol-Rel-Nl33-Cl32 95.3 (4) 
Sl 11-Cl 11-Cl 17-Cll8 141.3 (4) Nll3-Rel-Nl33-Cl32 -84.7 (8) 
Cl 12-Cl 1l-Cl17-Cl22 144.6 (8) 02-Rel-Nl33-Cl32 -83.51 (18) 
S 111-C 111-C 117-C 122 -36.2 (7) Slll-Rel-Nl33-Cl32 -t65.22 (LO) 
Cl22-Cll 7-Cl 18-Cll9 0.0 Sl31-Rel-Nl33-Cl32 0.04 (9) 
Cll 1-Cll 7-Cl 18-Cll9 -177.5 (4) Cl32-N 133-Cl34-C 135 -3.6 
Cll 7-C118-Cll9-Cl20 0.0 Rel-Nl33-Cl34-Cl35 -179.03 (10) 
C 118-C 119-C 120-0123 -179.0 N 133-C 134-C 135-C 136 1.2 
Cl 18-Cl 19-Cl20-Cl21 0.0 Cl34-Cl35-Cl36-Cl32 o.u 
0123-Cl20-Cl21-Cl22 179.0 Cl31-Cl32-Cl36-Cl35 l 79. l 
C 119-C 120-C 121-C 122 0.0 N 133-Cl32-Cl36-C 135 -2.1 
C 120-C 121-C 122-C 117 0.0 Cl32-Cl31-Cl37-Cl38 34. l ( 14) 
Cl 18-Cl l 7-Cl22-Cl:21 0.0 Cl47-Cl31-Cl37-Cl38 140 (2) 
Cl 11-Cl 17-Cl22-Cl21 177.6 (4) Sl31-Cl31-Cl37-Cl38 -126.4(10) 
C 119-C 120-0123-C 123 165.3 Cl32-Cl31-Cl37-Cl42 -142.0 (8) 
C 121-C 120-0123-C 123 -13.i Cl47-Cl31-Cl37-Cl42 -36.1(18) 
01-Rel-Sl31-Cl31 -97.8 (3) S131-Cl31-Cl37-C142 57.4 ( 10) 
Nl 13-Rel-Sl31-Cl31 163.5 (2) C142-Cl37-Cl38-Cl39 0.0 
N 133-Rel-Sl31-C131 0.88 (7) Cl31-C137-Cl38-Cl39 -176.0(14) 
02-Rel-Sl31-Cl31 83.74 ( 18) C137-Cl38-Cl39-Cl40 0.0 
Sll l-Rel-Sl31-Cl31 83.7 (4) Cl38-Cl39-Cl40-0143 178 (2) 
Rel-Sl31-Cl31-Cl32 -1.87 (6) Cl38-Cl39-C140-Cl41 0.0 
Re 1-S 131-C 13 l-Cl37 159.l (7) 0143-Cl40-C141-Cl42 -177.9 (19) 
Re 1-S 131-C 13 l-Cl4 7 -163.6 (8) Cl39-Cl40-Cl41-Cl42 0.0 
C137-C131-Cl32-N133 -158.1 (7) Cl40-Cl41-Cl42-Cl37 0.0 
C 147-C131-C 132-N 133 162.2 (8) Cl38-Cl37-Cl42-Cl41 0.0 
Sl31-C131-Cl32-Nl33 2.3 Cl31-Cl37-C142-Cl41 176.3(13) 
Cl37-C131-Cl32-Cl36 20.6 (7) Cl41-Cl40-0143-Cl43 -175 (2) 
C147-C131-Cl32-Cl36 -19.1 (8) C139-Cl40-0143-C143 i ( 4) 
S 131-C 131-C 132-C 136 -179.l Cl32-Cl31-Cl4i-Cl48 -19.5 (15) 
Cl31-Cl32-Nl33-Cl34 -177.5 Cl37-Cl31-Cl47-Cl48 -116 (2) 
C 136-C 132-N 133-C 134 3.6 S 131-C 13l-Cl47-C148 141.2 ( 10) 
Cl31-Cl32-Nl33-Rel -1.32 (8) Cl32-Cl31-Cl47-Cl52 15.5.4 (9) 
Cl36-C132-Nl33-Rel 179.73 (8) C137-C131-C147-Cl52 59.4 (18) 
01-Rel-Nl33-Cl34 -89.6 (4) Sl31-C131-Cl47-Cl52 -43.9 (12) 
Nl 13-Rel-Nl33-Cl34 90.4 (8) Cl52-Cl47-Cl48-Cl49 0.0 
02-Rel-Nl33-Cl34 91.59 (18) C 131-C 14 7-C148-Cl49 174.7 (15) 
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Cl4i-Cl48-Cl49-Cl50 0.0 N213i-Re2-N213-C214 129 (8) 
Cl48-Cl49-Cl50-0153 1 i9 (2) S2lli-Re2-N213-C214 -lil.3 (9) 
C 148-Cl49-Cl50-Cl51 0.0 S211-Re2-N213-C214 8.ï (9) 
0153-Cl50-Cl51-Cl52 -li9 (2) 02-Re2-N213-C212 -84.6 (6) 
Cl49-Cl50-Cl51-Cl52 0.0 021-Re2-N213-C212 95.4 (6) 
Cl50-Cl51-Cl52-Cl4i 0.0 N213i-Re2-N213-C212 -55 (9) 
Cl48-Cl4i-Cl52-Cl5 l 0.0 S2lli-Re2-N213-C212 4.8 (6) 
Cl31-Cl4i-Cl52-Cl51 -li5.2 (13) S21 l-Re2-N213-C212 -lï5.2 (6) 
C 151-C 150-0153-C 153 6 ( 4) C212-N213-C214-C215 0.5 ( 11) 
Cl49-Cl50-0153-Cl53 -173 (3) Re2-N213-C214-C215 1 ïï.O (ï) 
Re 1-02~ Re2-02' -55 ( 10) N213-C214-C215-C216 -1.4(13) 
Rel-02-Re2-N213' 162 (8) C214-C215-C216-C212 1.8 (13) 
Rel-02-Re2-N213 -18 (8) C211-C212-C216-C215 -li3.4 (11) 
Re l-02-Re2-S211' -100 (8) N213-C212-C216-C215 -1.5 (12) 
Rel-02-Re2-S211 80 (8) C212-C21 l-C217-C218 -43.l ( 10) 
02-Re2-S21 l-C21 l' 95.4 (4) S21 li-C2 l l-C2 l ï-C218 133.5 (5) 
02'-Re2-S2 l l-C21 l' -84.6 ( 4) C2 l 2-C2 l l-C2 l 7-C222 139.8 (i) 
N213'-Re2-S2ll-C2lli 4.6 (4) S211'-C211-C217-C222 -43.6 (8) 
N213-Re2-S21 l-C211' -li5.4 (4) C222-C21 i-C218-C219 0.0 
s211i-Re2-s211-c211i -173 (14) C2 l l-C2 l i-C2 l 8-C219 -1 ïï.l (6) 
C2li-C211-C212-N213 174.4 (7) C2 l 7-C218-C2 l 9-C220 0.0 
S211'-C211-C212-N213 -2.l (12) C218-C219-C220-0223 1 ï8.0 (Ï) 
C2 l ï-C211-C212-C216 -14.4 (16) C218-C2 l 9-C220-C22 l 0.0 
S2ll'-C21 l-C212-C216 169.l (9) 0223-C220-C22 l-C222 -lï8.2 (ï) 
C2 l l-C212-N213-C214 173.9 (9) C219-C220-C22 l-C222 0.0 
C216-C212-N213-C214 0.6 ( 10) C220-C22 l-C222-C217 0.0 
C211-C212-N213-Re2 -3.2 (11) C218-C2 l i-C222-C22 l o.o 
C216-C212-N213-Re2 -176.5 (6) C2 l l-C2 l i-C222-C22 l lïï.l (6) 
02-Re2-N213-C214 99.2 (9) C22 l-C220-0223-C223 -176.2 (9) 
02'-Re2-N213-C214 -80.8 (9) C219-C220-0223-C223 5.ï (12) 
Symmetry codes: (i) ! - x, ~ - y, l - z; (ii) 1 - x, y,~ - :. 
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Data collection: SMART (Bruker, 1999). Cell refinement: SAINT (Bruker, 1999). Data reduction: 
SAINT (Bruker, 1999). Program(s) used to solve structure: SHELXS97 (Sheldrick, 1997). 
Program(s) used to refine structure: SHELXL96 (Sheldrick, 1996). Molecular graphies: SHELXTL 
(Bruker, 1997). Software used to prepare material for publication: SHELXL96 (Sheldrick. UJ96). 
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spots. The program SADABS (Sheldrick, 1996) was utilized for the scaling of diffraction 
data. the application of a decay correction, and an empirical absorption correction based on 
redundant reflections. The space group was confirmed by XPREP routine in SHELXTL program 
(Sheldrick, 1997). The structure was solved by direct method using SHELXS91 (Sheldrick, 1997) 
and difmapsynthesis using SHELXL96 (Sheldrick, 1996). All non-H atoms anisotropie. hydrogen 
atoms isotropie. H atoms constrained to the parent site using a riding mode!; SHELXL96 
defaults, C-H 0.93 to 0.97 and 0-H 0.82 A. The isotropie factors, Uiso , were adjusted to 
50% higher value of the parent site (methyl and hydroxyl) and 20% higher (othcrsj. A final 
verification of possible voids was performed using the VOID routine of the PLATON pro gram 
(Spek. 1995). 
Data collection: SMART (Bruker, 1999). Cell refinement: SAINT (Bruker, 1999). Data re-
duction: SAINT (Bruker, 1999). Program(s) used to solve structure: SHELXS97 (Sheldrick, 
1997). Program(s) used to refine structure: SHELXL96 (Sheldrick, 1996). Molecular graph-
ies: SHELXTL (Bruker, 1997). Software used ta prepare material for publication: SHELXL96 
(Sheldrick, 1996). 
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Table Sl. Fractional atomic coordinates and equivalent isotropie displacement parameters (A~) 
U.,q = (1/3)EiEjUiiaiaia;.a;. 
Occupancy :i: y ;: U.:q 
Rel 0.215259 (17) 1.01072 (4) 0.55963 (2) 0.0569!1 ( 1 7) 
01 0.2024 (3) 1.1271 (8) 0.5857 (5) 0.087 (3) 
02 0.2327 (2) 0.8687 (5) 0.5267 (3) 0.0466 (13) 
Sll l 0.24794 (11) 0.8918 (3) 0.65804 (14) 0.0653 (7) 
Clll 0.3087 (4) 0.9193 (8) 0.7020 (5) 0.067 (3) 
Cll2 0.3237 (4) 0.9942 (8) 0.6752 (5) 0.062 (3) 
'."113 0.2886 (3) l.0440 (7) 0.6104 (4) 0.0559 ( 19) 
Cll4 0.3120 (5) 1.1091 (10) 0.5947 (6) 0.077 (3) 
Hll4 0.2973 l.1498 0.5539 0.093 
Cl 15 0.3627 (5) 1.1071 (11) 0.6498 (6) 0.086 (4) 
Hll5 0.3867 l.1479 0.6518 0.104 
Cl16 0.3705 (4) l.0365 (11) 0.6987 (6) 0.076 (3) 
Hl16 0.4007 l.0184 0.7401 0.092 
Cl17 0.34252 (14) 0.8572 (4) 0.76798 (14) 0.075 (3) eus 0.38702 ( 13) 0.8146 (4) 0.78778 (19) 0.098 (.5) 
H118 0.3965 0.8276 0.7603 0.117 
Cll9 0.41740 (16) 0.7526 (5) 0.8487 (2) 0.132(7) 
Hll9 0.4472 0.7242 0.8619 0.158 
Cl20 0.40327 (19) 0.7332 (5) 0.88979 ( 18) 0.138 (8) 
Cl'.?l 0.3588 (2) 0.7758 (5) 0.86999 (15) 0.115 (6) 
Hl21 0.3493 0.7628 0.8975 0.137 
C122 0.32839 (18) 0.8377 (4) 0.80909 (13) 0.084 (4) 
Hl22 0.2986 0.8662 0.7958 0.101 
0123 0.4320 (2) 0.6748 (6) 0.9502 (2) 0.202 (8) 
Cl23 0.4203 (3) 0.6828 (6) 0.99636 (18) 0.41 (3) 
H12A 0.4464 0.7212 1.0378 0.622 
Hl28 0.4161 0.6065 l.0073 0.6'.Z'.Z 
Hl2C 0.3905 0.7260 0.9750 0.622 
5131 0.18747 (9) l.0884 (2) 0.45056 (13) 0.0651 (7) 
Cl3l 0.13008 (9) 1.0284 (2) 0.39871 ( 13) O.Oi9 (4) 
Cl32 0.11573 (8) 0.9554 (3) 0.42803 (15) 0.071 (3) 
Nl33 O.H692 (9) 0.9341 (3) 0.49930 ( 15) 0.062 (2) 
Cl34 0.12562 (11) 0.8577 (4) 0.51412 (18) O.Oi7 (3) 
Hl34 0.1394 0.8264 0.5572 0.092 
Cl35 0.07777 ( 11) 0.8329 (5) 0.4518 (2) 0.084 (4) 
Hl35 0.0549 0.7842 0.4481 U.101 
Cl36 0.07110 (10) 0.8920 (4) 0.39848 (19) U.07.5 (3) 
Hl36 0.0434 0.8914 0.3526 0.090 
Ct37 U.50 0.0935 (4) 1.0839 (13) 0.3317(5) 0.054 (5) 
Cl38 0.50 0.0476 (4) 1.1195 (14) 0.3096 (6) 0.065 (5) 
Ht38 0.50 0.0393 1.1132 0.3388 0.078 
C139 0.50 0.0141 (4) 1.1646 (15) 0.2438 (7) 0.080 (7) 
Hl39 0.50 -0.0166 1.1885 0.2291 0.096 
CHO 0.50 0.0266 (5) 1.1740 (17) 0.2002 (5) 0.077 (7) 
Cl41 0.50 0.0725 (6) 1.138 (2) 0.2223 (7) 0.107 (14) 
S56 
HHl 0.50 0.0808 1.1447 0.1930 0.129 
Cl42 0.50 0.1060 (4) 1.0933 (18} 0.2880 (7) 0.068 (7) 
Hl42 0.50 0.1367 1.0694 0.3028 0.082 
0143 0.50 -0.0039{6} 1.2129 (19} 0.1347 (7) 0.100 (6) 
C143 0.50 -0.0499(9) 1.260 (3) 0.1097 (16) 0.129 (14) 
HHA 0.50 -0.0727 1.1984 0.0966 0.1!)3 
Hl4B 0.50 -0.0619 1.3079 0.0705 0.193 
H14C 0.50 -0.0463 1.3056 0.1451 0.193 
C147 0.50 0.1057 (6) 1.0307 (18) 0.3212 (6) 0.064 (6) 
C148 0.50 0.0775 (7) 0.9417 (15) 0.2755 (9) 0.103 (9) 
H148 0.50 0.0744 0.8724 0.2916 0.124 
C149 0.50 0.0539 {7) 0.9561 (18} 0.2056 (8) 0.113 (10) 
H149 0.50 0.0350 0.8965 0.1750 0.136 
C150 0.50 0.0585 (7) 1.060 (2) 0.1815 (6) 0.107 (9) 
C151 0.50 0.0867 (9) 1.1486 (18) 0.2272 (11) 0.110 {14) 
Hl5L 0.50 0.0898 1.2179 0.2110 0.132 
C152 0.50 0.1104 (8) 1.1342 (16) O.W71 (9) 0.102 (14) 
Hl52 0.50 0.1293 1.1938 0.3276 0.122 
0153 0.50 0.0355 (10} 1.071 (3) 0.1127 (9) 0.175 (12) 
Cl53 0.50 0.0422 (17) 1.168 (4) 0.085 (2) 0.23 (3) 
Hl5A 0.50 0.0659 1.2189 0.1210 0.351 
Hl58 0.50 0.0117 1.2079 0.0539 0.351 
Hl5C 0.50 0.0537 1.1427 0.0596 0.351 
Re2 1 1/4 3/4 0.5000 0.03744 ( 16) 
5211 0.29990 {8} 0.67193 {19} 0.61536 (10} 0.0467 (5) 
C211 0.2414 (3) 0.9230 (7) 0.3933 (4) 0.0468 (19) 
C212 0.2891 (3) 0.9276 (8) 0.4536 (4) 0.047 (2) 
N2L3 0.3028 (2) 0.8546 (6) 0.5092 (3) 0.0461 (16) 
C214 0.3508 (3) 0.8670 (9) 0.5574 (5) 0.058 (2) 
H214 0.3693 0.8283 0.5994 0.069 
C215 0.3700 (3) 0.9474 (11) 0.5361 (5) 0.069 (3) 
H215 0.4024 0.9il3 0.5615 0.083 
C216 0.3324 (3) 0.9826 {9} 0.4722 (5) 0.061 (3) 
H2L6 0.3345 1.0339 0.4451 0.073 
C217 0.2232 (2) 1.0038 (4) 0.3354 (2) 0.0416 (18) 
C218 0.2351 (2) 1.1205 (5) 0.3484 (2) 0.055 (:!) 
H218 0.2557 1.1472 0.3935 0.066 
C219 0.2163 (3) 1.1972 (4) 0.2941 (3) 0.060 (2) 
H219 0.2242 1.2752 0.3029 0.073 
C220 0.1855 (2) 1.1572 (5) 0.2267 (3) 0.054 (2) 
C221 0.1736 (2) 1.0406 (5) 0.2137 {2} 0.061 (2) 
H221 0.1530 1.0139 0.1686 0.073 
C.!22 0.1924 (2) 0.9639 (4) 0.2680 {3} 0.060 (2} 
H222 0.1845 0.8858 0.2592 0.072 
0223 0.1639 (3) 1.2255 (6) 0.1698 (4) 0.071 (2) 
C223 0.1768 (6) 1.3457 (9) 0.1790 (7) 0.098 (5) 
H22A 0.1654 1.3833 0.2015 0.147 
H22B 0.1618 1.3810 0.1350 0.147 
H22C 0.2117 1.3533 0.2068 0.147 
Rell 1/2 0.89117 {12} 0.1500 0.1346 (5) 
011 0.4486 (5) 0.8167 {15) 0.7149 {8) 0.200 (7) 
012 0.4919 (11) 0.983 {2) 0.6893 (10) 0.45 (3) 
021 0.4537 (8) 0.967 (2) 0.4866 {15) 0.226 (10) 
H21 0.4626 0.9308 0.4676 0.340 
C22 0.4963 (12) 0.997 (3) 0.5568 (15) 0.218 (15) 
H22D 0.4861 1.0409 0.5794 0.261 
H22E 0.5124 0.9269 0.5832 0.261 
C23 0.5299 (17) 1.065 (5) 0.553 (3) 0.41 (4) 
H23A 0.5294 1.1441 0.5642 0.610 
H23B 0.5199 1.0614 0.5068 0.610 
H23C 0.5625 1.0349 0.5844 0.610 
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Table S2. A nisotropic displacement parameters ( Â 2 ) 
Vu U22 U33 U12 U13 U:i3 
Rel 0.0683 (3) 0.0412 (3) 0.0678 (3) -0.00266 (19) 0.0482 (3) -0.01265 ( 19) 
01 0.083 (6) 0.081 (6) 0.103 (7) 0.006 (4) 0.060 (5) -0.021 (5) 
02 0.052 (3) 0.044 (3) 0.046 (3) -0.003 (3) 0.031 (3) -0.00S (2) 
5111 0.0753 (16) 0.0754 (18) 0.0632 (15) -0.0149 (13) 0.0518 ( 14) -0.0139(12) 
Clll 0.097 (8) 0.054 (6) 0.065 (6) -0.007(6) 0.057 (6) -0.018 (5) 
C112 0.079 (7) 0.048 (6) 0.065 (6) -0.011 (5) 0.047 (6) -0.007 (4) 
Nll3 0.064 (5) 0.052 (5) 0.058 (5) -0.008 (4) 0.041 (4) -0.014 (4) 
C114 0.107 (10) 0.056 (7) 0.089 (8) -0.010 (6) 0.071 (8) 0.004 (6) 
C115 0.097 (10) 0.077 (9) 0.099 (10) -0.030 (7) 0.068 (9) -0.001 (7) 
Cl16 0.014 (7) 0.078 (8) 0.014 (7) -0.015 (6) 0.044 (6) -0.006 (6) 
Cll7 0.090 (8) 0.070 (7) 0.061 (6) -0.038 (6) 0.045 (6) -0.018 (5) 
C118 0.075 (8) 0.107(11} 0.079 (8) -0.017 (8) 0.031 (7) 0.021 (7) 
Cl19 0.091 (10) 0.144 (15) 0.118 (13) -0.021 (10) 0.043 (9) 0.0·11 (11) 
c120 0.120 (13) 0.153 (15) 0.082 (10) -0.040 (11) 0.032 (9) 0.0•14 ( 10) 
c121 0.142 (13) 0.116 (12) 0.077 (9) -0.063 (11) 0.063 (9) -0.005 (8) 
c122 0.112 (10) 0.073 (8) 0.068 (i) -0.030 (7) 0.057 (7) -0.017(6) 
0123 0.14-1 (11) 0.266 (17) 0.128 (10) -0.042 (12) 0.049 (9) 0.087 (11) 
Cl23 0.41 (5) 0.47 (5) 0.29 (4) -0.12 (4) 0.18 (4) 0.17 (•I) 
5131 0.0662 ( 15) 0.0458 (13) 0.0792 (li) 0.0048 (11) 0.0426 (14) 0.0103 ( 11) 
Cl31 0.072 (7) 0.056 (7) 0.098 (9) 0.012 (5) 0.047 (7) 0.033 (6) 
C132 0.061 (6) 0.075 (7) 0.082 (8) 0.020 (6) 0.047 (6) 0.019 (6) 
Nl33 0.069 (5) 0.053 (5) 0.071 (5) 0.008 (4) 0.046 (5) -0.003(4) 
Cl34 0.079 (8) 0.085 (9) 0.084 (8) -0.011 {7) 0.059 (7) -0.003 (6) 
Cl35 0.086 (8) 0.090 (9) 0.098 (9) -0.012 (7) 0.067 (8) 0.000 (ï) 
Cl36 0.065 (i) 0.077 (8) 0.082 (8) -0.004 (6) 0.045 (6) 0.005 (6) 
C137 0.046 (10) 0.042 (11) 0.066 (12) 0.012 (8) 0.031 (9) 0.00•1 (9) 
C138 0.061 (12) 0.067 (14) 0.062 (12) 0.001 (10) 0.035 (10) 0.007 (10) 
Cl39 0.043 (12) 0.092 ( 17) 0.073 (14) 0.010 (11) 0.019 (11) 0.008 (13) 
Cl40 0.051 ( 12) 0.099 (19) 0.066 (14) 0.018 (12) 0.033 (11) 0.031 ( 13) 
Cl41 0.13 (3) 0.12 (3) 0.09 (3) 0.01 (3) 0.08 (2) 0.02 (2) 
C142 0.045 (12) 0.085 (19) 0.066 (15) 0.025 (11} 0.029 ( 11) 0.002 (14) 
0143 0.079 (12) 0.137 (17) 0.065 (10) 0.007 (12) 0.036 (9) 0.025 ( 11) 
Cl43 0.09 (2} 0.17(4) 0.09 (2) 0.06 (2) 0.039 (18) 0.04 (2) 
Cl47 0.048 (11) 0.051 (12) 0.081 (14) 0.011 (9) 0.034 (10) 0.013 (11) 
C148 0.097 (17) 0.12 (2) 0.107 (19) 0.026 {16) 0.071 (15) 0.021 (16) 
C149 0.078 (16) 0.14 (2) 0.12 (2) 0.007 (16) 0.062 (16) -0.002 (18) 
Cl50 0.063 (14) 0.16 (2) 0.081 (17) 0.015 (16) 0.036 (12) 0.029 ( 17) 
C151 0.084 (17) 0.11 (3) 0.13 (3) 0.019 ( 16) 0.064 ( 17) 0.03 (2) 
Cl52 0.11 (2) 0.10 (2) 0.10 (2) 0.013 (16) 0.072 ( 18) 0.01.5 ( 16) 
0153 0.122 (18) 0.22 (2) 0.16 (2) 0.027 (18) 0.077 {16) 0.053 (19) 
Cl53 0.14 (3) 0.35 (6) 0.25 (5) 0.00 (4) 0.14 (4) 0.09 (4) 
Rc2 0.0449 (3) 0.0339 (3) 0.0352 (3) 0.0000 (2) 0.0255 (2) -0.00139(18) 
5211 0.0485 (11) 0.0471 (12) 0.0387 (10) -0.0033 (9) 0.0239 (9) 0.0028 (8) 
C211 0.052 (5) 0.041 (5) 0.043 (4) -0.006 (4) 0.027 (4) -0.006(3) 
C212 0.050 (5) 0.061 (6) 0.041 (4) -0.009 (4) 0.033 (4) -0.010 (4) 
N213 0.047 (4) 0.045 (4) 0.042 (4) -0.007 (3) 0.025 (3) -0.003(3) 
C214 0.053 (5) 0.068 (6) 0.051 (5) 0.004 (5) 0.032 (4) 0.005 (4) 
C215 0.051 (6) 0.089 (8) 0.058 (6) -0.014 (5) 0.029 (5) -0.005 (6) 
C216 0.064 (6) 0.066 (7) 0.054 (6) -0.012 (5) 0.037 (5) 0.001 (5) 
C217 0.055 (5) 0.038 (4) 0.035 (4) 0.002 (3) 0.029 (4) 0.000 (3) 
C218 0.059 (5) 0.053 (6) 0.049 (5) -0.008 {'&) 0.032 (4) -0.005 (4) 
C219 0.088 (7) 0.040 (5) 0.068 (6) -0.003 (5) 0.056 (6) 0.002 (4) 
C220 0.069 (6) 0.050 (5) 0.058 (5) 0.001 (4) 0.047 (5) 0.005 (4) 
C221 0.071 (6) 0.066 (6) 0.044 (5) -0.004 (5) 0.035 (5) -0.003(4) 
C'222 0.088 (7) 0.052 (6) 0.054 (6) 0.002 (5) 0.051 (5) 0.006 (4) 
0223 0.108 {6) 0.060 (4) 0.059 (4) 0.013 (4) 0.059 (4) 0.01.5 (3) 
C223 0.156 (14) 0.057 (7) 0.082 (9) -0.001 (8) 0.073 (10) 0.018 (6) 
Rcll 0.0569 {5) 0.1163 (9) 0.1588 {11) 0.000 0.0304 (6) 0.000 
011 0.177 (15) 0.217 ( 17) 0.173 (15) -0.067 (14) 0.092 {13) -0.040 (14) 
012 0.32 (3) 0.45 (4) 0.50 (4) -0.ot (3) 0.21 (3) 0.28 (3) 
021 0.135 (13) 0.31 (3) 0.26 (2) 0.014 (15) 0.137 (16) 0.05 (2) 
C22 0.15 (2) 0.21 (2) 0.29 (3) 0.03i (17) 0.13 (2) 0.06 (2) 
C23 0.40 (6) 0.44 (6) 0.46 (6) 0.02 (5) 0.31 (5) 0.04 (5) 
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Table 53. Geomelric para met ers ( Â, 0 ) 
Rcl-01 1.667 (8) C147-Cl48 1.3900 
Rcl-Nll3 2.064 (8) C147-C152 1.3900 
Rcl-Nl33 2.066 (3) C148-Cl49 1.3900 
Rel-02 2.082 (6) C148-Hl48 0.9300 
Rel-5111 2.384 (3) C149-C150 1.3900 
Rel-5131 2.406 (2) C149-Hl49 0.9300 
02-Re2 1.779 (6) Cl50-0153 1.365 ( 14) 
5111-Clll 1.704 (10) Cl50-Cl51 1.3900 
C111-C112 1.371 (11) C151-Cl52 1.3900 
Clll-C117 1.481 (9) C151-Hl51 0.9300 
Cll2-Nll3 1.404 (11) C152-Hl52 0.9300 
Cll2-Cll6 1.431 (12) 0153-Cl53 1.-115 (18) 
Nll3-Cll4 1.327(11) C153-Hl5A 0.9600 
Cl 14-Cl 15 1.412 (13) C153-Hl5B 0.9600 
Cll4-H114 0.9300 Cl53-Hl5C 0.9600 
Cll5-Cll6 l.339 ( 12) Re2-021 l. 77~ (6) 
CllS-HllS 0.9300 Rc2-N2131 2.088 (7) 
Cll6-Hl 16 0.9300 Rc2-N213 2.088 (7) 
Cll7-Cll8 1.3900 Rc2-s211i 2.418 (2) 
Cll7-Cl22 1.3900 Rc2-S211 2.418 (2) 
Cll8-Cll9 1.3900 s211-c211i l.il l (9) 
Cll8-Hll8 0.9300 c211-c212 l.386 (9) 
Cll9-Cl20 1.3900 C211-C217 l.486 (8) 
Cll9-H119 0.9300 c211-s2111 1. 710 (8) 
Ct20-0t23 1.3581 C212-N213 l.420 (9) 
c120-c121 1.3900 C212-C216 1.421 (10) 
Cl21-Cl22 1.3900 N213-C2l•I 1.329 ( 10) 
Cl21-Hl21 0.9300 C214-C215 l.418 ( 12) 
Cl22-HL22 0.9300 C214-H214 0.9300 
0123-Cl23 1.4273 C215-C216 1.348 (11) 
Cl23-Hl2A 0.9600 C215-H215 0.9300 
Cl23-Hl2B 0.9600 C216-H216 0.9300 
Cl23-Hl2C 0.9600 C217-C218 1.3900 
Sl3t-Cl31 1.7145 C217-C222 1.3900 
Cl31-Cl32 1.3889 C218-C219 1.3900 
Cl31-Cl3i 1.473 (8) C218-H218 0.9300 
Cl31-Cl47 1.544 (12) C219-C220 1.3900 
Cl32-Nl33 1.4073 C219-H219 0.9300 
Cl32-Cl36 1.4396 C220-0223 l.366 (7) 
Nl33-Cl34 1.3392 c220-c221 1.3900 
Cl34-Cl35 1.4341 C221-C222 1.3900 
Cl34-Hl34 0.9300 C221-H221 0.9300 
Cl35-Cl36 1.3705 C222-H222 0.9300 
C135-H135 0.9300 0223-C223 1.435 (11) 
Cl36-HL36 0.9300 C223-H22A 0.9600 
C137-C138 1.3900 C223-H22B 0.9600 
C137-Cl42 1.3900 C223-H22C 0.9600 
C138-CL39 1.3900 Rcll-011 1.664 (lOj 
CL38-Hl38 0.9300 Rc11-011ii 1.664 (10) 
C139-C140 1.3900 Rell-012ii 1.712 (11) 
C139-Hl39 0.9300 Rell-012 l.il2 (11) 
C140-0143 1.352 (12) 021-C22 1.466 (19) 
C140-C141 1.3900 021-H21 0.8200 
C141-CL42 1.3900 C22-C23 1.46 (2) 
C141-Hl41 0.9300 C22-H22D 0.9700 
Cl42-Hl42 0.9300 C22-H22E 0.9700 
0143-C143 1.417 (16) C23-H23A 0.9600 
Cl43-Hl4A 0.9600 C23-H23B 0.9600 
C143-Hl4B 0.9600 C23-H23C 0.9600 
Cl43-Hl4C 0.9600 
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Ol-Rel-Nll3 97.9 (4) Ol-Rel-N133 99.5 (3) 
Nl 13-Rel-Nl33 162.6 (2) C137-Cl31-Sl31 lli.5 (6) 
01-Rel-02 178.2 (4) C147-C131-S131 114.5 (7) 
Nl 13-Rel-02 80.7 (3) Cl31-Cl32-Nl33 120.8 
Nl33-Rel-02 81.96 (19) Cl31-C132-C136 131.6 
01-Re1-S111 98.3 (4) Nl33-Cl32-Cl36 107.6 
1':113-Rel-Sl 11 81.6 (2) C134-Nl33-Cl32 109.2 
Nl33-Rel-Sll l 95.79 {10) C134-Nl33-Rel 131.81 (7) 
02-Rel-Slll 82.66 (17) Cl32-Nl33-Re l 118.86 (7) 
Ol-Rel-5131 96.4 (4) Nl33-Cl34-C135 107.9 
:-:113-Rel-5131 96.0 (2) Nl33-C134-Hl34 126.l 
Nl33-Rel-Sl31 82.12 (8) Cl35-Cl34-Hl34 126.1 
02-Rel-5131 82.56 (17) Cl36-Cl35-C134 109.2 
St l 1-Rel-5131 165.22 (9) C136-Cl35-H135 125..t 
Re2-02-Rel 177.6 (3) Cl34-Cl35-Hl35 125..t 
Clll-5111-Rel 99.5 (3) Cl35-Cl36-C132 106.0 
Cl 12-Cl 11-Cl 1; 124.0 (8) Cl35-Cl36-Hl36 127.0 
Cll2-Clll-Slll 119.9 (7) Cl32-CÏ36-Hl36 12i.O 
Clli-Clll-5111 116.l (6) Cl38-Cl37-Cl42 120.0 
Clll-Cll2-Nll3 119.2 (9) Cl38-Cl37-Cl31 123.i (8) 
Cl11-Cll2-Cll6 133.8 (9) Cl42-Cl37-Cl31 116.2 (8) 
Nll3-Cl12-Cll6 106.9 (8) Cl37-Cl38-C139 120.0 
C114-N 113-Cll 2 108.0 (8) Cl37-Cl38-Hl38 120.0 
Cl 14-Nl 13-Rel 132.4 (7) C139-Cl38-H138 120.0 
Cl 12-Nl 13-Rel 119.6 (6) Cl40-Cl39-Cl38 120.0 
Nl 13-Cl 14-Cl 15 109.3 (9) Cl40-Cl39-H139 120.0 
Nl l3-Cll4-Hl 14 125.3 Cl38-Cl39-Hl39 120.0 
Cl 15-Cl 14-Hl 14 125.3 0143-Cl40-Cl41 115.5(11) 
Cl 16-Cl 15-Cl l·I 108.6 (9) 0143-Cl40-Cl39 124.5 (11) 
Cl 16-Cl 15-Hl 15 125.i C141-Cl40-Cl39 120.0 
Cl 14-Cl 15-Hl 15 125.7 Cl40-C141-Cl42 120.0 
Cl 15-Cl 16-Cl 12 107.1 (9) C140-Cl41-Hl41 120.0 
Cl 15-Cl 16-Hl 16 126.4 C142-Cl41-Hl41 120.0 
Cll2-C116-Hll6 126.4 Cl41-C142-Cl37 120.0 
Cl18-Clli-Cl22 120.0 Cl41-C142-Hl42 120.0 
Cll8-Clli-Clll 120.8 (4) C13i-Cl42-Hl42 120.0 
Cl22-Cl 1ï-Cl11 119.1 (4) Cl40-0143-Cl43 119.3 (17) 
Cl l ï-Cl 18-Cl 19 120.0 0143-C143-Hl4A 109 (2) 
C117-Cll!!-Hll8 120.0 0143-C143-Hl4B 109.5 (15) 
Cl 19-Cl 18-Hl 18 120.0 Hl4A-C143-Hl48 109.5 
C120-C119-Cl 18 120.0 0143-C143-Ht4C 109.5 (16) 
C120-Cll9-Hll9 120.0 Hl4A-C143-Hl4C 109.5 
Cl 18-Cl 19-Hl 19 120.0 Hl4B-Cl43-Hl4C 109.5 
0123-Cl 20-Cl 19 122.2 Cl48-C147-C152 120.0 
0123-Ct20-Cl21 117.8 Cl48-Cl47-Cl31 124.6 {13) 
Cll9-C120-Cl21 120.0 C152-Cl47-Cl31 115.2 (13) 
c122-c121-c120 120.0 C149-C148-Cl47 120.0 
Cl22-C121-Hl21 120.0 Cl49-Cl48-Hl48 120.0 
Cl20-Cl21-Hl21 120.0 Cl41-C148-Hl48 120.0 
C121-C122-Clli 120.0 Cl48-Cl49-Cl50 120.0 
Cl21-Cl22-Hl22 120.0 C148-Cl49-Hl49 120.0 
Cl 17-Cl22-Hl22 120.0 Cl50-Cl49-Hl49 120.0 
Cl20-0123-C123 117.9 0153-Cl50-Cl51 121.2 (15) 
0123-Cl23-Hl2A 109.5 0153-Cl50-C149 118.8 (15) 
0123-Cl23-Hl2B 109.5 Cl51-Cl50-Cl49 120.0 
Hl2A-C123-Hl28 109.5 C150-C1Sl-Cl52 120.0 
0123-C123-Hl2C 109.5 Cl50-C151-Hl51 l'lO.O 
Hl2A-C123-Hl2C 109.5 Cl52-C151-Hl51 120.0 
Hl 2B-C123-Hl 2C 109.5 Cl51-C152-C147 120.0 
Cl31-S131-Rel 99.47 (6) C151-C152-H152 120.0 
C132-Cl31-C137 120.9 (6) Cl47-C152-Hl52 120.0 
C132-Cl31-Cl4i 123.9 (8) Cl50-0153-Cl53 123 (3) 
C132-Cl31-S131 118.7 0153-Cl53-Hl5A 109 
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0153-C153-Hl5B 109 C219--C218-C217 120.0 
Hl5A-C153-H15B 109.5 C219-C218-H218 120.0 
0153-Cl 53-Hl5C 109 C21 i-C218-H218 120.0 
Hl5A-C153-Hl5C 109.5 C218-C219-C220 120.0 
H158-C153-H15C 109.5 C218-C219-H219 120.0 
0:.?-Re2-02i 179.996 (2) C220-C219-H219 120.0 
02-Re2-N2131 90.8 (3) 0223-C220-C221 115.3 (5) 
02i-Re2-N213i 89.2 (3) 0223-C220-C219 124.i (5) 
02-Re2-N213 89.2 (3) C221-C220-C219 120.0 
021-Re2-N213 90.8 (3) C222-c221-c220 120.0 
N2131-Re2-N213 180.0 C222-C221-H221 120.0 
02-Re2-S21 li 89.34 (19} C220-C22 l-H221 120.0 
021-Re2-5211 i 90.7 (2) C221-C222-C217 1'20.0 
N213i _Rc2-5211 1 98.37 (18} C221-C222-H222 120.0 
'.'12 l 3-Re2-52 l l 1 81.63 ( 18} C2 l 7-C222-H222 1'20.0 
02-Re2-52 l l 90.66 (19) C220-0223-C223. 118.5 (8) 
021-Rc2-5211 89.3 (2) 0223-C223-H22A 109.5 
N2131-Re2-S21 l 81.63 (18} 0223-C223-H22B 109.5 
N213-Re2-S21 l 98.37 (18} H22A-C223-H22B 109.5 
5211 i-Re2-52 l l 180.0 0223-C223-H22C 109.5 
c211 1-s211-Re2 99.0 (3) H22A-C223-H22C 109.5 
c212-c211-c211 121.9 (7) H22B-C223-H22C 109.5 
c212-c211-s2111 120.9 (6) 011-Rell-011 ii 117.6 (13} 
C21 i-C21 l-S2111 117.2(5) 011-Re11-012ii lU!!.8 ( 11) 
C21 l-C212-N213 118.8 (7) 011 ii _Re11-012ii 108.7(11} 
c211-c212-c216 133.5 (8) 011-Rell-012 108.7(11) 
N213-C212-C216 107.3 (7) 011ii-Rell-Ot2 108.8 ( 10} 
C214-N213-C212 106.9 (7) 012ii_Rel 1-012 103.3 (18} 
C2H-N213-Re2 133.6 (6) C22-021-H2l 109.5 
C212-N213-Re2 119.4 (5) C23-C22-021 101! {2) 
N213-C214-C215 110.6 (8) C23-C22-H22D 110 
N213-C214-H214 124.7 021-c22-H220 110.1 
C215-C214-H214 124.7 C23-C22-H22E 110 
C216-C215-C214 107.3 (8) 021-c22-H22E 110.1 
C216-C215-H215 126.3 H220-C22-H22E 108.4 
C214-C2L5-H215 126.3 C22-C23-H23A 109 
C215-C216-C212 107.9 (8) C22-C23-H238 109 
C215-C216-H216 126.0 H23A-C23-H238 109.5 
C212-C216-H216 126.0 C22-C23-H23C 109 
C218-C217-C222 120.0 H23A-C23-H23C 109.5 
C218-C217-C211 119.9 (4) H23B-C23-H23C 109.5 
C222-C217-C21l 120.0 (4) 
01-Rel-02-Re2 28 (16) 01-Rel-N113-Cll4 -83.5 (10) 
Nl 13-Rel-02-Re2 -12 (8) N133-Rel-Nl 13-Cl 14 96.5 {12} 
N133-Re l-02-Re2 168 (8) 02-Rel-N113-Cl 14 95.3 {10) 
5111-Rel-02-Re2 -95 (8) Slll-Rel-Nll3-Cll4 179.2 (LO} 
Sl31-Rel-02-Re2 85 (8) Sl31-Rel-Nl 13-Cl 14 13.9 (10) 
01-Rel-5111-Cl 11 -95.9 (5) 01-Rel-N113-Cl 12 94.9 (8) 
Nl 13-Rel-Sl 11-Cl 11 1.0 (4) Nl33-Rel-Nl 13-Cl 12 -85.l (10} 
N133-Rel-Sl 11-Cl l 1 163.7 (4) 02-Rel-Nll3-C112 -86.3 (7) 
02-Rel-Sl 11-Cl 11 82.6 (4) Slll-Rel-Nll3-Cll2 -2.4 {7) 
5131-Rel-Sll 1-Ct 11 82.6 (5) Sl31-Rel-N113-C112 -167.7 (7) 
Rcl-Slll-Clll-Cl 12 0.4 {9) Cl 12-Nl 13-Cl14-C115 -2.l {13) 
Rel-Slll-Cl 11-Clli -178.9 (6) Rel-Nll3-Cl 14-Cl 15 176.4 (8) 
Cll 7-Clll-Cll2-Nll3 176.8 (8) Nll3-Cll4-Cll5-Cll6 2.2 (16) 
Sl 11-Cll l-Cl 12-Nll3 -2.4 (13) Cl14-Cl15-Cl 16-Cl 12 -1.2(15) 
Cl 17-Cl 11-Cl 12-Cl 16 -2.1 (18) Cl 11-Cl 12-Cl 16-Cl 15 178.9 (12) 
5111-Cl l l-Cl l 2-Cl 16 178.7 {11) Nl 13-Cl 12-Cl 16-Cll5 0.0 (14) 
Clll-C112-Nll3-Cll4 -177.8 (10) c112-c111-c11 ;-c118 -37.9 (11) 
Cl 16-Cl 12-Nl 13-Cl 14 1.4 (12) Sl l 1-Clll-Cll7-C118 141.3 (4) 
Cl 11-Cl 12-Nl 13-Re 1 3.4 (12) c112-c111-c111-c122 144.6 (8) 
Cl 16-Cl 12-Nl 13-Rel -177.4 (7) Slll-Clll-Cll7-Cl22 -36.2 (7) 
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Cl 22-Cl 17-Cl 18-Cl 19 0.0 C141-C140-0143-Cl43 -175 (2) 
Cl 11-Cl 17-Cl 18-Cl19 -177.5 (4) Cl39-Cl40-0143-Cl43 :- (4) 
Cl 17-Cl 18-Cll9-Cl20 o.o C132-Cl31-Cl47-Cl4S -19.5 (15) 
Cl18-Cll9-Cl20-0123 -179.0 Cl37-Cl31-Cl47-Cl48 -116 (2) 
Cl 18-Cl 19-Cl 20-Cl21 0.0 Sl31-Cl31-C147-Cl48 141.2 { 10) 
0123-Cl20-Cl21-Cl22 179.0 Cl32-Cl31-Cl47-Cl52 1.55.-1 (9) 
Cl 19-Cl20-Cl21-Cl22 0.0 Cl37-Cl31-Cl47-Cl52 59.4 (18) 
c120-c121-c122-c117 0.0 Sl31-Cl31-Cl47-C152 -·13.9 {12) 
Cl 18-Cl l 7-Cl22-Cl21 0.0 C152-Cl47-Cl48-Cl49 0.0 
Cl ll-Cll 7-Cl22-Cl21 177.6 (4) Cl31-Cl47-Cl48-Cl49 174.7 (15) 
Cl 19-Cl20-0123-Cl23 165.3 Cl47-Cl48-Cl49-Cl5a o.a 
Cl 21-Cl 20-0l 23-Cl23 -13.7 Cl48-C149-Cl50-0153 179 (2) 
01-Rel-5131-Cl31 -97.8 (3) Cl48-Cl49-Cl50-Cl51 0.0 
Nl 13-Rel-5131-Ct31 163.5 (2) 0153-Ct50-Cl51-Cl52 -179('l) 
Nl33-Rel-5131-Cl31 a.88 (7) Cl49-Cl50-C1Sl-Clo2 o.a 
02-Rel-5131-Cl31 83.74 {18) Cl50-Cl51-Cl52-Cl47 0.0 
51 l l-Rel-5131-Cl31 83.7 (4) Cl48-Cl47-Cl52-Cl51 0.0 
Rel-5131-CI31-Cl32 -1.87 (6) Cl31-Cl47-CI52-Cl51 -175.2 (13) 
Rel-Sl3l-Cl31-Cl37 159.1 (7) Cl51-Cl50-0l53-Cl53 6 (·I) 
Rel-Sl31-Cl31-C147 -163.6 (8) C149-Cl 50-0153-Cl 53 -173(3) 
Cl37-C131-Cl32-Nl33 -158.l (7) Re l-02-Re2-02i -55 (10) 
Cl47-Cl31-Cl32-Nl33 162.2 (8) Rel-02-Re2-N213i 162 (8) 
5131-Cl3t-Cl32-Nl33 2.3 Rel-02-Re2-N213 -18 (8) 
Cl37-C131-Cl32-Cl36 20.6 (7) Rel-02-Re2-521l1 -100 (8) 
Cl47-C131-Cl32-C136 -19.l (8) Rel-02-Re2-521 l 80 (8) 
S 131-Cl31-C132-Cl36 -179.1 02-Re2-5211-c211i 95.4 (4) 
C131-Cl32--N133-Cl34 -177.5 021-Re2-s211-c2111 -84.6 (4) 
Cl36-Cl32-Nl33-Cl34 3.6 N2131-Re2-S21l-C21l1 ·1.6 (•I) 
C131-C132-Nl33-Rel -1.32 (8) N213-Re2-S21l-C21l1 -175.•I (4) 
Cl36-Cl32-Nl33-Rel 179.73 (8) s211i-Re2-s211-c2111 -173 (14) 
Ot-Rel-N133-Cl34 -89.6 (4) C217-C211-C212-N213 174.4 (7) 
Nl 13-Rel-Nl33-Cl34 90.4 (8) s211i-c211-c212-N213 -2.l (12) 
02-Rel-N133-C134 91.59 ( 18) C217-C21 l-C212-C216 -14.4 (16) 
Sl ll-Rel-Nl33-Cl34 9.87(10) S211 1-C211-C212-C216 169.l (9) 
5131-Rel-Nl33-Cl34 175.l C21 l-C212-N213-C214 173.9 (9) 
01-Rel-Nl33-Cl32 95.3 (4) C216-C212-N213-C2H 0.6 (la) 
Nl 13-Rel-Nl33-Ct32 -84.7 (8) C21 l-C212-N213-Re2 -3.2 (11) 
02-Rel-N133-C132 -83.51 (18) C216-C212-N213-Re2 -176.5 (6) 
St l l-Rel-Nt33-Cl32 -165.22 {la) 02-Re2-N213-C214 99.2 (9) 
Sl31-Rel-N133-C132 0.04 (9) 02i-Re2-N2t3-C214 -80.8 (9) 
Cl32-Nl33-C134-Cl35 -3.6 N213i-Re2-N213-C214 129 (8) 
Rel-N133-C134-Cl35 -l 79.a3 ( 10) 5211 i-Re2-N213-C214 -1 :"1.3 (9) 
N133-Cl34-Cl35-Cl36 2.2 S21 l-Re2-N213-C214 8.7 (9) 
C134-Cl35-C136-Cl32 a.a 02-Re2-N213-C212 -84.6 (6) 
C131-Cl32-C136-C135 179.l 02i-Re2-N213-C212 95.4 (6) 
N133-C132-C136-C135 -2.1 N213i-Re2-N213-C212 -55 (9) 
Cl32-Cl31-Cl37-Cl38 34.l (14) 5211 i-Re2-N213-C212 4.8 (6) 
C147-Cl31-C137-Cl38 140 (2) 5211-Re2-N213-C212 -175.2 (6) 
St31-Ct31-Ct37-C138 -126.4 (10) C212-N213-C214-C215 0.5 (11) 
Cl32-C131-Ct37-Cl42 -142.a (8) Re2-N213-C214-C215 177.0 (7) 
C147-Ct31-Ct37-Cl42 -36.l ( 18) N213-C214-C215-C216 -1.4 (13) 
St31-C131-Cl37-Cl42 57.4 (10) C2t4-C215-C216-C212 1.8 ( 13) 
Cl42-Cl37-Cl38-Cl39 o.a C211-C212-C216-C215 -173.4 ( 11) 
Cl31-Cl37-Cl38-Cl39 -176.0 (14) N213-C212-C216-C215 -1.5 (12) 
Ct37-Cl38-Cl39-Cl40 0.0 c212-c211-c211-c218 -43.1 {10) 
Cl38-C139-C140-0143 178 (2) s211i-c211-c211-c218 133.5 (5) 
Cl38-Cl39-C140-Cl41 0.0 C212-C211-C217-C'l22 139.8 (7) 
0143-C140-C141-C142 -177.9 (19) s2111-c211-c211-cz22 -43.6 (8) 
C139-Cl40-Cl41-Cl42 0.0 C'l22-C217-C218-C219 0.0 
C14a-C141-Cl42-C137 a.o C211-C217-C218-C219 -177.1 (6) 
C138-C137-Cl42-Cl41 o.o C217-C218-C219-C220 0.0 
C131-C137-Cl42-Cl41 176.3 (13) C218-C219-C220-0223 178.0 (7) 
C218-C219-C220-C221 0.0 C218-C217-C'l22-C221 0.0 
0223-C220-C221-C.Z22 -178.2 (7) C21 l-C217-C.Z22-C221 177.1 (6) 
C219-C220-C221-C.Z22 0.0 C221-C220-0223-C223 -176.2 (9) 
C220-C221-C222-C217 0.0 C219-C220-0223-C223 5.7 (12) 
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Biodistribution chart 1. 
Comparison of the biodistribution of the free pertechnetate, lipophilic 









Biodistribution chart 2 
Comparison of the biodistribution of the compounds with different level of the 
sulphonation, increasing in the row 13d, 14d', 14d. 












Biodistribution chart 3 
Comparison of the biodistribution of the compounds with various substituents 
in the phenolic ring of the ligand molecule, where 12a is the unsubstituted 
compound, 12b has a methoxy-group, and 12c has two methoxy-groups in 
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Biodistribution as a function of the substituents in the 
phenolic ring 
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